---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Product information and disease description. Covers Product description and Place of product in therapy. 406 evidence topics quoted from 220 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Regulatory status: Submission planned; NDA planned for the fourth quarter of 2026

> “Alumis remains on track to submit its New Drug Application to the FDA for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026.”
> “Our fourth-quarter 2026 NDA submission remains on track.”
> “NDA submission (4Q 2026).”

Source: [Alumis press release, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000022/alms-ex99d1.htm)

> “We plan to submit an NDA for envu in PsO to the U.S. Food and Drug Administration (“FDA”) by the end of 2026.”
> “prepare to submit an NDA for envu in PsO by the end of 2026, including as we conduct activities that are required to complete our planned NDA submission;”

Source: [Alumis Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000024/alms-20260930x10q.htm)

<a id="topic-2.1.1-2"></a>

##### Launch

No evidence found.

<a id="topic-2.1.1-3"></a>

##### Investigational status

> “Envudeucitinib is an investigational drug, not reviewed or approved by any regulatory agency”

Source: [Alumis envudeucitinib for psoriasis page](https://www.alumis.com/pipeline/envudeucitinib-for-psoriasis/)

<a id="topic-2.1.1-4"></a>

##### NDA submission planned for the second half of 2026, January 2026, superseded in May 2026

> “Alumis plans to present additional results from ONWARD1 and ONWARD2 at an upcoming medical meeting and to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration in the second half of this year.”

Source: [Alumis press release, ONWARD1 and ONWARD2 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-1.htm)

> “Plan to submit NDA for envudeucitinib in PsO in 2H 2026”
> “NDA submission (2H2026)”

Source: [Alumis press release, year end 2025 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000004/alms-20260319xex99d1.htm)

> “We plan to submit an NDA for envu in PsO to the FDA in the second half of 2026.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

> “Alumis is continuing to evaluate the long-term efficacy and safety of envudeucitinib in the ONWARD3 long-term extension trial and plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of this year.”

Source: [Alumis press release, AAD 2026 ONWARD data (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_ex99-1.htm)

<a id="topic-2.1.1-5"></a>

##### First statement of an NDA submission in the fourth quarter of 2026, May 2026

> “Data continue to underscore envudeucitinib’s potential as a leading oral therapy for PsO; plans to submit NDA in 4Q 2026 remain on track”
> “We remain on track for our NDA submission in the fourth quarter of this year, as well as the potentially pivotal LUMUS Phase 2b topline readout in SLE in the third quarter.”

Source: [Alumis press release, first quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000009/alms-20260514xex99d1.htm)

<a id="topic-2.1.1-6"></a>

##### Development history: first phase 2 and phase 3 dosing milestones

> “In the year ended December 31, 2022, we incurred and made a $37.0 million milestone payment for the first administration of envu to a patient enrolled in a Phase 2 clinical trial of envu, which was recorded in research and development expenses in the consolidated statement of operations and comprehensive loss.”
> “In July 2024, we met a milestone in connection with the first administration of envu to a patient enrolled in a Phase 3 clinical trial of envu and made a $23.0 million milestone payment in August 2024, which was recorded in research and development expenses in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2024.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

<a id="topic-2.1.1-7"></a>

##### Development history: ONWARD enrollment in March 2025 and completion of enrollment in August 2025

> “ONWARD Phase 3 development program in plaque psoriasis ongoing, with over 600 patients enrolled to date”

Source: [Blauvelt et al. (2025a)](https://www.alumis.com/file.cfm/18/docs/aad2025_blauvelt_et_al_esk-001_52w_ole_vf.pdf)

> “Completed enrollment in Phase 3 ONWARD clinical trials for envudeucitinib in moderate-to-severe plaque psoriasis; topline readout expected in early Q1 2026”

Source: [Alumis press release, second quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000039/alms-20250813xex99d1.htm)

<a id="topic-2.1.1-8"></a>

##### Development history: ONWARD1 and ONWARD2 topline results, January 2026

> “SOUTH SAN FRANCISCO, Calif., Jan. 6, 2026 -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced positive topline results from its Phase 3 ONWARD1 and ONWARD2 clinical trials of envudeucitinib, a next-generation highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate-to-severe plaque psoriasis.”

Source: [Alumis press release, ONWARD1 and ONWARD2 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-1.htm)

> “We completed the pivotal Phase 3 ONWARD1 and ONWARD2 clinical trials of envu in patients with PsO, and reported positive topline results in the first quarter of 2026.”

Source: [Alumis Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000024/alms-20260930x10q.htm)

<a id="topic-2.1.1-9"></a>

##### Development history: AAD 2026 late-breaking presentation of ONWARD1 and ONWARD2, March 2026

> “SOUTH SAN FRANCISCO, Calif., March 28, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced new data from its Phase 3 ONWARD1 and ONWARD2 clinical trials evaluating envudeucitinib, a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor for moderate-to-severe plaque psoriasis.”
> “The data were presented in a late-breaking oral session at the 2026 AAD Annual Meeting.”

Source: [Alumis press release, AAD 2026 ONWARD data (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_ex99-1.htm)

<a id="topic-2.1.1-10"></a>

##### Development history: ONWARD3 topline results, August 2026

> “SOUTH SAN FRANCISCO, Calif., August 10, 2026 – Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced topline results from the ongoing ONWARD3 long-term extension (LTE) study.”

Source: [Alumis press release, ONWARD3 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_ex99-1.htm)

> “We reported data from the ongoing ONWARD3 LTE trial in the second half of 2026.”

Source: [Alumis Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000024/alms-20260930x10q.htm)

<a id="topic-2.1.1-11"></a>

##### Development history: Fall Clinical Dermatology Conference presentation of ONWARD1, ONWARD2, and ONWARD3, October 2026

> “SOUTH SAN FRANCISCO, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced new envudeucitinib data from the ONWARD Phase 3 clinical program—ONWARD1, ONWARD2, and the long-term extension ONWARD3.”
> “The results, presented at the 26th Annual Fall Clinical Dermatology Conference, reinforce the potential of envudeucitinib to become a leading oral therapy for patients with moderate-to-severe plaque psoriasis.”

Source: [Alumis press release, Fall Clinical 2026 ONWARD data (2026)](https://investors.alumis.com/news-releases/news-release-details/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib)

<a id="topic-2.1.1-12"></a>

##### ONWARD1 and ONWARD2 topline data expected in the first half of 2026, November 2024, superseded in March 2025

> “ESK-001: Psoriasis Phase 3 topline data (1H 2026)”

Source: [Alumis press release, third quarter 2024 results (2024)](https://www.sec.gov/Archives/edgar/data/1847367/000110465924117704/tm2428191d1_ex99-1.htm)

<a id="topic-2.1.1-13"></a>

##### ONWARD1 and ONWARD2 topline data expected in the first quarter of 2026, March 2025, superseded in May 2025

> “We continue to progress and enroll patients with moderate-to-severe psoriasis in the pivotal Phase 3 ONWARD studies and expect to report topline data in the first quarter of 2026.”

Source: [Alumis press release, AAD 2025 OLE data (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000110465925021990/tm258686d1_ex99-1.htm)

> “Phase 3 ONWARD program data readout now expected 1Q 2026”

Source: [Alumis press release, year end 2024 results (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000010/tmb-20250319xex99d1.htm)

<a id="topic-2.1.1-14"></a>

##### ONWARD1 and ONWARD2 topline data expected early in the first quarter of 2026, May 2025, superseded in January 2026

> “This includes advancement of the ongoing clinical trials for ESK-001 moving steadily toward pivotal topline Phase 3 data for our next-generation TYK2 inhibitor ESK-001 in moderate-to-severe plaque psoriasis now expected early in the first quarter of 2026 and data from ESK-001’s Phase 2b clinical trial in systemic lupus erythematosus expected in 2026.”

Source: [Alumis press release, first quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000026/alms-20250514xex99d1.htm)

> “Topline data from ONWARD1 and ONWARD2 are expected early in the first quarter of 2026.”

Source: [Alumis press release, second quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000039/alms-20250813xex99d1.htm)

> “Envu: topline data from ONWARD1 and ONWARD2 in moderate-to-severe plaque psoriasis are expected early in the first quarter of 2026.”

Source: [Alumis press release, third quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000048/alms-20251113xex99d1.htm)

<a id="topic-2.1.1-15"></a>

##### Phase 2 two-year safety data planned for the fourth quarter of 2026

> “Long-term data: Phase 2, two-year safety data (4Q 2026).”

Source: [Alumis press release, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000022/alms-ex99d1.htm)

<a id="topic-2.1.1-16"></a>

##### Phase 2 two-year safety data planned for the second half of 2026, March 2026, superseded in November 2026

> “Long-term data - ONWARD3 topline data and Phase 2, two-year safety data (2H 2026)”

Source: [Alumis press release, year end 2025 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000004/alms-20260319xex99d1.htm)

> “Long-term data: Phase 2, two-year safety data (2H 2026)”

Source: [Alumis press release, second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000016/alms-20260813xex99d1.htm)

<a id="topic-2.1.1-17"></a>

##### Going concern disclosure and cash runway statement, November 2026

> “The Company believes that, based on its current operating plan, its existing cash, cash equivalents and marketable securities of $431.3 million as of September 30, 2026, will not be sufficient to meet its operating and capital requirements for at least 12 months from the date of issuance of these unaudited condensed consolidated financial statements and there is substantial doubt about the Company’s ability to continue as a going concern.”
> “The Company will need to raise significant additional capital to fund ongoing research and development activities, support potential commercialization including market and launch preparation activities and maintain future operations.”

Source: [Alumis Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000024/alms-20260930x10q.htm)

> “Based on the Company’s current operating plan, Alumis continues to anticipate that its existing cash, cash equivalents and marketable securities as of September 30, 2026 are sufficient to fund operating expenses and capital expenditure requirements into the fourth quarter of 2027.”

Source: [Alumis press release, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000022/alms-ex99d1.htm)

<a id="topic-2.1.1-18"></a>

##### Liquidity sufficient for at least 12 months, August 2026, superseded in November 2026

> “Based on our current operating plan, our existing cash, cash equivalents and marketable securities of $502.3 million as of June 30, 2026, will be sufficient to meet our operating and capital requirements for at least 12 months from the date of issuance of the unaudited condensed consolidated financial statements included in Part I Item 1 of this Quarterly Report on Form 10-Q.”

Source: [Alumis Form 10-Q, second quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000018/alms-20260630x10q.htm)

<a id="topic-2.1.1-19"></a>

##### Financing: January 2026 public offering

> “Completed an upsized public offering raising $345.1 million in gross proceeds in Jan 2026”
> “Completed closing of its upsized underwritten public offering of 20,297,500 shares of its common stock, including the full exercise of the underwriters’ option to purchase an additional 2,647,500 shares, at a price to the public of $17.00 per share”

Source: [Alumis press release, year end 2025 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000004/alms-20260319xex99d1.htm)

<a id="topic-2.1.1-20"></a>

##### Financing: at-the-market sales agreement of March 2026

> “On March 18, 2026, we entered into the Sales Agreement with Cantor as sales agent, pursuant to which we may offer and sell, from time to time through Cantor, at our option, the ATM Shares.”
> “The ATM Shares include shares of our common stock having an aggregate offering price of up to $300.0 million.”
> “As of the date of issuance of these financial statements, no ATM Shares have been sold under the Sales Agreement.”

Source: [Alumis Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000024/alms-20260930x10q.htm)

<a id="topic-2.1.1-21"></a>

##### Patent protection: composition of matter, crystalline and salt forms, and methods of treatment

> “In regard to envu and A-005, we own one patent family with claims directed to composition of matter and methods of use that includes five issued U.S. patents, one pending U.S. patent application, over fifteen granted foreign patents in Europe (each validated in over 35 countries), and certain other countries, and over 10 foreign patent applications pending in various jurisdictions, such as Europe and Japan.”
> “Not accounting for any patent term adjustment or extensions or terminal disclaimers, and assuming that all applicable annuity and/or maintenance fees are paid timely, the issued patents, and, if granted, the pending patent applications in this family, are expected to expire in 2039.”
> “We also own three patent families with claims directed to crystalline and salt forms of envu, which includes three pending U.S. applications, and over 30 foreign patent applications pending in various jurisdictions such as Europe and Japan.”
> “Not accounting for any patent term adjustment or extension and assuming that all applicable annuity and/or maintenance fees are paid timely, the patent applications, if issued, and any patent applications claiming the benefit of these PCT applications, if issued, will be expected to expire in 2043.”
> “We own one patent family with claims directed to methods of treating a TYK2-mediated disease using envu, that includes a pending U.S. application and over 10 foreign applications pending in various jurisdictions such as Europe and Japan.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

<a id="topic-2.1.1-22"></a>

##### Cumulative clinical exposure: more than 2,000 participants

> “Envu has been administered to more than 2,000 participants and in some cases administered for up to three years.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

<a id="topic-2.1.1-23"></a>

##### Japan dermatology rights licensed to Kaken Pharmaceutical, March 2025

> “On March 25, 2025 (the “Effective Date”), the Company entered into the Kaken Collaboration Agreement.”
> “Under the terms of the Kaken Collaboration Agreement, the Company granted to Kaken an exclusive right to develop, manufacture and commercialize envu for dermatology indications in Japan, with options to expand the license, subject to opt-in payments and certain cost-sharing obligations on the part of Kaken, to include rheumatological and gastrointestinal diseases.”

Source: [Alumis Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000024/alms-20260930x10q.htm)

> “Kaken will be responsible for the clinical development, regulatory approvals and commercialization of ESK-001 in Japan, and Alumis will retain rights to ESK-001 in all other geographies.”

Source: [Alumis and Kaken press release, collaboration and licensing agreement (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000110465925027444/tm2510181d1_ex99-1.htm)

<a id="topic-2.1.1-24"></a>

##### LUMUS phase 2b trial in systemic lupus erythematosus: topline results, September 2026

> “SOUTH SAN FRANCISCO, Calif., September 1, 2026 – Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that its Phase 2b LUMUS trial of envudeucitinib for the treatment of moderate-to-severe systemic lupus erythematosus (SLE) did not meet its primary and secondary endpoints in the overall trial population.”
> “In LUMUS, IFNGS-high patients were unexpectedly under-represented, reducing response rates in the overall trial population.”
> “We are actively evaluating opportunities to maximize the value of our oral TYK2 portfolio and remain on track to file an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of this year.”

Source: [Alumis press release, LUMUS topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926104145/tm2624540d1_ex99-1.htm)

> “Alumis plans to conduct end-of-Phase 2 regulatory interactions and evaluate development options.”

Source: [Alumis press release, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000022/alms-ex99d1.htm)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Alumis

> “Alumis has reported positive results from its Phase 3 ONWARD program of envudeucitinib in moderate-to-severe plaque psoriasis and plans to file an NDA in moderate-to-severe plaque psoriasis in the fourth quarter of 2026.”

Source: [Alumis press release, LUMUS topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926104145/tm2624540d1_ex99-1.htm)

<a id="topic-2.1.2.1-2"></a>

###### Nonproprietary name, former development code, and therapeutic class

> “We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (“TYK2”) inhibitors: envudeucitinib (“envu”), formerly known as ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (“CNS”) penetrant allosteric TYK2 inhibitor.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

<a id="topic-2.1.2.1-3"></a>

###### Substance names and development codes in the FDA substance registration record

| Field | Quoted record |
| --- | --- |
| Preferred substance name | “ENVUDEUCITINIB” |
| International Nonproprietary Name synonym | “envudeucitinib [INN]” |
| Development code synonym | “ESK-001” |
| Second development code synonym | “FTP-637” |
| Systematic chemical name synonym | “N-[4-[2-methoxy-3-[1-(trideuteriomethyl)-1,2,4-triazol-3-yl]anilino]-5-(3,3,3-trideuteriopropanoyl)-2-pyridinyl]cyclopropanecarboxamide” |

Source: [FDA UNII record for envudeucitinib](https://precision.fda.gov/uniisearch/srs/unii/KD2MDJ4GAB)

<a id="topic-2.1.2.1-4"></a>

###### Development code FTP-637 in the first-in-human registry record

| Field | Quoted record |
| --- | --- |
| Public title | “A 2-part, randomised, double-blind, placebo-controlled study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of FTP 637 in healthy volunteers.” |
| Primary sponsor name | “Alumis Inc (formerly Esker Therapeutics, Inc)” |

Source: [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

<a id="topic-2.1.2.1-5"></a>

###### Company names and acquisition of envudeucitinib

> “Alumis was incubated by Foresite Labs and incorporated on January 29, 2021, as a Delaware corporation under the name FL2021-001, Inc. FL2021-001, Inc.’s name was changed to Esker Therapeutics, Inc. in March 2021, and to Alumis Inc. in January 2022.”
> “For example, we were founded in January 2021, and subsequently acquired envu via a stock purchase of FronThera U.S. Holdings, Inc. and its wholly owned subsidiary, FronThera U.S. Pharmaceuticals LLC.”
> “On March 5, 2021, we entered into the FronThera Acquisition, and the transaction was accounted for as an asset acquisition.”
> “Additionally, we consummated the ACELYRIN Merger in May 2025 and acquired lonigutamab.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Film-coated immediate-release tablet containing 20 mg

> “ESK-001 was administered as film-coated immediate-release tablets containing 20 mg of ESK-001.”

Source: [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf)

<a id="topic-2.1.2.2-2"></a>

###### Immediate-release tablet as the current formulation

> “Currently formulated as an immediate-release tablet.”

Source: [Ucpinar et al. (2024a)](https://www.alumis.com/file.cfm/18/docs/alumis_pub_3_aad_poster_2024.pdf)

<a id="topic-2.1.2.2-3"></a>

###### Replacement of the liquid formulation by a tablet formulation

> “The liquid formulation of ESK‐001 used in the SAD and MAD study was replaced by a tablet formulation, which was used in the multiple‐dose (MD) study and is the intended dosage form to collect PD data.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-2.1.2.2-4"></a>

###### Once-daily formulation under development

> “Once-daily formulation and pediatric plan under development”

Source: [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf)

> “Modified release (once daily) formulation development ongoing”

Source: [Blauvelt et al. (2025a)](https://www.alumis.com/file.cfm/18/docs/aad2025_blauvelt_et_al_esk-001_52w_ole_vf.pdf)

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### Pharmacologic class stated by the manufacturer

> “Envu is a potent, highly selective, allosteric TYK2 inhibitor.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

<a id="topic-2.1.2.4-2"></a>

###### Proposed International Nonproprietary Name and class description

| Field | Quoted record |
| --- | --- |
| Proposed INN (Latin) | “envudeucitinibum” |
| Class description | “Janus kinase inhibitor, anti-inflammatory” |
| Class description (French) | “inhibiteur de la kinase de Janus, anti-inflammatoire” |

Source: [World Health Organization proposed INN list 130 (2023)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl130.pdf)

<a id="topic-2.1.2.4-3"></a>

###### Nonproprietary name stem -citinib

> “-citinib (see –tinib) Janus kinase inhibitors”

Source: [World Health Organization INN stem book (2024)](https://iris.who.int/server/api/core/bitstreams/a042b526-4e17-4f77-b437-42ce85e66219/content)

<a id="topic-2.1.2.4-4"></a>

###### Nomenclature and drug dictionary entries in the FDA substance registration record

| Field | Quoted record |
| --- | --- |
| Substance type | “INGREDIENT SUBSTANCE” |
| Molecular formula | “C22H24N6O3” |
| United States Adopted Name synonym | “ENVUDEUCITINIB [USAN]” |
| WHO Drug Dictionary synonym | “ESK 001 [WHO-DD]” |

Source: [FDA UNII record for envudeucitinib](https://precision.fda.gov/uniisearch/srs/unii/KD2MDJ4GAB)

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Indication proposed for the planned NDA

> “Alumis plans to present additional results from the ONWARD program at upcoming medical meetings and to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration seeking approval for envudeucitinib for the treatment of moderate-to-severe plaque psoriasis in the fourth quarter of this year.”

Source: [Alumis press release, ONWARD3 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_ex99-1.htm)

> “Alumis plans to submit a New Drug Application (NDA) to the FDA seeking approval for envudeucitinib for the treatment of moderate-to-severe plaque psoriasis in the fourth quarter of 2026.”

Source: [Alumis envudeucitinib for psoriasis page](https://www.alumis.com/pipeline/envudeucitinib-for-psoriasis/)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Allosteric inhibition of TYK2 through the pseudokinase (JH2) domain

> “In contrast, allosteric TYK2 inhibitors such as envudeucitinib achieve selectivity by binding to the pseudokinase JAK homology 2 (JH2) domain, a regulatory site unique to TYK2”
> “This binding induces a conformational change that prevents the activation of the catalytic JH1 domain, thereby functionally blocking ATP binding and TYK2 signaling”
> “Because the TYK2 JH2 domain is structurally distinct from the JH2 domains of other JAK family members, this allosteric mechanism (indirect inhibition) confers high selectivity for TYK2, preserving JAK 1/2/3 activity and reducing the risk of adverse events associated with classic JAK inhibition”

Source: [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)

> “ESK‐001 is a highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2), which plays an essential role in mediating cytokine signaling in multiple immune‐mediated diseases.”
> “Here, we describe ESK‐001, an orally available and highly selective allosteric TYK2 inhibitor binding to the JH2 domain of TYK2, which is being developed for the treatment of plaque psoriasis, SLE, and other immune‐mediated diseases.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-2.1.2.6.1-2"></a>

###### Cytokine pathways mediated by TYK2

> “TYK2 mediates downstream signaling of IL-23 as well as other cytokines, including IL-12 and type I interferons (IFNs)”
> “Thus, inhibition of TYK2 provides comprehensive targeting that reduces both the signaling and production of the proinflammatory cytokines central to psoriasis pathogenesis.”
> “Inhibition of TYK2 reduces production and inflammatory signaling of cytokines associated with psoriasis without affecting cytokines involved in immune pathways, lipid metabolism, and blood cell development.”

Source: [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)

<a id="topic-2.1.2.6.1-3"></a>

###### Selectivity for TYK2 over JAK1, JAK2, and JAK3

> “Due to envu’s design as an allosteric inhibitor, the molecule is both potent and intrinsically selective for TYK2 over other protein kinases, including the related JAK family members.”
> “No JAK-related pharmacology has been observed with envu to date.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

> “Preclinical studies showed that ESK‐001 was pharmacologically active and highly selective against TYK2 (50% inhibitory concentration [IC50] of 104–149 nM in human whole blood), and had no off‐target effects on other kinases (IC50 of >30,000 nM for JAK1‐3).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-2.1.2.6.1-4"></a>

###### Human whole-blood inhibitory concentrations by cytokine pathway

| Stimulus (kinase pathway) | Human whole blood IC50 (nM) |
| --- | --- |
| IFNα (TYK2) | “104” |
| IL-12 (TYK2) | “149” |
| IL-2 (JAK1/JAK3) | “>30,000” |
| TPO (JAK2) | “>30,000” |

Source: [Ucpinar et al. (2024a)](https://www.alumis.com/file.cfm/18/docs/alumis_pub_3_aad_poster_2024.pdf)

<a id="topic-2.1.2.6.1-5"></a>

###### Kinome selectivity and binding to the JH2 allosteric pocket

> “Exclusive binding of ESK-001 to the JH2 allosteric binding pocket avoids JAK kinase liabilities.”
> “Highly selective for TYK2: no off-target binding across kinome, no measurable JAK pharmacology.”
> “Only 2 of 468 kinases inhibited”
> “JAK1 JH2 domain (no functional consequence)”

Source: [Ucpinar et al. (2024a)](https://www.alumis.com/file.cfm/18/docs/alumis_pub_3_aad_poster_2024.pdf)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Maximal TYK2 inhibition over 24 hours with twice-daily dosing

> “Indeed, preclinical and phase 1 studies demonstrated that envudeucitinib twice daily achieves maximal TYK2 target inhibition (90% inhibitory concentration [IC90]) at clinically relevant doses over 24 h”

Source: [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)

> “Envu demonstrated a robust and predictable PK/PD relationship in Phase 1 studies, enabling the identification of a dose level that achieved maximal TYK2 inhibition for 24 hours a day to take into Phase 2 clinical trials.”
> “We define maximal inhibition as reaching the plateau of biological inhibition in the assay readout with no further impact seen with higher drug concentrations.”
> “At the 40 mg BID dose, maximal TYK2 inhibition was confirmed in healthy volunteer and PsO patient blood samples by RNA-seq analysis, and a return to non-lesional baseline levels of TYK2 pathway (including IFN signature, IL-23, IL-17) and PsO-relevant disease biomarkers was confirmed in PsO patient skin biopsies.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

<a id="topic-2.1.2.6.2-2"></a>

###### Preclinical inhibition of STAT phosphorylation and interferon-gamma production

> “Additionally, ESK‐001 significantly inhibited STAT phosphorylation and downstream IFNγ production stimulated by IL‐12, IL‐23, and IFNα in human whole blood and peripheral blood mononuclear cells in a concentration‐dependent manner.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-2.1.2.6.2-3"></a>

###### Blood biomarkers of TYK2 inhibition in healthy participants

> “ESK‐001 inhibited the downstream TYK2 pathway as shown by inhibition of pSTAT1 expression.”
> “Transcriptomic analysis of unstimulated whole blood samples confirmed dose‐dependent inhibition of Type I IFN‐induced genes and SIGLEC1, a novel TYK2‐responsive biomarker.”
> “By correlating PK exposure data with PD readouts, a strong PK/PD relationship was demonstrated.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

> “SIGLEC1 expression is a novel biomarker to assess TYK2 target inhibition”

Source: [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)

<a id="topic-2.1.2.6.2-4"></a>

###### Blood and skin biomarkers in the STRIDE phase 2 study

> “STRIDE Ph2 Blood RNA-seq of Trough Drug Levels Shows Dose-Dependent Type I IFN Gene Signature Inhibition, Findings Consistent with Ph1”
> “Phase 2 Blood RNA-seq of Novel TYK2-Responsive Marker, SIGLEC1, Confirms Full Target Inhibition”
> “Lesional Skin Levels of Key Cytokines & Disease Related Biomarkers Return to Non-lesional Levels”
> “ESK-001 maximally inhibits TYK2, demonstrated by biomarkers in blood and confirmed in skin”
> “ESK-001 returned key psoriasis disease biomarkers in lesional skin to baseline/non-lesional levels and improved histological outcomes”
> “Modulation of TYK2 pathway and disease-related biomarkers closely mirrored clinical outcomes.”

Source: [Tilley et al. (2024)](https://www.alumis.com/file.cfm/18/docs/final_eadv_2024_biomarker_oral_presentation.pdf)

<a id="topic-2.1.2.6.2-5"></a>

###### Circulating IL-23, IL-17A, and IL-22 in the STRIDE phase 2 study

> “Proteomic analysis showed reduced expression of blood biomarkers IL-23 and IL-17A after 12 weeks of ESK-001 treatment.”
> “ESK-001 40 mg QD and 40 mg BID reduced circulating IL-23 protein plasma levels by a median of nearly 100%.”
> “ESK-001 40 mg QD and 40 mg BID reduced circulating IL-22 levels by 0.99 and 2.1 log2 foldchange, respectively.”
> “Patients with high intrinsic IL-23 pathway expression were most likely to achieve high and rapid PASI75 response in the dose group with maximal target engagement (ESK-001 40 mg BID).”

Source: [Narayan et al. (2025)](https://www.alumis.com/file.cfm/18/docs/20250129_aad2025_pstr_biomarkers_final.pdf)

<a id="topic-2.1.2.6.2-6"></a>

###### Skin tape-strip transcriptomics and proteomics in a STRIDE subgroup

> “Placebo (N=10), envudeucitinib 40 mg once daily (QD) (N=10), and envudeucitinib 40 mg twice daily (BID) (N=8)”
> “Greatest molecular suppression was observed in the envudeucitinib 40 mg BID group, paralleling dose-dependent improvements in clinical scores.”
> “In moderate-to-severe plaque PsO, envudeucitinib achieved robust suppression of pathogenic IL-23 and IFN-related pathways at transcriptomic and proteomic levels, underscoring its potential as an effective therapeutic strategy.”
> “IL-36A expression was inhibited to non-lesional levels in skin punch biopsies of patients after envudeucitinib treatment, primarily in supraspinous keratinocyte layer”

Source: [Tilley et al. (2026)](https://www.alumis.com/file.cfm/613/docs/aad2026_biomarkers_final.pdf)

> “Both 40 mg QD and BID groups showed downregulation of immune gene expression, with significant decreases in Interferon-, Th1-, and Th17-related markers”
> “Gene set variation analysis of tape strip RNA-seq revealed greater molecular suppression in the 40 mg BID group at Week 12”
> “Clinical improvements were strongly correlated with transcript reductions of IFNG, IL22, IL17A, and key cytokines”

Source: [Zhou et al. (2025)](https://www.alumis.com/file.cfm/613/docs/isds_poster_final.pdf)

<a id="topic-2.1.2.6.2-7"></a>

###### Spatial transcriptomics of skin biopsies in a STRIDE subgroup

> “Subjects selected based on availability of baseline and week 12 biopsies: placebo (n=4) and envudeucitinib 40 mg twice daily (BID) (highest dose, n=5) are presented.”
> “In the Phase 2 STRIDE study, spatial transcriptomic analysis demonstrated that envudeucitinib robustly inhibited pathogenic IL-23 and IL-17 pathway signaling in PsO-relevant skin cell types, including keratinocytes and myeloid/T cell subsets”
> “Expression of CCL19, CCR7, and IL4I1 return to non-lesional levels after envudeucitinib treatment”
> “CCR7+IL4I1+ dendritic cells are primary producers of IL-23 in PsO.”

Source: [Narayan et al. (2026a)](https://www.alumis.com/file.cfm/613/docs/20260427_sid2026_pstr_biomarkers_final.pdf)

> “Subjects dosed with envudeucitinib enriched in non‐inflammatory supraspinous keratinocytes compared to subjects dosed with placebo.”
> “Envudeucitinib suppressed a pathologic inflammatory supraspinous keratinocyte state associated with aberrant differentiation in psoriasis skin.”

Source: [Narayan et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/eadv2026_biomarker-data-poster.pdf)

<a id="topic-2.1.2.6.2-8"></a>

###### Trough coverage of the IC90 and exposure-response in the STRIDE open-label extension

> “The 40-mg BID regimen achieved continuous IC90 coverage at trough over 24 hours, surpassing the in vitro human whole blood pSTAT-IFNα IC90 (144 ng/mL) and ensuring sustained TYK2 inhibition for optimal target engagement.”
> “Higher envudeucitinib exposures were associated with improved PASI outcomes, with patients achieving PASI-90 and PASI-100 showing greater mean exposures compared to those achieving PASI-75.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-2.1.2.6.2-9"></a>

###### Interferon-pathway target engagement in the LUMUS phase 2b lupus trial

> “Pharmacodynamic data from LUMUS confirmed robust dose-dependent interferon-pathway target engagement, with maximal suppression at the highest dose, 40 mg twice daily.”

Source: [Alumis press release, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000022/alms-ex99d1.htm)

<a id="topic-2.1.2.6.2-10"></a>

###### Cardiac repolarization: structural hypothesis

> “Moreover, the presence of a cyclopropyl carboxamide group on envudeucitinib is hypothesized to reduce human ether-a-go-go-related gene (hERG) and cardiac repolarization-associated safety concerns”

Source: [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Absorption, dose proportionality, accumulation, and steady state in healthy participants

> “ESK‐001 was rapidly absorbed with systemic exposures generally increasing dose‐proportionally across all cohorts.”
> “The mean terminal half‐life ranged from 8 to 13 h with no to minimal accumulation of ESK‐001 following q.d. doses and ~2‐fold accumulation following Q12 doses.”
> “Following both single (≤100 mg) and multiple (≤60 mg q.d. and ≤40 mg Q12) dose administration, ESK‐001 was rapidly absorbed into the systemic circulation and afterward eliminated in an approximately monoexponential manner with less than 1% renal excretion.”
> “The systemic exposure of ESK‐001 showed linear dose‐dependent PK characteristics across the dose range, with steady state achieved by 3–5 days.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-2.1.2.6.3-2"></a>

###### Physicochemical properties, permeability, and tissue distribution

> “ESK‐001 was designed to deliver best‐in‐class pharmacokinetics (PK), including rapid absorption, low PK variability, high permeability with no efflux, and good penetration into relevant tissues.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

> “Molecular weight <500 g/mol.”
> “Low polar surface area.”

Source: [Ucpinar et al. (2024a)](https://www.alumis.com/file.cfm/18/docs/alumis_pub_3_aad_poster_2024.pdf)

> “Envu is highly permeable with low efflux resulting in high and rapid systemic absorption and favorable tissue distribution in vivo.”
> “These properties result in its highly predictable, linear PK profile in humans with low variability.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

<a id="topic-2.1.2.6.3-3"></a>

###### Elimination half-life as stated by the manufacturer and a narrative review

> “In addition, envu has a desirable half-life in humans of approximately 8 to 12 hours and we have not observed any concerns for drug-drug interactions with other therapies.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

> “Envudeucitinib demonstrated a favorable pharmacokinetic profile characterized by rapid absorption, an elimination half-life of approximately 8 h, a dose-proportional increase in exposure, minimal renal clearance, and low interindividual variability”

Source: [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)

<a id="topic-2.1.2.6.3-4"></a>

###### Hepatic clearance, metabolites, and deuteration

> “Envudeucitinib is primarily cleared through hepatic metabolism”
> “Studies evaluating absorption, distribution, metabolism, and excretion of envudeucitinib in healthy volunteers identified one major and seven minor metabolites (data on file).”
> “The major metabolite is pharmacologically inactive with no significant off-target effects; minor metabolites contribute minimally to the overall pharmacologic activity of envudeucitinib (data on file).”
> “Envudeucitinib includes a deuterated methyl triazole moiety that may enhance its metabolic stability by reducing cytochrome P450 1A2 (CYP1A2)-mediated demethylation, mitigating potential metabolite-driven off-target effects, and maximizing the pharmacodynamic response.”

Source: [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)

<a id="topic-2.1.2.6.3-5"></a>

###### Linear kinetics in participants with psoriasis

> “Envudeucitinib demonstrated consistent, dose-proportional linear kinetics with low interindividual variability in patients with psoriasis”

Source: [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)

<a id="topic-2.1.2.6.3-6"></a>

###### Peak and steady-state trough concentrations in the STRIDE open-label extension

> “On day 1 post-dose, mean plasma concentrations reached approximately 200 ng/mL around 2 hours after drug administration.”
> “At week 16, mean steady-state Ctrough levels were approximately 54 ng/mL for the 40-mg QD dose and 170 ng/mL for the 40-mg BID dose.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Females and males of reproductive potential: contraception requirements in the STRIDE protocol

> “Highly effective methods of birth control are defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly.”
> “Note: Hormonal contraception must be supplemented with another form of contraception that may include but is not limited to another form of highly effective contraception (e.g., IUD) or other barrier methods (such as male condom plus spermicide or female diaphragm).”
> “Women who have not menstruated for at least 12 months and with follicle-stimulating hormone (FSH) levels ≥30 mIU/mL will be considered postmenopausal and will not be required to use contraception.”
> “Men must agree to use two acceptable methods of contraception (e.g., condom plus spermicide), at least one of which must be a barrier method for the entire duration of the study, and for 3 months following last study drug administration.”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Envudeucitinib

<a id="topic-2.1.2.9.1-1"></a>

###### Overall drug interaction potential from in vitro and clinical studies

> “Completed in vitro and clinical drug–drug interaction (DDI) studies demonstrated a low potential for clinically relevant DDI with envudeucitinib (data on file).”

Source: [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Envudeucitinib on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### Drug interaction potential of the major metabolite

> “Further, in vitro and clinical DDI studies indicate that the major metabolite has minimal potential for DDI interactions.”

Source: [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)

<a id="topic-2.1.2.9.2-2"></a>

###### Drug interaction potential stated by the manufacturer for combination therapy

> “We believe that envu’s pharmacological properties, including its lack of drug-drug interaction potential and its clinical profile, positions it well as a partner for future combination therapies.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

<a id="topic-2.1.2.9.2-3"></a>

###### Phase 1 interaction study with metformin and paroxetine: research ethics committee record

| Field | Quoted record |
| --- | --- |
| Study title | “Phase 1 Study on impact of ESK-001 PK on Metformin and Paroxetine in Healthy Participants” |
| IRAS ID | “1012125” |
| REC name | “North East - York Research Ethics Committee” |
| REC reference | “25/NE/0105” |
| Date of REC Opinion | “14 Jul 2025” |
| REC opinion | “Further Information Favourable Opinion” |
| Research summary | “Publication of this data is currently deferred.” |

Source: [Health Research Authority research summary, ESK-001 metformin and paroxetine study (2025)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/phase-1-study-on-impact-of-esk-001-pk-on-metformin-and-paroxetine-in-healthy-participants/)

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Selection of 40 mg twice daily for the phase 3 trials

> “Additional data presented show that the 40 mg twice daily dose, which achieves maximal target inhibition according to blood and skin biopsy biomarkers, leads to the highest response rates.”
> “These findings support use of the 40 mg twice daily dose in the ongoing Phase 3 clinical program.”

Source: [Alumis press release, third quarter 2024 results (2024)](https://www.sec.gov/Archives/edgar/data/1847367/000110465924117704/tm2428191d1_ex99-1.htm)

<a id="topic-2.1.2.10.1-2"></a>

###### Once-daily modified-release formulation in development to replace twice-daily dosing

> “In parallel with the Phase 3 clinical program, Alumis is developing a once-daily modified release oral formulation of ESK-001 designed to replace the current immediate release oral formulation that is dosed twice daily.”

Source: [Alumis press release, AAD 2025 OLE data (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000110465925021990/tm258686d1_ex99-1.htm)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Administration with or without food

> “Envudeucitinib has been administered with or without food, with no fasting requirement.”

Source: [Alumis press release, Fall Clinical 2026 ONWARD data (2026)](https://investors.alumis.com/news-releases/news-release-details/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib)

> “PK analyses showed no clinically significant food effect on envudeucitinib.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

> “and food interaction studies indicate that envudeucitinib may be taken with or without food”

Source: [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)

> “Study drug can be taken with or without food.”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-2.1.2.10.2-2"></a>

###### Overdose management in the STRIDE protocol

> “Standard symptomatic support measures should be used in the case of excessive pharmacological effects or overdose.”
> “No antidotes are available.”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Launch preparation and commercial infrastructure

> “The increase was primarily attributable to costs related to launch preparation efforts and an increase in personnel-related expenses for the quarter ended September 30, 2026, partially offset by severance and transaction costs related to the merger with ACELYRIN, Inc. and legal costs in the quarter ended September 30, 2025.”

Source: [Alumis press release, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000022/alms-ex99d1.htm)

> “Given our stage of development, we do not yet have a fully established marketing or sales organization or commercial infrastructure; however, we have begun building foundational capabilities and intend to continue expanding the necessary sales, marketing and commercialization capabilities and infrastructure over time as our product candidates advance through clinical development and regulatory approval.”
> “Professional consulting services expenses increased by $0.4 million, to $8.4 million for the three months ended September 30, 2026, from $8.0 million for the three months ended September 30, 2025, primarily due to an increase in costs to support our launch preparation efforts, partially offset by legal expenses and other costs incurred in the prior year.”
> “procure manufacturing and supply chain capacity for our product candidates, including commercial manufacturing readiness and scale-up;”
> “take steps toward our goal of being an integrated biopharma company capable of supporting commercial activities, including establishing sales, marketing and distribution infrastructure;”

Source: [Alumis Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000024/alms-20260930x10q.htm)

> “With our fourth-quarter 2026 NDA submission firmly on track, our organization is focused on regulatory execution and building the foundation designed to bring this next-generation therapy to patients.”

Source: [Alumis press release, Fall Clinical 2026 ONWARD data (2026)](https://investors.alumis.com/news-releases/news-release-details/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib)

<a id="topic-2.1.2.11-2"></a>

###### Appointment of a Chief Commercial Officer

> “Jack Danilkowicz was appointed as Chief Commercial Officer bringing extensive experience successfully planning and executing commercial strategies at global biopharmaceutical companies.”

Source: [Alumis press release, year end 2024 results (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000010/tmb-20250319xex99d1.htm)

<a id="topic-2.1.2.11-3"></a>

###### Commercialization plans in the United States, the European Union, and Asia-Pacific

> “Given our stage of development, we have not yet established a full commercial organization or distribution capabilities.”
> “We have stage-appropriate commercial capabilities and we intend to build a commercial infrastructure to support sales of any approved products.”
> “In addition, we intend to commercialize our product candidates, if approved, in key markets in the United States, the European Union (“EU”) and APAC, either alone or with partners in order to maximize the worldwide commercial potential of our programs.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

<a id="topic-2.1.2.11-4"></a>

###### Contract manufacturing, redundant supply chain, and distribution of investigational product

> “We are in the process of implementing a redundant supply chain for envu API, drug product and critical raw material.”
> “Additional contract manufacturers are used to package, label, and distribute investigational drug products.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

<a id="topic-2.1.2.11-5"></a>

###### Distribution agreements and logistics required after approval

> “If approved for marketing by applicable regulatory authorities, our ability to generate revenue from our product candidates will depend on our ability to:”
> “establish and maintain agreements with wholesalers, distributors, pharmacies and group purchasing organizations on commercially reasonable terms;”
> “maintain a distribution and logistics network capable of product storage within our specifications and regulatory guidelines, and further capable of timely product delivery to commercial clinical sites; and”

Source: [Alumis Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000024/alms-20260930x10q.htm)

<a id="topic-2.1.2.11-6"></a>

###### Expanded access policy

> “Currently, production of our investigational drugs is limited to accommodate participants in clinical trials and therefore, Alumis does not offer expanded access.”
> “As we are not currently accepting expanded access requests for our investigational drug, we do not have a procedure for making an expanded access request or contact information for such requests.”
> “Alumis may review and update this policy over time as more clinical data becomes available.”

Source: [Alumis expanded access policy page](https://www.alumis.com/patients/expanded-access/)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Prohibited treatments and washout periods in the STRIDE protocol

| Treatment category | Examples | Washout period before randomization |
| --- | --- | --- |
| “Topical medications or treatments that could affect psoriasis evaluation” | “corticosteroids, anthralin, calcipotriene, vitamin D derivatives, retinoids” | “2 weeks” |
| “Phototherapy or systemic medications or treatments that could affect psoriasis evaluation” | “oral or injectable corticosteroids, retinoids, 1,25-dihydroxy vitamin D3” | “4 weeks” |
| “Therapeutic agents targeted to IL-12 or IL-23” | “ustekinumab, guselkumab, tildrakizumab, risankizumab” | “6 months” |
| “Therapeutic agents targeted to IL-17” | “secukinumab, ixekizumab, brodalumab” | “4 months” |
| “TNFα inhibitors” | “etanercept, infliximab, adalimumab” | “2 months” |
| “Systemic immunosuppressants or immunomodulatory drugs” | “corticosteroids (oral/IV/IM/SC), methotrexate, azathioprine, cyclosporine, mycophenolate mofetil” | “4 weeks or 5 half-lives” |
| “Agents that modulate B cells” | “rituximab, ocrelizumab” | “6 months” |
| “Agents that modulate T cells” | “abatacept, alemtuzumab” | “3 months” |
| “JAK inhibitors or TYK2 inhibitors” | “baricitinib, tofacitinib, upadacitinib, ruxolitinib, fedratinib, deucravacitinib” | “4 weeks” |
| “Investigational agents” |  | “30 days or 5 half-lives” |
| “Proton pump inhibitors” | “omeperazole, esomeprazole, pantoprazole” | “Prior to Study Day 1” |

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-2.1.2.12-2"></a>

###### Duration of the medication restrictions and recording of concomitant medications in the STRIDE protocol

> “Medication and treatment restrictions applicable before the dosing period are listed as exclusion criteria in Section 5.3. These restrictions are applicable for the duration of the study and are summarized in Table 2.”
> “Prior and concomitant medication as well as vaccination use after screening will be recorded on the prior and concomitant eCRF.”
> “Prior medications should be collected from the past 10 years.”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-2.1.2.12-3"></a>

###### Acid-reducing agents and antiviral medications in the STRIDE protocol

> “The use of Proton Pump Inhibitors (PPIs) are not permitted on study due to the potential to decrease ESK-001 exposure.”
> “However, the use of H2 blockers (e.g., famotidine or ranitidine) and calcium carbonate-containing antacids (eg, Tums”
> “are allowed during the study but should be taken at least 2 hours after a dose of study drug.”
> “Based on in vitro assessments, ESK-001 has the potential for drug-drug interaction with antiviral medications metabolized through CYP3A4, CYP2D6 and P-gp pathways (eg, Paxlovid [nirmatrelvir + ritonavir]).”
> “The benefit:risk assessment for administration of anti-viral medications with a narrow therapeutic index should be discussed with the medical monitor whenever possible.”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-2.1.2.12-4"></a>

###### Permitted vaccinations and dietary restrictions in the STRIDE protocol

> “Inactivated vaccines (including but not limited to COVID-19 vaccines and boosters) will be allowed while on study.”
> “Foods such as star fruit juice, Seville orange juice, and grapefruit juice that are strong to moderate inhibitors of P450 (CYP) 3A4 should be avoided.”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="topic-2.1.2.12-5"></a>

###### Discontinuation of study drug for new chronic psoriasis medication in the STRIDE protocol

> “Patients should discontinue study drug for any of the following reasons:”
> “Use of any medication, intended to chronically treat psoriasis (refer to Section 6.12.2), other than those documented at screening”

Source: [Alumis STRIDE protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/Prot_000.pdf)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Envudeucitinib on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### MIPS Quality ID 410: description, measure type, and denominator

> “Percentage of psoriasis vulgaris patients receiving systemic medication who meet minimal physician-or patient- reported disease activity levels.”
> “All patients with a diagnosis of psoriasis vulgaris and treated with a systemic medication.”
> “For this measure, the patient must ONLY be diagnosed with psoriasis vulgaris (L40.0) and no other concurrent psoriasis diagnosis.”
> “Therefore, patients meet criteria when they have been diagnosed with psoriasis vulgaris AND are on a systemic medication PRESCRIBED BY THE PROVIDER BEING EVALUATED FOR THE MEASURE.”
> “For the purposes of MIPS implementation, this patient-intermediate measure is submitted a minimum of once per patient during the performance period.”

Source: [CMS MIPS Quality ID 410 specification (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_410_MIPSCQM.pdf)

| Field | Specification text |
| --- | --- |
| Measure type | “Intermediate Outcome – High Priority” |
| Telehealth | “TELEHEALTH ELIGIBLE: This measure is appropriate for and applicable to the telehealth setting.” |

Source: [CMS MIPS Quality ID 410 specification (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_410_MIPSCQM.pdf)

<a id="topic-2.1.2.13-2"></a>

###### MIPS Quality ID 410: numerator benchmarks for PGA, BSA, PASI, and DLQI

> “Patients who have a documented physician global assessment (PGA; 5-point OR 6-point scale), body surface area (BSA), psoriasis area and severity index (PASI) and/or dermatology life quality index (DLQI) that meet any one of the below specified benchmarks.”
> “To satisfy this measure, a patient must achieve any ONE of the following:”

Source: [CMS MIPS Quality ID 410 specification (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_410_MIPSCQM.pdf)

| Instrument | Numerator benchmark |
| --- | --- |
| PGA | “PGA (5-point OR 6-point scale) ≤ 2 (clear to mild skin disease)” |
| BSA | “BSA < 3% (mild disease)” |
| PASI | “PASI < 3 (no or minimal disease)” |
| DLQI | “DLQI ≤ 5 (no effect or small effect on patient’s quality of life)” |

Source: [CMS MIPS Quality ID 410 specification (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_410_MIPSCQM.pdf)

<a id="topic-2.1.2.13-3"></a>

###### MIPS Quality ID 410: six-month treatment period and denominator exception

> “Consecutive Months – The consecutive treatment allows gaps in the medication treatment up to a total of 4 weeks during the 6 month period.”
> “Documentation that the patient declined change in medication or alternative therapies were unavailable, has documented contraindications, or has not been treated with a systemic medication for at least six consecutive months (e.g., experienced adverse effects or lack of efficacy with all other therapy options) in order to achieve better disease control as measured by PGA, BSA, PASI, or DLQI (G9765)”

Source: [CMS MIPS Quality ID 410 specification (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_410_MIPSCQM.pdf)

<a id="topic-2.1.2.13-4"></a>

###### MIPS Quality ID 410: reference list of systemic medications, oral agents

> “Denominator Criteria for Systemic Medication [G9764] may be defined by the following examples, however, other medications that meet the intent of this component may also be used:”

Source: [CMS MIPS Quality ID 410 specification (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_410_MIPSCQM.pdf)

| Brand name | Chemical name | Mechanism of action or type of systemic | Indication |
| --- | --- | --- | --- |
| Sotyktu | “deucravacitinib” | “Inhibits tyrosine kinase 2 (TYK2)” | “Psoriasis” |
| Otezla | “apremilast” | “Blocks phosphodiesterase-4” | “Psoriasis, Psoriatic arthritis” |
| Neoral | “cyclosporine, modified” | “Blocks lymphocytes (T cells) and lymphokines” | “Psoriasis” |
| Jylamvo | “methotrexate” | “Inhibits dihydrofolic acid reductase” | “Psoriasis” |
| Soriatane | “acitretin” | “Unknown; activates retinoid receptors” | “Psoriasis” |

Source: [CMS MIPS Quality ID 410 specification (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_410_MIPSCQM.pdf)

<a id="topic-2.1.2.13-5"></a>

###### MIPS Quality ID 410: rationale and clinical recommendation statements on treatment goals

> “A significant proportion of psoriasis patients who are receiving treatment remain unsatisfied with their therapies due to various reasons including lack of or loss of efficacy, side effects, and inconvenience, among others.”
> “Treatment dissatisfaction also contributes to patients discontinuing their medication.”
> “Treatment goals (assessment after 10 to 16 weeks, and every 8 weeks thereafter): PASI 75 or PGA of ‘clear’ or ‘almost clear’; or DLQI of 0 or 1 (Pathirana, 2009).”
> “Minimum efficiency (‘lowest hurdle’): PASI 50; DLQI<5 or improvement by at least 5 points (Pathirana, 2009).”
> “Treatment ‘success’ defined as PASI 75 response (or PASI 50 response and DLQI≤5) (Baker, 2013).”

Source: [CMS MIPS Quality ID 410 specification (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_410_MIPSCQM.pdf)

<a id="topic-2.1.2.13-6"></a>

###### MIPS Quality ID 485: description, measure type, denominator, and numerator for itch severity

> “The percentage of patients aged 8 years and older, with a diagnosis of psoriasis where at an initial (index) visit have a patient-reported itch severity assessment performed, score greater than or equal to 4, and who achieve a score reduction of 3 or more points at a follow-up visit.”
> “Patients who achieve an assessment score that is reduced by 3 or more points (minimal clinically important difference) from the initial (index) assessment score.”
> “To successfully report this measure, the physician(s) and/or provider(s) of the same clinical practice must use the same assessment tool for both the initial (index) AND follow-up assessments using one of the validated tools (NRS, VRS, or ItchyQuant).”
> “For the purposes of MIPS implementation, this visit measure is submitted each time a patient has a denominator eligible encounter during the performance period.”

Source: [CMS MIPS Quality ID 485 specification (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_485_MIPSCQM.pdf)

| Field | Specification text |
| --- | --- |
| Measure type | “Patient-Reported Outcome-based Performance Measure – High Priority” |
| Age | “Patients aged ≥ 8 years on the date of the encounter” |
| Diagnosis codes | “Diagnosis of psoriasis on the date of the encounter (ICD-10-CM): L40.0, L40.1, L40.2, L40.3, L40.4, L40.8, L40.9” |
| Encounters | “At least two patient encounters during the performance period” |
| Index itch score | “Initial (index visit) Numeric Rating Scale (NRS), Visual Rating Scale (VRS), or ItchyQuant assessment score of greater than or equal to 4” |

Source: [CMS MIPS Quality ID 485 specification (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_485_MIPSCQM.pdf)

<a id="topic-2.1.2.13-7"></a>

###### MIPS Quality ID 485: rationale on pruritus in psoriasis

> “Psoriasis is a chronic inflammatory disease in which pruritus is a frequent symptom.”
> “Chronic inflammatory skin diseases, such as psoriasis, are pruritic and tremendously burdensome; with more than 70 percent of psoriasis patients suffering from itch (Reich,2016).”
> “Recommendation: Pruritus is a significant symptom of psoriasis. An itch severity assessment is recommended to appropriately assess the degree of pruritus when present.”

Source: [CMS MIPS Quality ID 485 specification (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_485_MIPSCQM.pdf)

<a id="topic-2.1.2.13-8"></a>

###### QCDR measure AAD15: appropriate assessment and treatment of severe psoriasis

| Field | Specification text |
| --- | --- |
| Measure description | “Percentage of patients with a diagnosis of psoriasis with a documented Body Surface Area (BSA) greater than 10% for whom phototherapy or an oral systemic or biologic medication was prescribed.” |
| Denominator | “All patients regardless of age with a diagnosis of psoriasis.” |
| Numerator | “Performance Met: Patient with a documented BSA greater than 10% is prescribed phototherapy or an oral systemic or biologic medication.” |
| Denominator exceptions | “Patient declines treatment with phototherapy or an oral systemic or biologic medication; patient has contraindication(s) to therapy” |

Source: [CMS 2026 QCDR measure specifications (2026)](https://qpp-cm-prod-content.s3.amazonaws.com/uploads/3573/2026_QCDR_Measure_Specifications.xlsx)

<a id="topic-2.1.2.13-9"></a>

###### QCDR measure AAD8: patient-reported quality of life in chronic skin conditions including psoriasis

| Field | Specification text |
| --- | --- |
| Measure title | “Chronic Skin Conditions: Patient Reported Quality-of-Life” |
| Measure description | “The percentage of patients aged 18 years and older with a chronic skin condition whose self-assessed quality-of-life was recorded at least once in the medical record within the measurement period.” |
| Numerator | “Patients who have a patient-reported quality-of-life assessment completed AND recorded in the medical record with a care plan* at least once within the 12-month measurement period.” |
| Conditions included | “Common conditions such as psoriasis, dermatitis, acne, rosacea, and urticaria are included because of the impact they have on patient's health and well-being.” |

Source: [CMS 2026 QCDR measure specifications (2026)](https://qpp-cm-prod-content.s3.amazonaws.com/uploads/3573/2026_QCDR_Measure_Specifications.xlsx)

<a id="topic-2.1.2.13-10"></a>

###### HEDIS and NCQA measures for psoriasis

No evidence found.

<a id="topic-2.1.2.13-11"></a>

###### Product-specific effect of envudeucitinib on quality measure performance

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Manufacturer statement of competitive factors and comparator classes

> “We believe the key competitive factors that will affect the development and commercial success of our product candidates, if approved, will be efficacy, safety, tolerability profile, convenience of dosing, price and coverage by governmental and third-party payors.”
> “If approved, envu would compete with several currently approved or late-stage oral clinical therapeutics in each such indication as well as other drugs used to treat such patients.”
> “To compete successfully, we need to disrupt these currently marketed drugs, meaning that we will have to demonstrate that the relative cost, method of administration, safety, tolerability and efficacy of our product candidates provide a better alternative to existing and new therapies.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

<a id="topic-2.1.2.14-2"></a>

###### Dosage forms, dosing frequency, and administration: deucravacitinib, apremilast, and icotrokinra labels

| Feature | Deucravacitinib label text |
| --- | --- |
| Dosage form and strength | “SOTYKTU (deucravacitinib) tablets are supplied in 6 mg strength for oral administration.” |
| Accumulation with once-daily dosing | “The accumulation of deucravacitinib was <1.4-fold following once daily dosing in healthy subjects.” |
| Tablet handling | “Do not crush, cut, or chew the tablets.” |
| Food | “No clinically significant differences in the pharmacokinetics of deucravacitinib were observed following administration of a high-fat, high-calorie meal” |

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

| Feature | Apremilast label text |
| --- | --- |
| Dosage forms and strengths, immediate release | “OTEZLA (apremilast) tablets are supplied in 10 mg, 20 mg, and 30 mg strengths for oral administration.” |
| Dosage form and strength, extended release | “OTEZLA XR (apremilast) extended-release tablets are supplied in a 75 mg strength for oral administration.” |
| Switching between twice-daily and once-daily formulations | “Patients treated with OTEZLA 30 mg twice daily may be switched to OTEZLA XR 75 mg once daily the day following the last dose of OTEZLA 30 mg.” |
| Food | “Administer OTEZLA/OTEZLA XR with or without food.” |
| Tablet handling | “Swallow tablets whole. Do not crush, split, or chew.” |

Source: [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf)

| Feature | Icotrokinra label text |
| --- | --- |
| Dosage form and strength | “Tablets: 200 mg of icotrokinra, yellowish orange to yellowish brown, oval, film-coated tablets” |
| Tablet handling | “Swallow ICOTYDE whole. Do not crush, split, or chew tablets” |
| Alternative administration | “ICOTYDE 200 mg tablet can also be dispersed in water using the following instructions:” |
| Missed dose | “If a patient misses a dose, instruct patients to take the missed dose as soon as possible with a return to normal dosing schedule the following day.” |
| Food effect | “Icotrokinra AUC decreased by 43% and Cmax decreased by 59% following administration with a high-fat meal (1000 calories, 50% fat)” |

Source: [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

<a id="topic-2.1.2.14-3"></a>

###### Elimination half-life, steady state, and metabolism: deucravacitinib, apremilast, and icotrokinra labels

| Parameter | Deucravacitinib label text |
| --- | --- |
| Half-life | “The terminal half-life of deucravacitinib was 10 hours.” |
| Active metabolite | “The active deucravacitinib metabolite, BMT-153261, has comparable potency to the parent drug” |
| Metabolic pathways | “Deucravacitinib is also metabolized by CYP2B6, CYP2D6, carboxylesterase (CES) 2, and uridine glucuronyl transferase (UGT) 1A9.” |

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

| Parameter | Apremilast label text |
| --- | --- |
| Half-life | “The plasma clearance of apremilast is about 10 L/hr in healthy subjects, with a terminal elimination half-life of approximately 6-9 hours.” |
| Metabolic pathways | “In vitro, CYP metabolism of apremilast is primarily mediated by CYP3A4, with minor contributions from CYP1A2 and CYP2A6.” |

Source: [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf)

| Parameter | Icotrokinra label text |
| --- | --- |
| Half-life | “Icotrokinra median elimination half-life is 12 hours with an apparent (oral) clearance of 6550 L/h.” |
| Steady state | “Icotrokinra steady state is reached in approximately 3 days.” |
| Metabolism | “Icotrokinra is a peptide and it is metabolized by peptide catabolism into smaller peptides.” |

Source: [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

<a id="topic-2.1.2.14-4"></a>

###### Contraindications and hypersensitivity: deucravacitinib, apremilast, and icotrokinra labels

| Feature | Deucravacitinib label text |
| --- | --- |
| Contraindication | “SOTYKTU is contraindicated in patients with a history of hypersensitivity reaction to deucravacitinib or to any of the excipients in SOTYKTU” |
| Hypersensitivity | “Hypersensitivity reactions, such as angioedema, have been reported in subjects receiving SOTYKTU.” |

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

| Feature | Apremilast label text |
| --- | --- |
| Contraindication | “OTEZLA/OTEZLA XR is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation” |
| Hypersensitivity | “Hypersensitivity reactions, including cases of angioedema and anaphylaxis, have been reported during post marketing surveillance.” |

Source: [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf)

| Feature | Icotrokinra label text |
| --- | --- |
| Contraindications | “None.” |

Source: [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

<a id="topic-2.1.2.14-5"></a>

###### Infection, hepatitis, and immunization requirements: deucravacitinib and icotrokinra labels

| Requirement | Deucravacitinib label text |
| --- | --- |
| Active infection | “Avoid use of SOTYKTU in patients with an active or serious infection.” |
| Viral hepatitis screening | “Consider viral hepatitis screening and monitoring for reactivation in accordance with clinical guidelines before starting therapy and during therapy with SOTYKTU.” |
| Active hepatitis | “SOTYKTU is not recommended for use in patients with active hepatitis B or hepatitis C.” |
| Immunizations before treatment | “Prior to initiating therapy with SOTYKTU, complete all age-appropriate immunizations according to current immunization guidelines including prophylactic herpes zoster vaccination.” |
| Live vaccines | “Avoid use of live vaccines in patients treated with SOTYKTU.” |

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

| Requirement | Icotrokinra label text |
| --- | --- |
| Infection risk | “Medicines that interact with the immune system may increase the risk of infection.” |
| Active infection | “Avoid treatment with ICOTYDE in patients with any clinically important active infection until the infection resolves or is adequately treated.” |
| Tuberculosis monitoring | “Monitor patients for signs and symptoms of active TB during and after ICOTYDE treatment.” |
| Active tuberculosis | “Avoid administering ICOTYDE to patients with active TB.” |
| Immunizations before treatment | “Prior to initiating therapy with ICOTYDE, complete immunizations according to current immunization guidelines.” |
| Vaccine response | “No data are available on the response to live or inactive vaccines.” |

Source: [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

<a id="topic-2.1.2.14-6"></a>

###### Pretreatment screening requirements of deucravacitinib and apremilast

> “Before initiating treatment, patients should be screened for tuberculosis (TB) and viral hepatitis, which is not required, for example, before starting apremilast”

Source: [Andrzejczak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13029673/)

> “Before initiating treatment, screening for tuberculosis, viral hepatitis, and HIV is recommended.”
> “Vaccination status should also be reviewed, and baseline assessment of triglycerides, liver transaminases, and creatine phosphokinase levels should be performed prior to treatment initiation”

Source: [De Luca et al. (2026)](https://link.springer.com/article/10.1007/s40257-026-01095-2)

<a id="topic-2.1.2.14-7"></a>

###### Laboratory and clinical monitoring: deucravacitinib, apremilast, and icotrokinra labels

| Monitoring item | Deucravacitinib label text |
| --- | --- |
| Liver enzymes | “Evaluate liver enzymes at baseline and during SOTYKTU treatment in patients with known or suspected liver disease.” |
| Creatine phosphokinase | “Discontinue SOTYKTU if markedly elevated CPK levels occur or myopathy is diagnosed or suspected.” |
| Triglyceride change | “Mean triglycerides increased by 10.3 mg/dL during the 16-week treatment period in subjects treated with SOTYKTU and by 9.1 mg/dL during the 52-week treatment period.” |
| Alanine aminotransferase | “ALT elevations ≥3 times the ULN was reported in 9 subjects (3.6 per 100 patient-years) treated with SOTYKTU, and 2 subjects (1.6 per 100 patient-years) treated with placebo.” |
| Malignancy | “Malignancies, including lymphomas, were observed in clinical trials with SOTYKTU” |

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

| Monitoring item | Apremilast label text |
| --- | --- |
| Body weight | “Regularly monitor the weight of patients treated with OTEZLA/OTEZLA XR.” |
| Weight decrease of 10% or more | “Weight decrease of ≥ 10% of body weight occurred in 2% (16/784) of subjects treated with OTEZLA 30 mg twice daily compared to 1% (3/382) subjects treated with placebo.” |
| Gastrointestinal events | “There have been reports of severe diarrhea, nausea, and vomiting associated with the use of OTEZLA.” |
| Timing of gastrointestinal events | “Most events occurred within the first few weeks of treatment. In some cases, patients were hospitalized.” |
| Older adults | “Because patients 65 years of age or older may be at a higher risk of complications such as volume depletion or hypotension from severe diarrhea, nausea, or vomiting, monitor geriatric patients closely for such complications” |

Source: [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf)

| Monitoring item | Icotrokinra label text |
| --- | --- |
| Reduced renal function | “Monitor for potential adverse reactions when ICOTYDE is used in patients with an estimated glomerular filtration rate (eGFR) <60 mL/min” |
| Anti-drug antibodies | “In four Phase 3 clinical studies through Week 52, 9.6% (199/2083) of subjects treated with ICOTYDE developed anti-drug antibodies.” |
| Neutralizing antibodies | “No neutralizing antibodies were detected.” |

Source: [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

> “Adverse reactions that occurred in < 1% of subjects in the ICOTYDE group and at a higher rate than in the placebo group through Week 16 in Trials PSO-1, PSO-2, PSO-3, and PSO-4 were: gastritis, abdominal discomfort, and one fatal case involving upper gastrointestinal bleeding in a subject with underlying risk factors.”
> “A relationship of this event to ICOTYDE is not established.”

Source: [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

<a id="topic-2.1.2.14-8"></a>

###### Drug interactions: deucravacitinib, apremilast, and icotrokinra labels

| Interaction | Deucravacitinib label text |
| --- | --- |
| Effect on coadministered drugs | “No clinically significant differences in the pharmacokinetics of the following drugs were observed when concomitantly administered with deucravacitinib: Rosuvastatin, methotrexate, mycophenolate mofetil (MMF), metformin and oral contraceptives (norethindrone acetate and ethinyl estradiol).” |
| Cytochrome P450 inhibition | “Deucravacitinib is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4.” |

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

| Interaction | Apremilast label text |
| --- | --- |
| Strong CYP450 inducers | “Co-administration with strong CYP450 inducers (such as rifampin) decreases apremilast exposure and may result in loss of efficacy of OTEZLA/OTEZLA XR” |

Source: [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf)

| Interaction | Icotrokinra label text |
| --- | --- |
| Clinical interaction studies | “No formal drug-drug interaction studies have been conducted with icotrokinra. No clinically significant drug interactions have been identified.” |
| Cytochrome P450 enzymes | “Icotrokinra does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4.” |

Source: [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

<a id="topic-2.1.2.14-9"></a>

###### Pregnancy, lactation, pediatric use, and geriatric use: deucravacitinib, apremilast, and icotrokinra labels

| Population | Deucravacitinib label text |
| --- | --- |
| Pregnancy | “Available data from case reports on SOTYKTU use during pregnancy are insufficient to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.” |
| Lactation | “There are no data on the presence of deucravacitinib in human milk, the effects on the breastfed infant, or the effects on milk production.” |
| Pediatric use | “The safety and effectiveness of SOTYKTU in pediatric patients have not been established.” |
| Geriatric use | “During the Week 0-16 period of the clinical trials 80 subjects ≥ 65 years old, including 12 subjects ≥ 75 years old, who received SOTYKTU without switching treatment arms, had a higher incidence of overall serious adverse reactions, including serious infections, and discontinuations due to adverse reactions compared with younger adult subjects.” |

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

| Population | Apremilast label text |
| --- | --- |
| Pregnancy, human data | “Available data with OTEZLA use in pregnant women have not identified a drug-associated risk of major birth defects or adverse maternal or fetal outcomes” |
| Pregnancy, animal data | “Based on findings from animal reproduction studies, OTEZLA/OTEZLA XR may increase the risk for fetal loss” |
| Pregnancy counseling | “Advise pregnant women of the potential risk of fetal loss.” |
| Lactation | “There are no data on the presence of apremilast in human milk, its effects on the breastfed infant, or its effects on milk production.” |
| Pediatric use | “The safety and effectiveness of OTEZLA have been established in pediatric patients 6 years of age and older and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.” |
| Pediatric growth | “Closely monitor growth (height and weight) in pediatric patients treated with OTEZLA.” |

Source: [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf)

| Population | Icotrokinra label text |
| --- | --- |
| Pregnancy | “The available data on the use of ICOTYDE during pregnancy are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.” |
| Pregnancy safety study | “There is a pregnancy safety study for ICOTYDE.” |
| Lactation | “There are no data on the presence of icotrokinra in human milk, the effects on the breastfed infant, or the effects on milk production.” |
| Pediatric use | “The safety and effectiveness of ICOTYDE in pediatric patients younger than 12 years of age or who weigh less than 40 kg have not been established.” |
| Geriatric use | “No overall differences in safety and effectiveness of ICOTYDE have been observed between subjects 65 years of age and older and younger adult subjects” |

Source: [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

<a id="topic-2.1.2.14-10"></a>

###### Renal and hepatic impairment: deucravacitinib, apremilast, and icotrokinra labels

| Impairment | Deucravacitinib label text |
| --- | --- |
| Renal | “No dose adjustment of SOTYKTU is recommended in patients with mild, moderate, or severe renal impairment or in patients with end stage renal disease (ESRD) on dialysis” |
| Hepatic | “SOTYKTU is not recommended for use in patients with severe hepatic impairment (Child-Pugh C)” |

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

| Impairment | Apremilast label text |
| --- | --- |
| Severe renal, immediate release | “In adult patients with severe renal impairment, reduce the maintenance dosage to OTEZLA 30 mg once daily.” |
| Severe renal, extended release | “OTEZLA XR is not recommended for adult patients with severe renal impairment; the appropriate dosage for these patients has not been determined” |
| Hepatic, population studied | “Apremilast pharmacokinetics were characterized in subjects with moderate (Child Pugh B) and severe (Child Pugh C) hepatic impairment.” |
| Hepatic, dosage | “No dosage adjustment is necessary in these patients.” |

Source: [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf)

| Impairment | Icotrokinra label text |
| --- | --- |
| Moderate and severe renal | “Icotrokinra AUC increased by 2.47-fold in patients with moderate (eGFR ≥30 to <60 mL/min, [calculated according to Chronic Kidney Disease Epidemiology Collaboration]) and 2.78-fold in severe (eGFR ≥15 to <30 mL/min) renal impairment.” |
| Hepatic, elimination | “Hepatic impairment is unlikely to affect icotrokinra elimination since the drug is not metabolized hepatically.” |
| Hepatic, severe | “However, patients with severe hepatic impairment were not studied in clinical trials.” |

Source: [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

<a id="topic-2.1.2.14-11"></a>

###### Selectivity for TYK2 over JAK1, JAK2, and JAK3 across allosteric TYK2 inhibitors

> “Orthosteric inhibitors with activity against TYK2 (e.g., brepocitinib and ropsacitinib) bind the JAK homology 1 (JH1) domain and compete with the natural substrate, ATP, to occupy the active site”

Source: [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)

> “In cellular signaling assays, deucravacitinib exhibited more than 100-fold greater selectivity for TYK2 over JAK1 and JAK3, and more than 2000-fold greater selectivity for TYK2 over JAK2”
> “Similarly, zasocitinib showed no measurable inhibition of JAK1/3 or JAK2 signaling in human whole-blood assays”
> “However, biochemical and cellular selectivity should not be equated with superior clinical safety.”

Source: [De Luca et al. (2026)](https://link.springer.com/article/10.1007/s40257-026-01095-2)

> “Zasocitinib bound the TYK2 Janus homology 2 domain with an inhibitory constant of 0.0087 nM, demonstrating more than 1 millionfold selectivity over Jak1.”

Source: [Mehrotra et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/40441292/)

> “In contrast, deucravacitinib has an 87-fold greater biochemical selectivity for the TYK2/JH2 domain compared to the JAK1/JH2 domain.”
> “In fact, there is no measurable inhibition of JAK1, JAK2, or JAK3 by envudeucitinib.”
> “Envudeucitinib has a molecular structure that separates it from other TYK2 inhibitors, with a modified arrangement and strategic deuteration sites that contribute to its metabolic stability and pharmacodynamic properties.”

Source: [Burshtein and Schlesinger (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13588483/)

> “Zasocitinib is an allosteric TYK2 inhibitor with a mechanism of action analogous to that of deucravacitinib.”
> “It has been bioengineered to demonstrate enhanced selectivity for the TYK2 JH2 domain.”

Source: [Andrzejczak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13029673/)

<a id="topic-2.1.2.14-12"></a>

###### Duration of TYK2 inhibition across the dosing interval and dosing frequency of TYK2 inhibitors

> “In preclinical and phase 1 studies, oral administration of envudeucitinib twice daily achieved maximal (90% inhibitory concentration [IC90]) TYK2 inhibition over 24 h, highlighting a level of sustained target engagement that distinguishes envudeucitinib from other oral immunomodulators.”

Source: [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)

> “It also exhibits >24 hours of steady state time above IC50 and IC90, indicating prolonged and consistent TYK2 targeting.”

Source: [Burshtein and Schlesinger (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13588483/)

> “Simulated clinical concentrations of 30 mg zasocitinib once daily exceeded the TYK2 half-maximal inhibitory concentration for 24 hours, maintaining >90% daily inhibition, with no Jak1/2/3 inhibition.”

Source: [Mehrotra et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/40441292/)

> “This suggests that the degree and duration of TYK2i achieved with deucravacitinib 6 mg once daily may limit its efficacy, as also proposed on the basis of pharmacokinetic-pharmacodynamic modeling”
> “Given these differences, pharmacokinetic parameters such as maximum plasma concentration should not be compared directly across agents.”

Source: [De Luca et al. (2026)](https://link.springer.com/article/10.1007/s40257-026-01095-2)

> “The study enrolled 606 participants, who received zasocitinib 30 mg once daily or deucravacitinib 6 mg once daily up to week 16.”
> “The primary endpoint was the percentage of participants achieving PASI 100 at week 16.”

Source: [Takeda press release, LATITUDE Atlas results (2026)](https://www.takeda.com/newsroom/newsreleases/2026/zasocitinib-superior-efficacy/)

<a id="topic-2.1.2.14-13"></a>

###### Efficacy and tolerability of deucravacitinib relative to apremilast and injectable biologics in narrative reviews

> “When compared with apremilast, deucravacitinib exhibits improved tolerability, with fewer discontinuations due to adverse events, as well as greater efficacy, with ≥ 75% improvement from baseline in Psoriasis Area and Severity Index score (PASI 75) response rates of approximately 55% vs. 37% at week 16”
> “While the efficacy of deucravacitinib is lower than that of most injectable IL-23 or IL-17 inhibitors”

Source: [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)

> “Given its mechanism of action, deucravacitinib causes less modification of cytokine signaling vs other JAK inhibitors, resulting in a narrower adverse effect (AE) profile.”
> “It is the only JAK or TYK2 inhibitor indicated for psoriasis that does not have a boxed warning.”

Source: [Burshtein and Schlesinger (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13588483/)

> “Deucravacitinib was superior to apremilast but inferior to risankizumab”
> “the next-generation agents have been compared only with placebo, apremilast, or deucravacitinib, but not with IL-17 or IL-23 inhibitors.”
> “On current evidence, TYK2i may therefore be regarded as options for patients who prefer or require oral treatment, rather than as alternatives of equivalent efficacy to these biologics.”

Source: [De Luca et al. (2026)](https://link.springer.com/article/10.1007/s40257-026-01095-2)

> “Another potential drawback is the need for daily oral dosing, compared with biologic therapies that may allow for injections every 2–3 months”

Source: [Andrzejczak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13029673/)

<a id="topic-2.1.2.14-14"></a>

###### Zasocitinib versus apremilast at week 24 as summarized in a review

> “At week 24, PASI90 responses were 69.0% and 62.7%, compared with 20.4% and 17.0% with apremilast, with no new safety signals”
> “However, the trial has so far been reported only as a congress abstract, and long-term safety data for zasocitinib and envudeucitinib are not yet available.”

Source: [De Luca et al. (2026)](https://link.springer.com/article/10.1007/s40257-026-01095-2)

<a id="topic-2.1.2.14-15"></a>

###### Head-to-head trial: risankizumab versus deucravacitinib in biologic-naive moderate psoriasis, week 16

> “IMMpactful is a phase 4 multicenter, randomized, open-label, efficacy assessor-blinded, active comparator study examining the safety and efficacy of RZB compared with DEU in patients with moderate psoriasis who are candidates for systemic therapy.”
> “In period A, patients either received a single subcutaneous injection of RZB 150 mg on day 1 and week 4 or oral DEU 6 mg daily.”
> “Of the 393 patients enrolled in IMMpactful, 131 were randomized to RZB and 262 to DEU (1 patient did not receive study drug) in period A (Fig. 2).”
> “A significantly higher proportion of patients treated with RZB achieved PASI 90 (57.3% versus 22.9%), sPGA 0/1 (80.2% versus 39.7%), PASI 100 (27.5% versus 6.5%), and sPGA 0 (27.5% versus 6.9%) compared with patients treated with DEU at week 16 (P < 0.0001).”
> “A greater proportion of patients treated with RZB (64.1% [95% CI 55.9%, 72.3%]) achieved DLQI 0/1 compared with patients treated with DEU (30.5% [95% CI 25.0%, 36.1%]) (Fig. 5A).”
> “In period A, TEAEs were reported in 33.6% of patients treated with RZB compared with 42.9% of patients treated with DEU.”
> “One potential limitation is that this study employs an open-label design rather than a double-blinded design.”
> “AbbVie funded this study (NCT06333860) and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication.”

Source: [Magnolo et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13280295/)

<a id="topic-2.1.2.14-16"></a>

###### Matching-adjusted indirect comparison: deucravacitinib versus adalimumab through week 112

> “Before reweighting, on average, patients in the POETYK PSO-LTE (N = 329) versus the REVEAL (N = 345) extension were older, had a lower body weight, received more prior systemic treatments, and had higher baseline PASI scores and week 16 placebo PASI 75 and PASI 90 response rates.”
> “Following reweighting, adjusted week 112 PASI 75 response rates were significantly higher for deucravacitinib versus adalimumab (67.2% vs. 54.0%; mean difference [95% CI], 13.2 [4.0–22.5] percentage points).”
> “Deucravacitinib had a numerically higher adjusted week 112 PASI 90 response rate (41.3% vs. 34.0%; mean difference [95% CI], 7.3 [−2.0 to 16.7] percentage points).”
> “The treatments had similar week 52 adjusted PASI 75 and PASI 90 response rates.”
> “This study was sponsored by Bristol Myers Squibb.”

Source: [Armstrong et al. (2023c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10613163/)

<a id="topic-2.1.2.14-17"></a>

###### Network meta-analyses of TYK2 inhibitors and other oral agents

> “In total, 13 RCTs (five for TYK2 inhibitors and eight for PDE4 inhibitors) involving 5274 patients were included.”
> “In addition, deucravacitinib (3 mg BID, 6 mg QD, 6 mg BID, and 12 mg QD), and ropsacitinib (400 mg QD) showed superior efficacy than apremilast (30 mg BID).”
> “In terms of safety, deucravacitinib or ropsacitinib at any dose did not lead to a higher incidence of AEs than apremilast (30 mg BID).”

Source: [Xu et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10272578/)

> “Twenty RCTs containing 7,564 patients with moderate-to-severe psoriasis were included.”
> “Deucravacitinib at all dose levels (except for 3 mg every other day) and tofacitinib (10 mg BID) ranked best in achieving PGA 0/1 and PASI-75 at 12- 16 weeks.”
> “Tofacitinib (10 mg BID) was considered the most unsafe.”

Source: [Zheng et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38899421/)

> “This study included 66 trials of 27,074 patients.”
> “Deucravacitinib has demonstrated moderate efficacy and tolerability; however, additional head-to-head comparative trials are warranted to substantiate its effects due to the paucity of existing studies.”

Source: [Chen et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40846809/)

<a id="topic-2.1.2.14-18"></a>

###### Manufacturer cross-trial comparison: PASI 100 with envudeucitinib, icotrokinra, and zasocitinib

> “Envudeucitinib: Leading PASI 100 Skin Clearance Across Next Gen Orals, with No Substantial Difference between Envudeucitinib Trials”
> “Note: The results of this retrospective post hoc cross-trial comparison may not be directly comparable.”
> “Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across unrelated studies.”

Source: [Alumis corporate presentation, November 2026 (2026)](https://investors.alumis.com/static-files/08630d4b-a14b-447f-a46d-c963632af8a4)

| Product | Trial | PASI 100 responders, % |
| --- | --- | --- |
| Envudeucitinib | ONWARD1 | “41.0%” |
| Envudeucitinib | ONWARD2 | “39.5%” |
| Icotrokinra | ICONIC-ADVANCE 1 | “41.5%” |
| Icotrokinra | ICONIC-ADVANCE 2 | “33.2%” |
| Zasocitinib | LATITUDE 3001 | “42.3%” |
| Zasocitinib | LATITUDE 3002 | “32.1%” |

Source: [Alumis corporate presentation, November 2026 (2026)](https://investors.alumis.com/static-files/08630d4b-a14b-447f-a46d-c963632af8a4)

<a id="topic-2.1.2.14-19"></a>

###### Manufacturer cross-trial comparison: itch improvement of at least 4 points on the PSSD at weeks 2, 4, and 16

> “Envudeucitinib: Earliest and Most Robust ≥4-point Improvement in PSSD Itch Score”
> “PSSD outcomes were assessed using the same validated instrument, endpoint definitions, and assessment timepoints across the programs shown, allowing for a more aligned descriptive comparison.”
> “These are descriptive cross-trial comparisons and should not be interpreted as head-to-head evidence.”
> “Data for icotrokinra and zasocitinib are estimated for weeks 2 and 4 based on line graphs”

Source: [Alumis corporate presentation, November 2026 (2026)](https://investors.alumis.com/static-files/08630d4b-a14b-447f-a46d-c963632af8a4)

| Trial | Week 2, % | Week 4, % | Week 16, % |
| --- | --- | --- | --- |
| Envudeucitinib, ONWARD1 | “29%” | “44%” | “70%” |
| Envudeucitinib, ONWARD2 | “24%” | “45%” | “64%” |
| Icotrokinra, ICONIC-ADVANCE 1 | “6%” | “22%” | “62%” |
| Icotrokinra, ICONIC-ADVANCE 2 | “6%” | “21%” | “60%” |
| Zasocitinib, LATITUDE 1 | “4%” | “23%” | “51%” |
| Zasocitinib, LATITUDE 2 | “5%” | “24%” | “58%” |

Source: [Alumis corporate presentation, November 2026 (2026)](https://investors.alumis.com/static-files/08630d4b-a14b-447f-a46d-c963632af8a4)

<a id="topic-2.1.2.14-20"></a>

###### Absence of head-to-head trials and formal indirect comparisons that include envudeucitinib

> “Additionally, direct (e.g., head-to-head) and formal indirect (e.g., meta-analyses) comparisons of oral agents for the treatment of psoriasis are not presently available.”
> “By achieving full target engagement without compromising safety, envudeucitinib may offer efficacy comparable to biologics (e.g., IL-23 and IL-17 inhibitors) in an oral formulation.”
> “Medical writing assistance was funded by Alumis Inc. The journal’s Rapid Service Fee was funded by Alumis Inc.”

Source: [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)

> “Moreover, comparisons between agents are largely indirect and limited by differences in study populations, endpoints, and timing, and the pharmacokinetic data summarized in Table 1 derive from heterogeneous doses and populations.”
> “First, it remains uncertain whether next-generation inhibitors differ meaningfully from deucravacitinib.”

Source: [De Luca et al. (2026)](https://link.springer.com/article/10.1007/s40257-026-01095-2)

> “In addition, comparisons between studies are limited as varying methodologies were used.”
> “As more TYK2 inhibitors, such as zasocitinib and envudeucitinib, emerge, additional studies will be essential to delineate differences in efficacy, safety, and long-term outcomes.”

Source: [Burshtein and Schlesinger (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13588483/)

> “Solid comparative data are currently available for apremilast; however, a key limitation is the lack of head-to-head studies with newer biologics, such as IL-17 and IL-23 inhibitors.”

Source: [Andrzejczak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13029673/)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Definition: chronic immune-mediated skin disease with distinct subtypes

> “Psoriasis is a chronic immune-mediated inflammatory skin disease with multiple phenotypically distinct subtypes eg plaque, flexural, guttate, pustular or erythrodermic.”

Source: [Raharja et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8140694/)

<a id="topic-2.2.1.1-2"></a>

###### Definition: chronic papulosquamous disease presenting at any age

> “Psoriasis is a common, chronic papulosquamous skin disease occurring worldwide, presenting at any age, and leading to a substantial burden for individuals and society.”

Source: [Griffiths et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33812489/)

<a id="topic-2.2.1.1-3"></a>

###### Case definition in the Global Burden of Disease Study 2021

> “In the GBD 2021, psoriasis was defined as a common, chronic, and recurrent inflammatory skin disease characterized by abnormal epidermal keratinization and hyperproliferation.”
> “Psoriasis diagnosis was based on the international Classification of diseases 10 (ICD-10: L40 and L41).”

Source: [Gu et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12744867/)

<a id="topic-2.2.1.1-4"></a>

###### Plaque psoriasis as the most common variant

> “Plaque psoriasis is the most common variant of psoriasis.”

Source: [Armstrong and Read (2020b)](https://pubmed.ncbi.nlm.nih.gov/32427307/)

<a id="topic-2.2.1.1-5"></a>

###### Etiology of chronic plaque psoriasis: HLA-C risk allele and environmental triggers

> “Its most common form, chronic plaque or psoriasis vulgaris, is a consequence of genetic susceptibility, particularly in the presence of the HLA-C*06:02 risk allele, and of environmental triggers such as streptococcal infection, stress, smoking, obesity, and alcohol consumption.”

Source: [Griffiths et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33812489/)

<a id="topic-2.2.1.1-6"></a>

###### Heritability: population-based twin study of 10,725 twin pairs

> “Data on psoriasis in 10 725 twin pairs, aged 20-71 years, from the Danish Twin Registry was collected via a questionnaire survey.”
> “Genetic factors explained 68% (60-75%) of the variation in the susceptibility to psoriasis, whereas the rest of the variation was explained by nonshared environmental factors.”

Source: [Lønnberg et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23574549/)

<a id="topic-2.2.1.1-7"></a>

###### Heritability range and susceptibility loci from genome-wide association studies

> “This was demonstrated by twin, family-based and large-scale population-level studies, with heritability estimated to be 60–90%.”
> “More than 60 susceptibility loci have now been identified using genome-wide association studies.”
> “Many of the candidate causal genes are involved in antigen presentation (HLA-C and ERAP1), NF-kappa B signalling (TNIP1), type 1 interferon pathway (RNF113 and IFIH1), interleukin (IL)-23/Th17 axis (IL23R, IL12B and TYK2) and skin barrier function (LCE3).”

Source: [Raharja et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8140694/)

<a id="topic-2.2.1.1-8"></a>

###### Major histocompatibility complex share of detectable heritability

> “In all populations, the strongest psoriasis association signals map to the major histocompatibility complex (MHC), comprising approximately 40% of the detectable heritability of psoriasis.”

Source: [Stuart et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8682265/)

<a id="topic-2.2.1.1-9"></a>

###### Environmental triggers: obesity, stress, medications, and smoking

> “Environmental triggers have been known to exacerbate psoriasis such as obesity, stress, beta-blockers, smoking and lithium.”

Source: [Raharja et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8140694/)

<a id="topic-2.2.1.1-10"></a>

###### Body mass index as a causal risk factor: mendelian randomization

> “Overall, a 1 kg/m2 increase in BMI was associated with 4% higher odds of psoriasis (meta-analysis odds ratio [OR] = 1.04; 95% CI 1.03–1.04;”
> “MR analyses provided evidence that higher BMI causally increases the odds of psoriasis (by 9% per 1 unit increase in BMI; OR = 1.09 (1.06–1.12) per 1 kg/m2”

Source: [Budu-Aggrey et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6354959/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Moderate-to-severe plaque psoriasis

<a id="topic-2.2.1.2.1-1"></a>

###### Incidence of psoriasis in a retrospective cohort, electronic health records 2014 to 2018

> “Retrospective cohort analysis of psoriasis patients identified with electronic health records between 2014 and 2018.”
> “Incidence rate in the overall population (n = 2,152,192) was 63.8 (95% confidence interval [CI] 61.8-65.8) per 100,000 person-years.”
> “Incidence appears to be stable within a recent 5-year period.”

Source: [Burshtein et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33253841/)

<a id="topic-2.2.1.2.1-2"></a>

###### Incidence of psoriasis by age, sex, and race

> “Incidence increased with age and peaked among individuals aged 70 to 79 years (92.3 [95% CI 85.1-100.0] per 100,000 person-years).”
> “Incidence was similar between men (62.8 [95% CI 59.8-65.9] per 100,000 person-years) and women (64.8 [95% CI 62.2-67.4] per 100,000 person-years).”
> “Standardized incidence rate for Whites (75.3 [95% CI 72.7-78.0] per 100,000 person-years) was greater than that for Hispanic/Latino patients (52.2 [95% CI 44.9-60.3] per 100,000 person-years; P < .001), patients of other race (54.3 [95% CI 46.5-62.9] per 100,000 person-years; P < .001), and Blacks (24.9 [95% CI 21.4-28.8] per 100,000 person-years; P < .001).”

Source: [Burshtein et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33253841/)

<a id="topic-2.2.1.2.1-3"></a>

###### Overall incidence and incidence trend, 1970 to 1999

> “The overall age and sex adjusted annual incidence of psoriasis was 78.9 per 100,000 (95% confidence interval [CI]: 75.0, 82.9).”
> “Incidence of psoriasis increased significantly over time from 50.8 in 1970–74 to reach 100.5 per 100,000 in 1995–1999 time period (p=0.001).”
> “Overall age-adjusted incidence in males (85.5 per 100,000; 95% CI: 79.5, 91.6) was higher than in females (73.2 per 100,000; 95% CI: 68.0, 78.4; p=0.003).”

Source: [Icen et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3028518/)

<a id="topic-2.2.1.2.1-4"></a>

###### Range of adult incidence across countries: systematic review

> “In adults, the incidence of psoriasis varied from 30.3 per 100 000 person years (95% confidence interval 26.6 to 34.1) in Taiwan to 321.0 per 100 000 person years in Italy.”
> “The 23 studies that reported on the incidence of psoriasis in the general population were conducted mainly in western and eastern Europe (16 studies), and North America (six studies).”

Source: [Parisi et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7254147/)

<a id="topic-2.2.1.2.1-5"></a>

###### Global and high-income North America incidence, Global Burden of Disease Study 2021

| Location | ASIR in 1990 (per 100,000) | ASIR in 2021 (per 100,000) | Cases in 2021 |
| --- | --- | --- | --- |
| Global | “57.0(55.3–58.8)” | “62.0(60.1–63.9)” | “5,099,418.3 (4,945,748.1–5,254,031)” |
| High-income North America | “96.5 (93.6–99.4)” | “103.5 (100.8–106.1)” | “422,371.3 (410,310.8–434,102.1)” |

Source: [Gu et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12744867/)

<a id="topic-2.2.1.2.1-6"></a>

###### Global incident cases and trend, Global Burden of Disease Study 2021

> “In 2021, the global burden of psoriasis remained severe with a total incidence of 5.10 million cases (95% CI: 4.95~5.25 million), representing a 78.76% increase since 1990.”
> “It was projected to increase from about 5.10 million cases in 2021 to 8.25 million cases in 2036, an increase of about 61.74%, indicating that the number of people with psoriasis has increased by at least twofold in the last 15 years.”

Source: [Gu et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12744867/)

<a id="topic-2.2.1.2.1-7"></a>

###### Age-standardized incidence trend, Global Burden of Disease Study 2019

> “From 1990 to 2019, the global ASR significantly increased for RA (AAPC = 0.21), albeit the ASRs significantly decreased for AD (AAPC = −0.15), asthma (AAPC = −0.41), MS (AAPC = −0.26), psoriasis (AAPC = −0.77), IBD (AAPC = −0.32).”
> “The ASR of psoriasis unanimously decreased among the 21 regions, with the highest decrement observed in North Africa and the Middle East (AAPC = −0.90).”

Source: [GBD 2019 IMID Collaborators (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10507198/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Moderate-to-severe plaque psoriasis

<a id="topic-2.2.1.2.2-1"></a>

###### Prevalence in U.S. adults: National Health Interview Survey 2023

> “In this study we investigate the prevalence of psoriasis in adults (aged 18 years and older) using the 2023 National Health Interview Survey database.”
> “Our study includes 29,486 participants, of which 942 subjects reported a history of psoriasis.”
> “On cross sectional analysis using the most recently available data, approximately 3.0% of individuals aged 18 years and older reported a history of psoriasis (Table I).”
> “approximately 7.9 million US adults had psoriasis in 2023.”

Source: [Smith et al. (2025)](https://www.jaad.org/article/S0190-9622%2824%2903365-6/fulltext)

<a id="topic-2.2.1.2.2-2"></a>

###### Prevalence in U.S. adults by sex, race and ethnicity, and body mass index, 2023

> “The prevalence of psoriasis was similar between males (3.1%) and females (2.9%). Overall, psoriasis was more prevalent in non-Hispanic White individuals (3.8%), individuals with a body mass index (BMI) of 30 or higher (3.6%), and those with health insurance (3.1%) (Table I).”

Source: [Smith et al. (2025)](https://www.jaad.org/article/S0190-9622%2824%2903365-6/fulltext)

<a id="topic-2.2.1.2.2-3"></a>

###### Prevalence in U.S. adults 20 years or older

> “Psoriasis prevalence among US adults 20 years or older was 3.0% (95% CI, 2.6%-3.4%).”
> “Based on the 2020 census data, psoriasis affects approximately 7.55 million US adults aged 20 years or older.”

Source: [Armstrong et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8246333/)

<a id="topic-2.2.1.2.2-4"></a>

###### Prevalence in U.S. adults by race and ethnicity and over time, NHANES

> “Overall, White individuals reported the highest prevalence of psoriasis at 3.6% (95% CI, 2.9%-4.2%). The lowest psoriasis prevalence was found in Black individuals, with a prevalence of 1.5% (95% CI, 1.0%-2.0%).”
> “The prevalence of psoriasis among those aged 20 to 59 years within the 2011-2014 NHANES data was 2.9% (95% CI, 2.5%-3.4%). This most recent prevalence estimate was not statistically different from prevalence estimates from prior years of 2.9% (95% CI, 2.3%-3.5%) during the 2009-2010 NHANES cycle and 3.2% (95% CI, 2.2%-4.5%) from the 2003-2004 NHANES cycle (P = .84).”

Source: [Armstrong et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8246333/)

<a id="topic-2.2.1.2.2-5"></a>

###### Prevalence trend in U.S. adults: NHANES and NHIS, 2003 to 2024

> “Data from the 2003-2006 and 2009-2014 National Health and Nutrition Examination Survey and the 2023-2024 National Health Interview Survey were analyzed.”
> “The total sample included 53,225 participants.”
> “No temporal trends in prevalence were found in any sociodemographic subgroup.”

Source: [Schneiderman and Derrick (2026)](https://pubmed.ncbi.nlm.nih.gov/42083649/)

<a id="topic-2.2.1.2.2-6"></a>

###### Diagnosed and undiagnosed psoriasis in U.S. adults

> “The prevalence of diagnosed psoriasis was 3.15% (95% CI 2.18, 4.53), corresponding to 5 million adults. The prevalence of undiagnosed active psoriasis by conservative estimate was 0.4% (95% CI 0.19, 0.82) corresponding to approximately 600,000 US adults.”

Source: [Kurd and Gelfand (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4762027/)

<a id="topic-2.2.1.2.2-7"></a>

###### Moderate-to-severe fraction: three or more palms of body surface area

> “In this study, we found that 21.5% of participants reported having moderate to severe psoriasis (≥3 palms of body surface area involvement).”
> “The majority of patients with psoriasis reported having little or no psoriasis at the time of the survey.”

Source: [Armstrong et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8246333/)

<a id="topic-2.2.1.2.2-8"></a>

###### Reported severity: no or little, mild, and moderate or severe disease

> “Psoriasis severity was generally mild: 54.5% (95% CI=44.8, 63.9) reported no or little disease; 27.3% (95% CI=21.1, 34.6) reported mild disease; and 18.2% (95% CI=12.4, 25.9) reported moderate or severe disease.”

Source: [Helmick et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4653077/)

<a id="topic-2.2.1.2.2-9"></a>

###### Moderate-to-severe fraction and number affected, ages 20 to 59

| Body surface area category | Proportion of psoriasis patients |
| --- | --- |
| Little or no psoriasis | “51.59%” |
| 1% to 2% | “31.68%” |
| 3% to 10% | “11.38%” |
| More than 10% | “5.25%” |

Source: [Kurd and Gelfand (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4762027/)

> “83.37% of psoriasis patients with a history of physician diagnosis had mild psoriasis (little/no to 1–2% BSA) while 16.63% had moderate to severe disease (3% or greater BSA).”
> “Furthermore, we estimate that 1.4 million patients age 20–59 have moderate to severe disease and that 2.1 million consider psoriasis to be a large problem in daily life.”

Source: [Kurd and Gelfand (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4762027/)

<a id="topic-2.2.1.2.2-10"></a>

###### Psoriasis prevalence and severity distribution in the adult population

> “The median prevalence of psoriasis in the adult population using the Bayesian estimate was 3.0% (95% credibility interval, 2.7–3.3%), compared with the estimated mean prevalence of 3.4% (95% confidence interval, 2.2–4.9%). By EE, the estimated cumulative distribution of disease severity assessed by BSA suggests that approximately 50% of patients have a BSA of < 3% and 78% of patients have a BSA of < 10%, with only 2% having a BSA of > 50%.”
> “Based on EE, approximately 22% of the adult population with psoriasis has 10% or more of BSA involved.”

Source: [Papp et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8163919/)

<a id="topic-2.2.1.2.2-11"></a>

###### Insured U.S. population with moderate-to-severe psoriasis and untreated share

> “There were an estimated 1.7 million insured US patients with moderate to severe psoriasis. Of these, 1 million (59%) were not treated for their condition in the preceding year.”
> “Assigning disease severity by treatment types, excluding patients with mild disease (4,065,721) and those prescribed treatment for a related inflammatory comorbidity (191,753), resulted in an estimated 1,700,266 insured patients with moderate to severe psoriasis in the 5-year analysis window (Fig. 4). Of these, 546,814 (32.2%) were diagnosed but not treated.”

Source: [Armstrong et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5336424/)

<a id="topic-2.2.1.2.2-12"></a>

###### Treatment types received by insured U.S. patients with moderate-to-severe psoriasis

> “Furthermore, of the patients treated (lapsed + currently treated) in the prior year, 156,409 (22.5%), 222,657 (32.0%), 22,911 (3.3%), and 293,511 (42.2%) received a biologic, traditional oral systemic, phototherapy, or a topical treatment, respectively (Fig. 4).”
> “In conclusion, this large health-plan-claims-based study showed that 40.9% of 1.7 million eligible US patients were receiving therapy for moderate to severe psoriasis in the 12 months up to September 2012.”

Source: [Armstrong et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5336424/)

<a id="topic-2.2.1.2.2-13"></a>

###### Claims-based prevalence and severity distribution

> “Based on several psoriasis identification algorithms, the claims-based prevalence for psoriasis in the United States ranged from 0.51% to 1.23%.”
> “Using this method, 70.9% of patients had mild disease and 27.3% had moderate to severe disease (Table 4).”

Source: [Takeshita et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4549797/)

<a id="topic-2.2.1.2.2-14"></a>

###### Therapies received in the claims analysis

> “Most patients had at least one claim for psoriasis therapy (83.5%), and 16.5% received no therapy. Topical therapies were used by 76.6% (N=3,551), the majority of whom received topical corticosteroids (97.9%). Phototherapy was used by 7% (N=324). Oral systemic medications were used by 14.3% (N=664), the majority of whom received methotrexate (85.7%).”

Source: [Takeshita et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4549797/)

<a id="topic-2.2.1.2.2-15"></a>

###### Prevalence, severity at its worst, and undertreatment

> “The prevalence of psoriasis/PsA ranged from 1.4% to 3.3%; 79% had psoriasis alone and 21% had PsA. When rating disease severity at its worst, 27% (psoriasis) and 53% (PsA ± psoriasis) of patients rated it as severe.”
> “Of psoriasis patients, 45% had not seen a physician in a year; >80% of psoriasis patients with ≥ 4 palms body surface area and 59% of PsA patients were receiving no treatment or topical treatment only.”

Source: [Lebwohl et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24576585/)

<a id="topic-2.2.1.2.2-16"></a>

###### Regional prevalence, including high income North America

> “The prevalence of psoriasis varied from 0.14% (95% uncertainty interval 0.05% to 0.40%) in east Asia to 1.99% (0.64% to 6.60%) in Australasia.”
> “Other regions with an occurrence of the disease above 1% were western Europe (1.92%, 1.07% to 3.46%), central Europe (1.83%, 0.62% to 5.32%), high income North America (1.50%, 0.63% to 3.60%)”

Source: [Parisi et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7254147/)

<a id="topic-2.2.1.2.2-17"></a>

###### Global prevalent cases, Global Burden of Disease Study 2021

> “In 2021, the global prevalence number of people with psoriasis reached 42.98 million cases (95% CI: 41.65~44.31 million), representing an increase of approximately 86.4% compared to the number of cases in 1990.”

Source: [Gu et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12744867/)

<a id="topic-2.2.1.2.2-18"></a>

###### Worldwide number of people with psoriasis

> “Approximately 125 million people worldwide have psoriasis.”

Source: [Armstrong and Read (2020b)](https://pubmed.ncbi.nlm.nih.gov/32427307/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Lifelong course with associated morbidity

> “Psoriasis is a lifelong immune-mediated inflammatory skin disease, associated with morbidities such as psoriatic arthropathy, psychological, cardiovascular and hepatic diseases.”

Source: [Raharja et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8140694/)

<a id="topic-2.2.1.3-2"></a>

###### No cure: management aims

> “Psoriasis cannot currently be cured, but management should aim to minimise physical and psychological harm by treating patients early in the disease process, identifying and preventing associated multimorbidity, instilling lifestyle modifications, and employing a personalised approach to treatment.”

Source: [Griffiths et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33812489/)

<a id="topic-2.2.1.3-3"></a>

###### Age at onset: bimodal distribution

> “Findings revealed consistency across studies about the bimodal age pattern of the onset of the disease.”
> “When we examined the incidence of psoriasis by sex and age bands, the two peaks for age at onset in women were more frequently around 18-29 and 50-59 years, whereas in men they occurred more frequently around 30-39 and 60-69 or 70-79 years.”

Source: [Parisi et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7254147/)

<a id="topic-2.2.1.3-4"></a>

###### Age at diagnosis, 1970 to 1999

> “The mean age at diagnosis (± standard deviation) of psoriasis was 43.2 ± 17.0 years and 828 (51.0%) subjects were male (Table 1).”
> “Average age at incidence increased across the three decades from 39.8 years in 1970–1979, to 41.9 years in 1980–1989 and 45.5 years in 1990–1999 (p<0.001).”

Source: [Icen et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3028518/)

<a id="topic-2.2.1.3-5"></a>

###### Progression between clinical forms and erythroderma

> “Patients with guttate psoriasis may later develop plaque psoriasis. In rare cases of severe uncontrolled disease, psoriasis causes a widespread erythematous rash (erythroderma) that is life-threatening due to potential complications including hypothermia, risk of infection, acute kidney injury and high-output cardiac failure.”

Source: [Raharja et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8140694/)

<a id="topic-2.2.1.3-6"></a>

###### Mortality and life expectancy in severe psoriasis

> “There was no overall effect of mild psoriasis on mortality (HR, 1.0; 95% confidence interval [CI], 0.97-1.02), whereas patients with severe psoriasis demonstrated an increased overall mortality risk (HR, 1.5; 95% CI, 1.3-1.7).”
> “Male and female patients with severe psoriasis died 3.5 (95% CI, 1.2-5.8) and 4.4 (95% CI, 2.2-6.6) years younger, respectively, than patients without psoriasis (P < .001).”

Source: [Gelfand et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/18086997/)

<a id="topic-2.2.1.3-7"></a>

###### Cause-specific mortality and age at death in severe psoriasis

> “Patients with severe psoriasis were at increased risk of death from cardiovascular disease (HR 1.57; 95%CI 1.26–1.96), malignancies (HR 1.41; 95%CI 1.07–1.86), chronic lower respiratory disease (HR 2.08; 95%CI 1.24–3.48), diabetes (HR 2.86; 95%CI 1.08–7.59), dementia (HR 3.64; 95%CI 1.36–9.72), infection (HR 1.65; 95%CI 1.26–2.18), kidney disease (HR 4.37; 95%CI 2.24–8.53), and unknown/missing causes (HR 1.44; 95%CI 1.09–1.88).”
> “Overall, psoriasis patients died at a younger age than unexposed patients (mean age of 73 vs 79 years respectively, p<0.001), as shown graphically in Figure 1.”

Source: [Abuabara et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2966545/)

<a id="topic-2.2.1.3-8"></a>

###### Cardiovascular mortality in severe psoriasis

> “Severe psoriasis was an independent risk factor for CV mortality (HR 1.57; 95% CI 1.26, 1.96) when adjusting for age, sex, smoking, diabetes, hypertension, and hyperlipidaemia. Overall, severe psoriasis patients experienced one extra CV death per 283 patients per year, even when adjusting for major CV risk factors.”
> “For example, the RR of CV death for a 40-year-old and 60-year-old with severe psoriasis was 2.69 (1.45, 4.99) and 1.92 (1.41, 2.62), respectively.”

Source: [Mehta et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2894736/)

<a id="topic-2.2.1.3-9"></a>

###### All-cause and cardiovascular mortality by severity: meta-analysis of 12 studies

> “We included 12 studies. The pooled RRs for all-cause mortality were 1.21 (95% CI 1.14-1.28) in psoriasis, 1.13 (95% CI 1.09-1.16) in mild psoriasis, and 1.52 (95% CI 1.35-1.71) in severe psoriasis. The pooled RRs for cardiovascular mortality were 1.15 (95% CI 1.09-1.21) in psoriasis, 1.05 (95% CI 0.92-1.20) in mild psoriasis, and 1.38 (95% CI 1.09-1.74) in severe psoriasis.”
> “For noncardiovascular causes, mortality risk from liver disease, kidney disease, and infection was significantly increased in psoriasis, regardless of disease severity.”

Source: [Dhana et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30590074/)

<a id="topic-2.2.1.3-10"></a>

###### All-cause mortality over a median follow-up of 52.3 months

> “Over an average median follow-up of 52.3 months, psoriasis was significantly associated with increased mortality risk (HR, 1.99; 95% CI, 1.01-3.93; P = .047) with adjustment for demographics, smoking, and comorbidities including cardiovascular disease, diabetes, chronic obstructive pulmonary disease, cancer, chronic kidney disease, and stroke.”

Source: [Semenov et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/31415837/)

<a id="topic-2.2.1.3-11"></a>

###### Survival compared with the Minnesota white population

> “Survival in the overall psoriasis cohort was similar to that expected in the Minnesota white population (standardized mortality ratio [SMR]: 0.95, 95% CI: 0.84, 1.07, p=0.36) over the entire time period.”

Source: [Icen et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3028518/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### IL-23/IL-17 axis as the central immune pathway

> “Over the last two decades, research has unequivocally shown that psoriasis represents a bona fide T-cell mediated disease primarily driven by pathogenic T-cells that produce high levels of IL-17 in response to IL-23.”
> “Psoriatic disease is, therefore, best understood as a patterned response to chronic activation of the IL-23/T17 pathway.”

Source: [Hawkes et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5600287/)

<a id="topic-2.2.1.4-2"></a>

###### IL-17 and IL-23 as key drivers identified by immunological and genetic studies

> “Immunological and genetic studies have identified IL-17 and IL-23 as key drivers of psoriasis pathogenesis.”

Source: [Griffiths et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33812489/)

<a id="topic-2.2.1.4-3"></a>

###### Interplay of T cells, dendritic cells, and keratinocytes

> “This suggests a complex interplay between T cells, dendritic cells and keratinocytes as the likely underlying the pathophysiology of psoriasis, with the IL-23/Th17 axis being the central driver of immune activation, chronic inflammation and keratinocyte proliferation.”

Source: [Raharja et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8140694/)

<a id="topic-2.2.1.4-4"></a>

###### Keratinocyte responses to IL-17: epidermal hyperplasia and leukocyte recruitment

> “Epidermal hyperplasia, a hallmark of psoriatic plaques, is associated with STAT3 activation and indirectly regulated by IL-17 through the induction of IL-19 and/or IL-36 by keratinocytes.”
> “IL-17 induces keratinocytes to synthesize and release CXCL1, CXCL2, CXCL3, CXCL5, and CXCL8 (i.e. IL-8), which leads to the recruitment of neutrophils and macrophages.”

Source: [Hawkes et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5600287/)

<a id="topic-2.2.1.4-5"></a>

###### TYK2 signaling downstream of IL-12, IL-23, and type I interferon receptors

> “Plaque psoriasis is a common, chronic, systemic, immune-mediated inflammatory disease. The Janus kinase-signal transducer and activator of transcription pathway plays a major role in intracellular cytokine signaling in inflammatory processes involved in psoriasis.”
> “Tyrosine kinase 2 (TYK2) is a member of the JAK family of kinases and regulates signaling and functional responses downstream of the interleukin 12, interleukin 23, and type I interferon receptors.”

Source: [Krueger et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34224773/)

<a id="topic-2.2.1.4-6"></a>

###### TYK2 partner kinases and STAT proteins by cytokine

> “TYK2 pairs with JAK2 and engages mainly STAT4 to mediate signal transduction of IL-12.”
> “The TYK2/JAK2 heterodimer, acting through STAT1, STAT3, and STAT4, is likewise required for IL-23 signalling, which regulates the differentiation and survival of Th17 cells.”

Source: [Jensen et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10589750/)

<a id="topic-2.2.1.4-7"></a>

###### Loss-of-function TYK2 variant P1104A: protection against psoriasis and other autoimmune diseases

> “Rs34536443 leads to the substitution of a highly conserved proline residue with an alanine at position 1104 (P1104A) in the kinase domain of the TYK2 protein”
> “In contrast, the rs34536443 minor allele is protective across all of the diseases tested, and surprisingly, its dosage effect shows a previously unrecognized significant departure from additivity”
> “This arises from minor allele homozygosity at the rs34536443 SNP, which drives a near complete loss of TYK2 function and consequently impairs type I IFN, IL-12 and IL-23 signaling.”

Source: [Dendrou et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5737835/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Clinical diagnosis with biopsy in doubtful cases

> “In most subjects, the diagnosis was made according to clinical manifestation, while in doubtful cases, a histopathological assessment of skin biopsies was performed.”

Source: [Jaworecka et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8304988/)

<a id="topic-2.2.1.5-2"></a>

###### Clinical assessment: body surface area, PASI, PGA, and DLQI

> “Psoriasis is assessed by the extent of skin involvement (body surface area (BSA)) and the severity of erythema, induration and scaling. In secondary care, validated scores such as Psoriasis Area Severity Index (PASI) and Physician Global Assessment Scale are routinely used along with patient reported outcome measures such as Dermatology Life Quality Index (DLQI).”

Source: [Raharja et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8140694/)

<a id="topic-2.2.1.5-3"></a>

###### Psoriasis Area and Severity Index: origin

> “The clinical efficacy was evaluated by means of a new index, psoriasis area and severity index (PASI) based on severity and area of psoriatic lesions.”

Source: [Fredriksson and Pettersson (1978)](https://pubmed.ncbi.nlm.nih.gov/357213/)

<a id="topic-2.2.1.5-4"></a>

###### Measures of disease activity: PASI, PGA, body surface area, and DLQI

> “Although it has its drawbacks, the most established parameter to measure the severity of skin symptoms in patients with psoriasis is the Psoriasis Area and Severity Index (PASI), which was first introduced in 1978 as an outcome measure in a retinoid trial.”
> “A physician global assessment (PGA) score to evaluate disease severity can be beneficial in daily clinical care in order to rapidly assess the severity of psoriasis. It is important to note that different PGAs exist and that they may differ in the way they are defined and scales that are used. An estimate of the percentage of the affected body surface area (BSA) is also used as a means to measure disease severity.”
> “So far, the Dermatology Life Quality Index (DLQI) has been the most commonly used score for assessing the impact of psoriasis on HRQoL.”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

<a id="topic-2.2.1.5-5"></a>

###### Body surface area estimated by palm count

> “In the 2003–2006 cycles, psoriasis severity was assessed by a question about current patches that could be covered by the respondent’s palm, where one palm corresponded to 1% body surface area (BSA)”

Source: [Helmick et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4653077/)

<a id="topic-2.2.1.5-6"></a>

###### Limitations of PASI and other clinical severity measures: systematic review of 53 measures

> “The purpose of this study was to identify all clinical measures of psoriasis severity and outcome in use and to evaluate the quality of these measures using clinimetric criteria; we identified 53 separate clinical measures, which were regrouped into 11 measures for quality analysis.”
> “The Psoriasis Area and Severity Index is the most commonly used clinical measure in research, but it has substantial limitations such as low response distribution, no consensus on interpretability, and low responsiveness in mild disease.”

Source: [Spuls et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20043014/)

<a id="topic-2.2.1.5-7"></a>

###### Reliability of PASI, body surface area, and PGA

> “In all 3 scales the ICCs were > 0.75, indicating high intra-rater reliability. The highest ICC was for the BSA (0.96) and the lowest one for the PGA (0.87). The CV for the PGA and PASI were 29.3 and 36.9, respectively, indicating moderate inter-rater variability. The CV for the BSA was 57.1, indicating high inter-rater variability.”

Source: [Bożek and Reich (2017)](https://pubmed.ncbi.nlm.nih.gov/29068583/)

<a id="topic-2.2.1.5-8"></a>

###### Five-point Investigator's Global Assessment scale

> “The Psoriasis Area and Severity Index (PASI) score is most widely used as a primary endpoint in clinical trials, although it is not routinely used in clinical practice.”
> “The 5-point IGA has a more stringent definition for a score of 1 ("almost clear") compared with 6-point IGA/Physician's Global Assessment (PGA) tools used in previous trials of other biologics in moderate-to-severe psoriasis.”

Source: [Langley et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/24354461/)

<a id="topic-2.2.1.5-9"></a>

###### Dermatology Life Quality Index score bands

> “DLQI scores 0-1 = no effect on patient's life (GQ = 0, n = 754); DLQI scores 2-5 = small effect on patient's life (GQ = 1, n = 611); DLQI scores 6-10 = moderate effect on patient's life (GQ = 2, n = 327); DLQI scores 11-20 = very large effect on patient's life (GQ = 3, n = 242); DLQI scores 21-30 = extremely large effect on patient's life (GQ = 4, n = 59)”

Source: [Hongbo et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16185263/)

<a id="topic-2.2.1.5-10"></a>

###### Severity classification: mild and moderate-to-severe definitions with upgrade criteria

> “Currently, the disease definition most commonly used for psoriasis is strongly influenced by the definition used in clinical trials. It was thoroughly discussed and formally agreed upon in a European consensus project in 2011.”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

| Category | Definition |
| --- | --- |
| Mild psoriasis | “BSA ≤ 10 and PASI ≤ 10 and DLQI ≤ 10” |
| Moderate to severe psoriasis | “(BSA > 10 or PASI > 10) and DLQI > 10” |
| Criteria to upgrade mild disease to moderate-to-severe | “major involvement of visible areas, major involvement of the scalp, involvement of the genitals, palms of hands or soles of feet, onycholysis or onychodystrophy of at least two fingernails, pruritis leading to scratching, and presence of recalcitrant plaques.” |
| Particularly severe psoriasis | “Criteria for particularly severe psoriasis include PASI ≥ 20, DLQI ≥ 15; rapid deterioration of findings, severe involvement of hands and/or feet, scalp, face, nails, or genitals.” |

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

<a id="topic-2.2.1.5-11"></a>

###### Severity classification: topical or systemic candidacy

> “This most preferred statement rejects the mild, moderate, and severe categories in favor of a dichotomous definition: Psoriasis patients should be classified as either candidates for topical therapy or candidates for systemic therapy; the latter are patients who meet at least one of the following criteria: (1) body surface area >10%, (2) disease involving special areas, and (3) failure of topical therapy.”

Source: [Strober et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31425723/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Skin lesions: well-demarcated plaques with silvery-white scale on extensor surfaces, trunk, and scalp

> “The most common form is plaque psoriasis, which presents as well-demarcated salmon pink plaques with silvery-white scale, typically in a symmetrical distribution and affecting the extensor surfaces (especially elbows and knees), trunk and scalp (Fig 1). Bleeding points may be noted where scales have been removed (Auspitz sign).”
> “Koebner phenomenon describes the appearance of psoriasis at skin areas affected by trauma.”

Source: [Raharja et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8140694/)

<a id="topic-2.2.1.6-2"></a>

###### Skin symptoms: itching, redness, flaking, and scales in patient survey

> “Patients commonly reported PsO involvement in special areas, and more than half of patients had scalp involvement (Table 2). Most patients reported PsO symptoms; itching, redness, flaking, and scales occurred in ~ 90% of patients or more (Table 2).”

Source: [Lebwohl et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8547901/)

<a id="topic-2.2.1.6-3"></a>

###### Pruritus: lifetime and point prevalence

> “Pruritus ever in the course of psoriasis (the lifetime prevalence of pruritus) was experienced by the great majority (92.9%) of patients, while 81% reported the presence of this symptom within the 3 days preceding the examination (the point prevalence of pruritus).”

Source: [Jaworecka et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8304988/)

<a id="topic-2.2.1.6-4"></a>

###### Most bothersome symptoms: itching, scales, and flaking

> “Psoriasis patients indicated that their most bothersome signs or symptoms were itching (43%), scales (23%), and flaking (20%).”

Source: [Lebwohl et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24576585/)

<a id="topic-2.2.1.6-5"></a>

###### Nail involvement: pitting, onycholysis, and dystrophy

> “Nails may be affected in up to 50% of patients and may manifest as nail pitting (indentation in the nails), onycholysis (separation of nail plate from nail bed), oil spots (discoloration of the nailbed), dystrophy and subungual hyperkeratosis.”

Source: [Raharja et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8140694/)

<a id="topic-2.2.1.6-6"></a>

###### Nail involvement: prevalence and associated severity in 3,531 patients

> “Nail psoriasis was diagnosed in 40·9% of the patients; prevalence was 11·2 percentage points higher in men than in women.”
> “Patients with nail involvement had a longer disease duration (21·9 vs. 18·1 years), higher disease severity (mean Psoriasis Area and Severity Index 12·7 vs. 9·3), higher frequency of PsA (26·0% vs. 12·7%), stronger impairment of HRQoL (mean Dermatology Life Quality Index 8·9 vs. 7·3), and a 2·5-fold higher rate of inpatient treatments.”

Source: [Augustin et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20456340/)

<a id="topic-2.2.1.6-7"></a>

###### Genital involvement: prevalence, itch, pain, and dyspareunia

> “One hundred thirty-four patients (38%) had current genital involvement while 224 (63%) had a current and/or previous history of genital involvement. Eighty-seven percent reported itch, 39% pain, 42% dyspareunia, 32% a worsening of their genital psoriasis after intercourse, and 43% a decreased frequency of intercourse.”

Source: [Ryan et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25824273/)

<a id="topic-2.2.1.6-8"></a>

###### High-impact sites: scalp, face, nails, genitalia, palms, and soles

> “High-impact and difficult-to-treat psoriasis sites include scalp, face, nails, genitalia, palms and soles.”

Source: [Raharja et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8140694/)

<a id="topic-2.2.1.6-9"></a>

###### Musculoskeletal symptoms: joint discomfort in patients with psoriasis alone

> “Among patients with PsO alone (n = 2550), 58% reported experiencing joint discomfort; of these (n = 1485), 63% had ≤ 4 involved joints (consistent with oligoarthritis). When asked if they have experienced PsA symptoms, many patients with PsO alone reported morning stiffness of the joints (44%), nail involvement (32%), pain and/or swelling of the feet (24%), or”

Source: [Lebwohl et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8547901/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Psoriatic arthritis: incidence and risk factors in a prospective cohort

> “The data obtained from the 464 patients who were followed up for 8 years were analyzed. A total of 51 patients developed PsA during the 8 years since enrollment. The annual incidence rate of PsA was 2.7 cases (95% confidence interval 2.1-3.6) per 100 psoriasis patients.”
> “A severe psoriasis phenotype, presence of nail pitting, low level of education, and uveitis are predictive of the development of PsA in patients with psoriasis.”

Source: [Eder et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26555117/)

<a id="topic-2.2.1.7-2"></a>

###### Psoriatic arthritis: pooled prevalence, 266 studies

> “A total of 266 studies examining 976,408 patients with psoriasis were included. Overall, the pooled proportion (95% confidence interval [CI]) of PsA among patients with psoriasis was 19.7% (95% CI, 18.5%-20.9%).”
> “The PsA prevalence was 22.7% (95% CI, 20.6%-25.0%) in European patients with psoriasis, 21.5% (95% CI, 15.4%-28.2%) in South American patients with psoriasis, 19.5% (95% CI, 17.1%-22.1%) in North American patients with psoriasis”
> “The incidence of PsA among patients with psoriasis ranged from 0.27 to 2.7 per 100 person-years.”

Source: [Alinaghi et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/29928910/)

<a id="topic-2.2.1.7-3"></a>

###### Psoriatic arthritis: onset after skin disease

> “In most patients, psoriasis precedes joint disease by up to 10 years.”

Source: [Raharja et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8140694/)

<a id="topic-2.2.1.7-4"></a>

###### Myocardial infarction risk by severity and age

> “The incidences per 1000 person-years for control patients and patients with mild and severe psoriasis were 3.58 (95% confidence interval [CI], 3.52-3.65), 4.04 (95% CI, 3.88-4.21), and 5.13 (95% CI, 4.22-6.17), respectively.”
> “For example, for a 30-year-old patient with mild or severe psoriasis, the adjusted RR of having an MI is 1.29 (95% CI, 1.14-1.46) and 3.10 (95% CI, 1.98-4.86), respectively. For a 60-year-old patient with mild or severe psoriasis, the adjusted RR of having an MI is 1.08 (95% CI, 1.03-1.13) and 1.36 (95% CI, 1.13-1.64), respectively.”

Source: [Gelfand et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17032986/)

<a id="topic-2.2.1.7-5"></a>

###### Major adverse cardiovascular events: meta-analysis of nine studies

> “Severe psoriasis was associated with a significantly increased risk of cardiovascular mortality (RR, 1.39; 95% CI, 1.11 to 1.74), myocardial infarction (RR, 1.70; 95% CI, 1.32 to 2.18), and stroke (RR, 1.56 95% CI, 1.32 to 1.84).”
> “Based on these risk ratios and the background population event rates, psoriasis is associated with an estimated excess of 11 500 (95% CI, 1169 to 24 407) major adverse cardiovascular events each year.”

Source: [Armstrong et al. (2013c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3647278/)

<a id="topic-2.2.1.7-6"></a>

###### Diabetes: prevalence and incidence meta-analysis

> “Among studies assessing the prevalence, psoriasis was associated with an odds ratio (OR) of 1.59 (95% CI, 1.38-1.83) for diabetes. The pooled OR was 1.53 (95% CI, 1.16-2.04) for mild psoriasis and 1.97 (1.48-2.62) for severe psoriasis.”
> “Among studies that assessed incidence, psoriasis was associated with a relative risk of 1.27 (95% CI, 1.16-1.40) for developing diabetes.”

Source: [Armstrong et al. (2013a)](https://pubmed.ncbi.nlm.nih.gov/23407990/)

<a id="topic-2.2.1.7-7"></a>

###### Metabolic syndrome: pooled odds ratio and dose-response relationship

> “Based on random-effects modeling of cross-sectional and case-controlled studies, the pooled odds ratio (OR) for metabolic syndrome among patients with psoriasis was 2.26 (95% confidence interval [CI] 1.70-3.01) compared with the general population.”
> “A dose-response relationship was also observed between psoriasis severity and prevalence of metabolic syndrome.”

Source: [Armstrong et al. (2013b)](https://pubmed.ncbi.nlm.nih.gov/23360868/)

<a id="topic-2.2.1.7-8"></a>

###### Non-alcoholic fatty liver disease: meta-analysis in chronic plaque psoriasis

> “We identified 15 observational (case–control and cross-sectional) studies for a total of 249,933 patients with psoriasis (49% with NAFLD) and 1,491,402 controls (36% with NAFLD). Psoriasis was associated with prevalent NAFLD (n = 11 studies; pooled random-effects odds ratio [OR] 1.96, 95% CI 1.70–2.26; I2 = 97%, p < 0.01).”

Source: [Bellinato et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9184411/)

<a id="topic-2.2.1.7-9"></a>

###### Inflammatory bowel disease: meta-analysis

> “Significant associations were found between psoriasis and Crohn disease (odds ratio, 1.70; 95% CI, 1.20-2.40) and between psoriasis and ulcerative colitis (odds ratio, 1.75; 95% CI, 1.49-2.05). Patients with psoriasis had an increased risk of Crohn disease (risk ratio, 2.53; 95% CI, 1.65-3.89) and ulcerative colitis (risk ratio, 1.71; 95% CI, 1.55-1.89).”

Source: [Fu et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6583370/)

<a id="topic-2.2.1.7-10"></a>

###### Depression: prevalence and odds meta-analysis

> “The prevalence of depressive symptoms was 28% using questionnaires and the prevalence of clinical depression was 12% using International Classification of Diseases codes, 19% using Diagnostic and Statistical Manual of Mental Disorders IV, and 9% for antidepressant use.”
> “Psoriasis patients had significantly more depressive symptoms (SMD 1.16; 95% confidence interval (CI) 0.67-1.66), and population-based studies showed that they were at least one and a half times more likely to experience depression (OR 1.57; 95% CI 1.40-1.76) and used more antidepressants than did controls (OR 4.24, 95% CI 1.53-11.76).”

Source: [Dowlatshahi et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24284419/)

<a id="topic-2.2.1.7-11"></a>

###### Comorbidities in moderate-to-severe psoriasis compared with matched controls

> “A total of 5,492 matched pairs of moderate-to-severe PsO patients and controls were selected, with a mean age of 47.6 years and 55.5% of patients being male.”
> “PsA was present among 22.1% of PsO patients. Excluding PsA, the most common comorbidities in PsO patients were related to metabolic syndrome, including hyperlipidemia (33.3% vs. 27.3%, adjusted OR [aOR] = 1.3), hypertension (32.8% vs. 23.5%, aOR = 1.6), and diabetes (15.8% vs. 9.7%, aOR = 1.7). Obesity, another condition related to metabolic syndrome, was observed in 4.8% of PsO patients, compared with 2.3% of controls (aOR = 1.9). Depression and anxiety affected 9.1% and 6.3% PsO patients, respectively (aOR = 1.7 and 1.4).”
> “Additionally, PsO patients had an elevated risk of coronary heart disease (aOR = 1.5), cerebrovascular disease (aOR = 1.7), peripheral vascular disease (aOR = 1.6), skin cancer (aOR = 1.9) including nonmelanoma skin cancer (aOR = 2.1), and lymphoma (aOR = 22.7).”

Source: [Feldman et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10397856/)

<a id="topic-2.2.1.7-12"></a>

###### Cardiometabolic comorbidity rising with severity

> “Individuals with psoriasis are more likely to suffer from obesity, cardiovascular disease, non-alcoholic fatty liver disease, diabetes and metabolic syndrome than the general population, with rates being especially elevated in those with more severe psoriasis.”

Source: [Raharja et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8140694/)

<a id="topic-2.2.1.7-13"></a>

###### Psoriatic arthritis: prevalence of 30% to 33% and onset 10 to 11 years after psoriasis

> “Psoriasis is associated with inflammatory arthritis, known as psoriatic arthritis (PsA), with an incidence of 30%-33% in psoriatic patients.”
> “Thus, after reviewing the body of evidence, the prevalence of PsA among psoriasis patients is 30%-33%, with an onset time of 10-11 years.”
> “Uncontrolled arthritis causes radiologic signs of joint damage in >50% of patients evaluated in tertiary care rheumatology centers.”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

<a id="topic-2.2.1.7-14"></a>

###### Psoriatic arthritis: prevalence by psoriasis duration and odds by body surface area involvement

> “The prevalence of PsA increased steadily with disease duration, reaching 20.5% among patients with a 30-year history of psoriasis.”
> “Patients with a higher body surface area (BSA) involvement were more likely to acquire PsA (odds ratio [OR] for 1% increase in BSA 1.020, 95% CI 1.012-1.029, P < .0005).”
> “A study of the prevalence of PsA in the United States in 2005 showed that 11% of psoriasis patients had PsA, with 39% indicating it caused a significant impact on activities of daily living.”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

<a id="topic-2.2.1.7-15"></a>

###### Coronary artery calcification in moderate-to-severe psoriasis

> “Mansouri et al compared coronary artery calcification in 127 moderate-to-severe psoriasis patients with that in diabetic patients without psoriasis.”
> “The 2 groups had equivalent calcification risk, 3 times higher than a subgroup of normal patients.”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

<a id="topic-2.2.1.7-16"></a>

###### Stroke: adjusted hazard ratios and excess risk by severity

> “After adjusting for major risk factors for stroke, both mild (adjusted hazard ratio [aHR] 1.06, 95% CI 1.0-1.1) and severe (aHR 1.43, 95% CI 1.1-1.9) psoriasis were independent risk factors for stroke.”
> “The excess risk for stroke attributable to patients with psoriasis with mild and severe disease was 1 in 4115 per year and 1 in 530 per year, respectively.”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

<a id="topic-2.2.1.7-17"></a>

###### Metabolic syndrome: prevalence in a practice-matched cohort

> “Langan et al compared 4065 patients with psoriasis to 40,650 practice-matched control patients.”
> “In total, 34% of psoriasis patients met the criteria for metabolic syndrome, compared with 26% of the controls (OR 1.50, 95% CI 1.40-1.61).”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

<a id="topic-2.2.1.7-18"></a>

###### Hypertension and diabetes: prevalence in a German health insurance database

> “In a review of a large health insurance database in Germany, Augustin et al identified 33,981 psoriatic patients from a data set of 1,344,071 patients.”
> “The prevalence of hypertension in this cohort was higher for psoriasis patients (35.6%) than controls (20.6%) (prevalence rate 1.73, 95% CI 1.71-1.76).”
> “In this data set, the prevalence rate of diabetes was higher in patients with psoriasis (12.1%) than controls (6.0%) (prevalence rate ratio 2.02, 95% CI 1.96-2.08).”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

<a id="topic-2.2.1.7-19"></a>

###### Dyslipidemia: hazard and odds ratios compared with controls

> “In a study designed to assess the risk factors for MI occurring after the diagnosis of psoriasis, Kaye et al compared 44,164 psoriasis patients with 219,784 controls matched by age, sex, and index date.”
> “The psoriasis cohort had a higher risk for hyperlipidemia than the control patients (HR 1.17, 95% CI 1.11-1.23).”
> “The OR for dyslipidemia in psoriasis patients was 4.35 (95% CI 3.73-5.06) versus controls.”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

<a id="topic-2.2.1.7-20"></a>

###### Depression: likelihood compared with controls

> “In a 2014 systematic review and meta-analysis, psoriatic patients had significantly greater symptoms of depression and were at least 1.5 times more likely to have depression than controls.”
> “The use of antidepressants by psoriatic patients was also increased relative to nonpsoriatic patients.”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

<a id="topic-2.2.1.7-21"></a>

###### Crohn disease and ulcerative colitis: prevalence compared with matched controls

> “In a retrospective analysis of 33,981 patients with psoriasis compared with 1,310,090 matched controls, the likelihood of Crohn's disease was 0.92% for psoriatic patients versus 0.45% for the control group.”
> “The likelihood of ulcerative colitis was also increased, with a 1.1% risk for psoriasis patients versus 0.56% for the controls (prevalence rate 1.91).”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

<a id="topic-2.2.1.7-22"></a>

###### Malignancy: nonmelanoma skin cancer, lymphoma, and other cancers

> “Frentz et al studied 6905 psoriasis patients who were hospitalized for their skin disease.”
> “They found an increase in the standard incidence rate (SIR) for nonmelanoma skin cancer (NMSC; SIR 2.46, 95% CI 2.13-2.83) and mycosis fungoides (SIR 15.1, 95% CI 4.1-38).”
> “In a systematic review and meta-analysis of 37 observational studies, there was an increased rate of NMSC, respiratory tract cancer, cancer of the upper aerodigestive tract, urinary tract, and non-Hodgkin lymphoma in psoriasis patients relative to controls.”
> “Thus, there appears to be an increased incidence of certain malignancies in patients with psoriasis, particularly lymphohematopoietic cancers (particularly cutaneous T-cell lymphoma), head and neck cancers, and digestive tract malignancies.”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

<a id="topic-2.2.1.7-23"></a>

###### Chronic kidney disease: adjusted hazard ratios by severity

> “The aHRs for CKD in the overall, mild, and severe psoriasis groups were 1.05 (95% CI 1.02-1.07), 0.99 (95% CI 0.97-1.02), and 1.93 (95% CI 1.79-2.08), respectively.”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

<a id="topic-2.2.1.7-24"></a>

###### Obstructive sleep apnea and chronic obstructive pulmonary disease

> “The prevalence of OSA in psoriasis patients was increased compared with those in the control group (2.7% vs 1.5%, P < .001).”
> “The pooled OR of psoriatic patients with COPD versus nonpsoriatic controls was 1.45 (95% CI 1.21-1.73).”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

<a id="topic-2.2.1.7-25"></a>

###### Nonalcoholic fatty liver disease: prevalence on liver ultrasound

> “The psoriasis group had a significantly higher rate of NAFLD relative to healthy controls (65.6% vs 35%; P < .01).”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

<a id="topic-2.2.1.7-26"></a>

###### Comorbidity guideline scope and development under American Academy of Dermatology regulations in collaboration with the National Psoriasis Foundation

> “This guideline addresses the management of extracutaneous manifestations of psoriasis in adults, including comorbid conditions, mental health, psychosocial wellness, and quality of life (QoL).”
> “This guideline has been developed in accordance with the American Academy of Dermatology (AAD) and AAD association administrative regulations for evidence-based clinical practice guidelines (May 2014)”
> “Additionally, this guideline is developed in collaboration with the National Psoriasis Foundation and as part of the review process; the National Psoriasis Foundation medical board members provided their feedback.”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Moderate-to-severe plaque psoriasis

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Dermatology Life Quality Index overall and by body surface area: UPLIFT survey in North America, Europe, and Japan

> “UPLIFT was a large, online, population-based survey conducted in North America, Europe, and Japan.”
> “Overall, in patients with PsO and/or PsA (n = 3614), mean DLQI score was 9.3, and 56% of patients experienced at least a moderate impact on QOL (DLQI score > 5).”
> “Among patients with PsO and/or PsA with limited BSA (≤ 3 palms; n = 2497), 56% had DLQI score > 5; 80% of patients with moderate BSA (4–10 palms) and 88% of patients with large BSA (> 10 palms) had DLQI total score > 5.”

Source: [Lebwohl et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8547901/)

<a id="topic-2.2.1.8.1-2"></a>

###### Dermatology Life Quality Index with special-area involvement and limited body surface area: UPLIFT survey

> “In patients with PsO involvement in at least one special area (n = 2776), the mean (SD) DLQI total score was 9.9 (8.5) and 57.9% reported DLQI total score > 5.”
> “In UPLIFT, 60% of PsO patients with limited BSA and involvement (BSA ≤ 3 palms) in at least one special area (n = 1927) reported their current disease as moderate or severe. Of these, 51% were receiving topical treatment or no treatment. In this group of patients, mean DLQI score was 9.4, and more than half of patients (56.4%) had a DLQI score > 5.”

Source: [Lebwohl et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8547901/)

<a id="topic-2.2.1.8.1-3"></a>

###### Positive depression screen and quality of life impairment in survey respondents with psoriasis or psoriatic arthritis

> “Approximately half of patients (52%) with PsO and/or PsA (n = 3806) screened positive for potential major depressive disorder, according to PHQ-2 guidelines (i.e., PHQ-2 score ≥ 3).”
> “Patients with DLQI total score > 5 and PsO in at least one special area who also had PHQ-2 score ≥ 3 had higher mean (SD) DLQI total scores [16.8 (6.7); n = 1203] compared with all patients with DLQI total score > 5 and PsO in at least one special area [15.5 (6.85); n = 1607, without positive depression screen].”

Source: [Lebwohl et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8547901/)

<a id="topic-2.2.1.8.1-4"></a>

###### Itch, pain, fatigue, Dermatology Life Quality Index, and EQ-VAS by severity: U.S. Corrona Psoriasis Registry, 1,529 patients on systemic therapy

> “The Corrona Psoriasis Registry is an independent, prospective observational cohort launched in April 2015 in collaboration with the National Psoriasis Foundation, with a target enrolment of 10 000 patients with psoriasis from 200 sites throughout the USA.”
> “1529 adult patients with psoriasis being treated with biological or non-biological systemic psoriasis treatment by 31 May 2016.”
> “As of 31 May 2016, 1529 patients were enrolled in the registry; the mean age was 50.6 years and 47% were female.”
> “BSA percentages were categorised as mild (0%–5%), moderate (>5%–10%), severe (>10%–15%) and very severe (>15%).”
> “Across BSA categories, mean fatigue scores ranged from 26.5 to 40.2, itching was 24.7 to 55.7 and pain was 15.2 to 41.7. Among IGA categories, mean fatigue scores ranged from 21.9 to 41.8, itching was 12.1 to 57.3 and pain was 7.4 to 44.3.”
> “Across BSA and IGA categories, mean DLQI scores ranged from 5.2 to 10.2 and 4.3 to 9.7, respectively. Mean EQ-VAS scores ranged from 62.9 (very severe) to 76.4 (mild) across BSA categories and 62.1 (severe) to 78.8 (clear/almost clear) across IGA categories, with higher scores indicating better health.”
> “Overall DLQI and EQ-VAS scores also worsened with disease severity (p<0.05 for each level of BSA and IGA) (table 2).”

Source: [Strober et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6500315/)

<a id="topic-2.2.1.8.1-5"></a>

###### EQ-5D and Dermatology Life Quality Index differences by severity: U.S. survey of 694 patients

> “During a recent US survey, dermatologists provided information on overall disease severity, symptom severity and comorbidities.”
> “The study analysed 694 patients (55% male; mean age: 44 years); 48%, 46% and 6% had mild, moderate and severe psoriasis, respectively. Scaling was the most common symptom, which was experienced by 82% of patients, followed by itching (73%) and pain (32%). Increased psoriasis severity was associated with increased itching, pain and scaling, and with reduced QoL (decrease in EQ-5D scores: moderate vs. mild -0.04, severe vs. mild -0.18; increase in DLQI: moderate vs. mild 2.97, severe vs. mild 7.95).”

Source: [Korman et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27061102/)

<a id="topic-2.2.1.8.1-6"></a>

###### EQ-5D health state utility values: meta-analysis of 59 studies

> “For meta-analysis, we identified 70 utility scores from 59 studies: 22 for plaque psoriasis, 26 for psoriasis as a general condition, and 22 for psoriatic arthritis.”
> “The mean (95% CIs; I2) of the EQ-5D utility scores for psoriasis as a general condition, plaque psoriasis, and psoriatic arthritis was 0.748 (0.718, 0.777; 98.8%), 0.755 (0.727, 0.783; 98.6%), and 0.585 (0.538, 0.632; 98.2%), respectively.”
> “For psoriasis as a general condition and plaque psoriasis, factors such as country, psoriasis area and severity index (PASI), dermatology life quality index (DLQI) and questionnaire version (EQ-5D-3L or EQ-5D-5L) all significantly influenced the utility scores.”

Source: [Yang et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/32716651/)

<a id="topic-2.2.1.8.1-7"></a>

###### Emotional wellbeing, embarrassment, concealment, pain, and pruritus: National Psoriasis Foundation surveys, 2003 to 2011

> “The National Psoriasis Foundation (NPF) conducts semiannual surveys and collects information regarding comorbid conditions, medication use, treatment patterns, impact on quality of life, and disease burden.”
> “From 2003 to 2011, 5,604 patients completed the surveys. Psoriasis and psoriatic arthritis affected overall emotional wellbeing in 88% of patients, and they interfered with enjoyment of life in 82%. Most patients reported experiencing anger (89%), frustration (89%), helplessness (87%), embarrassment (87%), and self-consciousness (89%). Many patients also actively concealed physical manifestations of their diseases (83%), and experienced pain (83%) and pruritus (93%) regularly.”

Source: [Armstrong et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3532407/)

<a id="topic-2.2.1.8.1-8"></a>

###### Problem in daily life by self-reported severity: survey of 5,452 respondents

> “The patients were asked to assess how much of a problem psoriasis has been in their daily life on a scale of 0–10 (0 = no problem and 10 = a very large problem).”
> “A total of 5452 patients reported a median of 5 (interquartile range 3–7)”
> “Among these respondents, patients with mild psoriasis reported a median of 3 (interquartile range 1–6), whereas patients with severe psoriasis reported a median of 7 (interquartile range 4–9).”

Source: [Armstrong et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3532407/)

<a id="topic-2.2.1.8.1-9"></a>

###### Emotional wellbeing, quality of life, self-image, and stigma: U.S. online survey of 793 patients, 2020 to 2021

> “In brief, the study was a cross-sectional, quantitative online survey conducted in the USA between 12 November 2020 and 19 May 2021 and comprised a 5-min eligibility screener followed by a 25-min online questionnaire.”
> “This analysis included 793 US patients with psoriasis; 43% also had PsA.”
> “Psoriasis negatively affected emotional well-being and quality of life (QoL) in the majority of patients (87% and 91%, respectively).”
> “Patients stated that their skin symptoms made them feel unattractive (42%), less confident about themselves (37%), ashamed of their skin (35%), depressed (33%), or ashamed of their body (30%; Supplementary Material Fig. S5b).”
> “Many patients also noted that they had experienced stigma and discrimination, such as people not understanding the impact the disease had on the patient’s life (36%), being asked if they were contagious (36%), and being stared at in public (34%) (Supplementary Material Fig. S5a).”

Source: [Armstrong et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12634971/)

<a id="topic-2.2.1.8.1-10"></a>

###### Negative comments from others in conversations about psoriasis

> “The patients reported that, on an average month, their psoriasis came up in conversations with others a mean of 5.8 times (SD±10). Among these conversations on psoriasis, 51% contained negative comments from others regarding the disease.”

Source: [Armstrong et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3532407/)

<a id="topic-2.2.1.8.1-11"></a>

###### Anticipated negative stereotypes and perceived stigma by patient-reported severity: University of Pennsylvania dermatology clinics, 106 participants

> “Patients with psoriasis were recruited from dermatology clinics at the University of Pennsylvania.”
> “Patients (n = 106) were 48.11% female, 70.75% white, and had a mean age ± SD of 47.90 ± 16.19 years old.”
> “Linear regression analyses demonstrated that patient-reported severe psoriasis, compared to mild psoriasis, was associated with greater anticipation of negative stereotypes, social avoidance, and perceived stigma from others (P values < .05). Physician-measured body surface area and global assessment scores were not significantly associated with any outcome.”

Source: [Wan et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7963348/)

<a id="topic-2.2.1.8.1-12"></a>

###### Anxiety disorders and anxiety symptoms: meta-analysis of 101 studies

> “A total of 101 eligible articles were identified. Meta-analysis revealed different prevalence rates depending on the type of anxiety disorder: 15% [95% confidence interval [CI] 9–21] for social anxiety disorder, 11% [9–14] for generalized anxiety disorder, and 9% [95% CI 8–10] for unspecified anxiety disorder.”
> “Meta-analysis also showed a high prevalence of anxiety symptoms (34% [95% CI 32–37]). Case-control studies showed a positive association between psoriasis and unspecified anxiety disorder (odds ratio 1.48 [1.18; 1.85]) and between psoriasis and anxiety symptoms (odds ratio 2.51 [2.02; 3.12]).”

Source: [Jalenques et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9558761/)

<a id="topic-2.2.1.8.1-13"></a>

###### Incident depression, anxiety, and suicidality by severity: UK population-based cohort

> “A population-based cohort study using data collected as part of patient's electronic medical record from 1987 to 2002.”
> “Clinical diagnosis of depression, anxiety and suicidality were compared among 146,042 mild psoriasis, 3,956 severe psoriasis, and 766,950 control patients.”
> “The adjusted hazard ratios for receiving a diagnosis of depression, anxiety and suicidality in patients with psoriasis compared to controls, were 1.39 (95% CI 1.37, 1.41), 1.31 (95% CI 1.29, 1.34) and 1.44 (95% CI 1.32, 1.57), respectively. The adjusted relative risk of depression was higher in severe (HR 1.72, 95% CI 1.57, 1.88), compared to mild psoriasis (HR 1.38, 95% CI 1.35, 1.40).”
> “We estimate that in the UK, in excess of 10,400 diagnoses of depression, 7,100 diagnoses of anxiety, and 350 diagnoses of suicidality are attributable to psoriasis annually.”

Source: [Kurd et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2928071/)

<a id="topic-2.2.1.8.1-14"></a>

###### Sleep quality and sleep disturbance: meta-analysis of 15 studies

> “Fifteen studies including 1274 patients with psoriasis and 775 controls were analysed. A higher PSQI (weighted mean difference [WMD] = 3.397, P < 0.001, I2 = 84.2%) and a higher risk for SD (odds ratio [OR] = 6.640, P < 0.001, I2 = 67.5%) were observed in patients with psoriasis compared with controls. Subgroup analyses revealed a greater difference in PSQI score and/or risk for SD between patients with psoriasis and controls in subgroups of psoriatic arthritis, moderate-to-severe psoriasis, shorter psoriasis duration, and younger age.”

Source: [Guo et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37956475/)

<a id="topic-2.2.1.8.1-15"></a>

###### Avoidance of sexual activity because of psoriatic disease

> “In terms of relationships, although 32% of patients reported that their partner loved them just the way they were, 21% said that they avoided having sex because of their condition or could not stand the thought of someone touching or seeing their skin (Supplementary Material Fig. S5c).”

Source: [Armstrong et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12634971/)

<a id="topic-2.2.1.8.1-16"></a>

###### Erectile dysfunction: meta-analysis of eight studies

> “Overall, 1829449 participants (the mean age ranged from 44 years to 56.3 years) were included from 8 studies (6 cross-sectional, 1 cohort, and 1 case-control study); 39490 of whom were patients with psoriasis, with the mean disease duration from 6 months to 19.9 years.”
> “Synthesis results from the included studies revealed that psoriasis was significantly associated with an increased risk of ED in psoriatic patients (OR = 1.62, 95%CI: 1.37-1.91, P < 0.001; heterogeneity: I2 = 62.6%, P = 0.009).”

Source: [Zhao et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30470802/)

<a id="topic-2.2.1.8.1-17"></a>

###### Female sexual dysfunction: meta-analysis of eight studies

> “Eight studies (five case-control, three cross-sectional) were eligible for review, encompassing 563 women with psoriasis and 525 controls.”
> “Psoriasis was associated with greater odds of female sexual dysfunction (OR 2.67, 95% CI 1.93,3.69; p < 0.0001).”

Source: [Shah et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/36456639/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Total annual U.S. cost of psoriasis in 2013 U.S. dollars: systematic review of 22 studies

> “Among 100 identified articles, 22 studies were included in the systematic review. The direct psoriasis costs ranged from $51.7 billion to $63.2 billion, the indirect costs ranged from $23.9 billion to $35.4 billion, and medical comorbidities were estimated to contribute $36.4 billion annually in 2013 US dollars.”
> “The annual US cost of psoriasis amounted to approximately $112 billion in 2013.”

Source: [Brezinski et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25565304/)

<a id="topic-2.2.1.8.2-2"></a>

###### Annual U.S. burden by component: incremental medical costs, quality of life, and productivity, 2013

> “The prevalence of psoriasis in the US was estimated to be 7.4 million in 2013. Comparatively, psoriasis patients incurred incremental medical costs of $2284, experienced a $2203 reduction in HRQOL, and a $1935 reduction in productivity. The total burden of psoriasis was estimated as $35.2 billion, with $12.2 billion in incremental medical costs (35%), $11.8 billion from reduced HRQOL (34%), and $11.2 billion from productivity losses (32%).”

Source: [Vanderpuye-Orgle et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25882886/)

<a id="topic-2.2.1.8.2-3"></a>

###### All-cause costs and resource use in moderate-to-severe psoriasis versus matched controls: OptumHealth claims, 2007 to 2012

> “Adults aged 18-64 years with at least 2 PsO diagnoses (ICD-9-CM code 696.1) were identified in the OptumHealth Reporting and Insights claims database from January 2007 to March 2012. Moderate-to-severe PsO patients were identified as those receiving ≥ 1 systemic therapy or phototherapy during the 12-month study period following the index date (randomly selected date after the first PsO diagnosis). Controls were free of PsO and psoriatic arthritis (PsA) and were matched 1:1 with PsO patients on age, gender, and geographic region.”
> “All-cause health care costs and PsO-related costs (PsO treatment costs and PsO-related medical costs, calculated for moderate-to-severe PsO patients only) were calculated as reimbursed amounts from payers and were adjusted to 2012 U.S. dollars using the medical care component of the Consumer Price Index.”
> “Compared with controls, PsO patients incurred higher annual total health care costs per patient ($22,713 vs. $4,993, adjusted cost difference [ACD] = $18,960; P < 0.001), driven by significantly higher costs in all-cause medications ($14,698 vs. $1,101, ACD = $13,990; P < 0.001) and all-cause medical services ($8,015 vs. $3,892, ACD = $3,895; P = 0.002; Figure 2).”
> “During the 12-month study period, the moderate-to-severe PsO patients incurred an average of $13,731 PsO-related costs, a majority of which were attributed to treatment costs for systemic PsO therapies ($12,958) that included biologics, nonbiologics, and phototherapies (Table 5).”
> “In addition, PsO patients were more likely to incur all-cause medical services, including any inpatient admissions (9.3% vs. 6.4%, aOR = 1.3), ER visits (21.4% vs. 16.4%, aOR = 1.3), and outpatient visits (99.0% vs. 84.5%, aOR = 29.3; all P < 0.001). On average, PsO patients had more inpatient admissions (0.15 vs. 0.09, aIRR = 1.3; P = 0.001), ER visits (0.40 vs. 0.27, aIRR = 1.3; P < 0.001), and outpatient visits (20.46 vs. 8.41, aIRR = 2.4; P < 0.001). PsO patients also spent more hospitalization days (1.03 vs. 0.55, aIRR = 1.9; P < 0.001) than controls.”

Source: [Feldman et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10397856/)

<a id="topic-2.2.1.8.2-4"></a>

###### Annual all-cause costs in psoriasis versus matched controls: U.S. claims study

> “To compare healthcare resource utilization and costs among patients with psoriasis, psoriatic arthritis (PsA), and a control group of patients without psoriasis and PsA in the USA.”
> “Healthcare resource utilization and costs (in 2019 USD) were evaluated descriptively and through mixed models for five years of follow-up.”
> “A total of 142,531 psoriasis and 21,428 PsA patients were matched to the control group (N = 163,959). Annual all-cause healthcare costs per patient were $7,470, $11,062, and $29,742 for the control, psoriasis, and PsA groups, respectively. All-cause healthcare costs increased over time and were significantly greater among PsA vs. psoriasis (p < 0.0001) and the control groups (p < 0.0001).”

Source: [Merola et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33934270/)

<a id="topic-2.2.1.8.2-5"></a>

###### All-cause costs by severity, psoriatic arthritis, and biologic use over five years: MarketScan claims, 2009 to 2014

> “Administrative data from Truven Health Analytics MarketScan Research Database were used to select adult patients with psoriasis from January 2009 to January 2014.”
> “Costs are presented per-patient-per-year (PPPY) and by years 1, 2, 3, 4, and 5 of follow-up, expressed in 2014 US dollars.”
> “A total of 108,790 psoriasis patients were selected, with a mean age of 46.0 years (52.7% females). Average follow-up was 962 days. All-cause healthcare costs were $12,523 PPPY. Outpatient pharmacy costs accounted for 38.6% of total costs. All-cause healthcare costs were highest for patients on biologics ($29,832), then for patients with psoriatic arthritis ($23,427) and those with moderate-to-severe disease ($21,481). Overall, all-cause healthcare costs and outpatient pharmacy costs presented an upward trend over a 5-year period.”

Source: [Al Sawah et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28635342/)

<a id="topic-2.2.1.8.2-6"></a>

###### Costs and outpatient encounters by severity among biologic-treated patients: linked U.S. claims and electronic health records

> “To describe healthcare resource utilization (HCRU) and costs among biologic-treated psoriasis patients in the US, overall and by disease severity.”
> “IQVIA PharMetrics Plus administrative claims data were linked with Modernizing Medicine Data Services Electronic Health Record data and used to select adult psoriasis patients between April 1, 2010 and December 31, 2014.”
> “This study identified 2,130 biologic-treated psoriasis patients: 282 (13%) had mild, 116 (5%) moderate, and 49 (2%) severe disease; 1,683 (79%) could not be classified.”
> “Relative to mild psoriasis patients, patients with moderate or severe disease had more median all-cause outpatient encounters (28.0 [mild] vs 32.0 [moderate], 36.0 [severe]), more median psoriasis-related outpatient encounters (6.0 [mild] vs 7.5 [moderate], 8.0 [severe]), and a higher proportion of overall claims for medications that were psoriasis-related (28% [mild] vs 37% [moderate], 34% [severe]).”
> “Relative to mild psoriasis patients, patients with moderate or severe disease had higher median all-cause total costs ($37.7k [mild] vs $42.3k [moderate], $49.3k [severe]), higher median psoriasis-related total costs ($32.7k [mild] vs $34.9k [moderate], $40.5k [severe]), higher median all-cause pharmacy costs ($33.9k [mild] vs $36.5k [moderate], $36.4k [severe]), and higher median psoriasis-related pharmacy costs ($32.2k [mild] vs $33.9k [moderate], $35.6k [severe]).”

Source: [Murage et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29718756/)

<a id="topic-2.2.1.8.2-7"></a>

###### Six-month direct and indirect costs in moderate-to-severe plaque psoriasis: nine U.S. sites

> “A total of 200 adults seeking MSPP treatment enrolled in 9 US sites.”
> “Most patients (79.5%) were prescribed 1 or more MSPP medications (mean: 1.5); 36.0% and 9.0% received self-administered biologics and systemic therapies, respectively. Mean number of nonprescription treatments was 12.3. Differences by PASI group were observed for overall work and activity impairment (P < .02). Six-month total MSPP direct costs per patient were $11,291; indirect costs were $2101 and differed across PASI groups (P = .0008).”

Source: [Schaefer et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26253364/)

<a id="topic-2.2.1.8.2-8"></a>

###### Annual medication costs, biologics versus oral systemic therapies, and visit use by severity: U.S. dermatology electronic health records

> “Data for adults (≥18-years) with a dermatology provider-given diagnosis of psoriasis from 9/2014–9/2015 were obtained from dermatology practices using a widely used US dermatology-specific EHR containing over 500,000 psoriasis patients.”
> “In 28,754 patients, higher disease severity was associated with increased healthcare resource utilization (increased visit frequency and complexity). When compared between treatment groups (n = 10,454), healthcare resource utilization was highest for phototherapy. Annual medication costs were higher for biologics ($21,977) than oral systemics ($3413).”

Source: [Armstrong et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6025830/)

<a id="topic-2.2.1.8.2-9"></a>

###### Annual net cost of first-line biologics, 2007 to 2021

> “Trends in the proportion of patients initiating each biologic medication and the average estimated annual treatment costs over time, using commercial estimates of net prices accounting for average manufacturer rebates.”
> “Among 76 781 patients with plaque psoriasis who initiated biologic medications, 50.4% were female and 49.6% male, 71.8% were age 30 to 59 years, and 30% had concurrent inflammatory arthritis.”
> “The average annual treatment cost increased from $21 236 in 2007 to $47 125 in 2021. In 2021, costs ranged from $12 413 (infliximab) to $70 043 (risankizumab). If patients initiated the lowest-cost medication in each class, the average annual treatment cost would have been 44% lower in 2021 ($26 363).”

Source: [Rome et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12004245/)

<a id="topic-2.2.1.8.2-10"></a>

###### Costs and resource use by biologic treatment pattern: switchers, discontinuers, and nonswitchers

> “Of the 8,710 patients with psoriasis included in the study, 5,000 (57.4%) were categorized as nonswitchers, 1,001 (11.5%) as switchers, and 2,709 (31.1%) as discontinuers. Emergency department and inpatient visits, respectively, were more common among switchers (adjusted incidence rate ratio [95% CI]: 1.10 [0.93-1.30] and 1.13 [0.84-1.53]) and discontinuers (1.50 [1.34-1.63] and 2.05 [1.70-2.48]) than among nonswitchers. Compared with nonswitchers, switchers had higher adjusted mean total health care costs (mean difference [95% CI]: $10,120 [$8,235-$12,033]), which were driven by increased prescription costs ($8,988 [$7,535-$10,610]) and medical costs ($2,746 [$1,090-$4,677]).”
> “Conversely, the adjusted mean total health care cost for discontinuers was lower than that for nonswitchers (mean difference [95% CI]: -$18,611 [-$20,254, -$17,025]) due to reduced prescription costs (-$20,486 [-$21,319, -$19,636]); however, discontinuers had a higher mean medical cost ($3,729 [$1,970-$5,527]).”

Source: [Feldman et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10398133/)

<a id="topic-2.2.1.8.2-11"></a>

###### Comorbidity-related medical costs in moderate-to-severe psoriasis versus the general population: U.S. claims, 2006 to 2019

> “Comorbidity-related HCRU (incidence rate ratios [IRRs]) and direct medical cost burden (per patient per month [PPPM] 2020 USD) in patients with moderate to severe PsO in the USA, previously apremilast- and biologic-naive, but currently treated, versus the general population were assessed through a retrospective cohort study using IBM (now Merative) MarketScan Commercial and Medicare Claims data (1 January 2006 to 31 December 2019).”
> “These differences (PsO–general population) in HCRU and costs (IRR visits; PPPM) are associated with specific comorbidities, including mental health (1.08; $372), chronic pulmonary disease (1.07; $135), diabetes (1.10; $159), hyperlipidemia (1.13; $203), hypertension (1.13; $305), liver disease (1.21; $360), and obesity (1.12; $145, all P < 0.01).”

Source: [Wu et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9823180/)

<a id="topic-2.2.1.8.2-12"></a>

###### Total and work-loss costs by number of psoriasis-related comorbidities: U.S. privately insured patients

> “Adults with psoriasis (≥2 diagnoses, the first designated as the index date) and non-psoriasis controls (no psoriasis diagnoses, randomly generated index date) were identified in a US healthcare claims database of privately-insured patients (data between January 2010 and March 2017 were used).”
> “A total of 9,078 psoriasis (mean age = 44 years, 51% female) and 48,704 non-psoriasis (mean age = 41 years, 50% female) patients were selected.”
> “Psoriasis patients incurred greater total healthcare costs (mean cost differences [MCDs] = $1,590, $5,870, and $18,427, in patients with 0, 1-2, and ≥3 comorbidities, respectively [all p < 0.01]), and work-loss-related costs (MCDs = $335, $655, and $1,695, in patients with 0, 1-2, and ≥3 comorbidities, respectively [all p < 0.01]).”

Source: [Pilon et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30523738/)

<a id="topic-2.2.1.8.2-13"></a>

###### Work productivity loss and annual indirect costs by severity: Adelphi survey in the U.S. and five European countries

> “To estimate total WPL and related indirect costs, and identify predictors of WPL associated with psoriasis severity in France, Germany, Spain, the U.K. and Italy (EU5) and the U.S.A.”
> “Data from the 2015 Adelphi Real World Psoriasis Disease Specific Programme, analysed for absenteeism, presenteeism and total WPL, were quantified (0–100%) from participants who completed the Work Productivity and Activity Impairment (WPAI) instrument.”
> “Of the 936 respondents (29·6% U.S.A., 70·4% EU5) who completed the WPAI, 32·6%, 40·7% and 26·6% had mild [body surface area (BSA) 0–2%], moderate (BSA 3–10%) and severe (BSA > 10%) psoriasis, respectively.”
> “Mean percentages of total WPL for respondents with mild, moderate and severe psoriasis were 10·1%, 18·9% and 29·4%, respectively.”
> “Mean annual indirect costs due to WPL per patient were highest in the U.S.A. (9591 U.S. dollars, 95% CI 8407–10 775), reflecting a particularly high contribution from presenteeism (9173 U.S. dollars, 95% CI 8063–10 283).”

Source: [Villacorta et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7497177/)

<a id="topic-2.2.1.8.2-14"></a>

###### Work productivity and activity impairment and disability by body surface area category

> “By BSA category, the ‘work hours missed’ domain was 2.3%–5.9%, ‘impairment while working’ was 8.4%–19.0%, ‘work hours affected’ was 9.5%–20.0% and ‘daily activities impaired’ was 13.1%–31.5%.”
> “Increasing proportions of patients were disabled as severity increased according to BSA (range: 7%–14%) and IGA (range: 5%–15%; table 1).”

Source: [Strober et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6500315/)

<a id="topic-2.2.1.8.2-15"></a>

###### Work productivity and activity impairment score differences by severity

> “WPAI scores increased with severity, indicating greater impairment (moderate vs. mild: 11.77, severe vs. mild 18.73).”

Source: [Korman et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27061102/)

<a id="topic-2.2.1.8.2-16"></a>

###### Unemployment and missed work days among survey respondents

> “Of note, 12% of patients were unemployed, and 11% worked part-time. Among unemployed patients, 92% cited psoriasis and/or psoriatic arthritis as the sole reasons for not working. Among working patients, 49% missed work days regularly due to psoriasis. Compared to patients with mild psoriasis, patients with severe psoriasis have 1.8 times greater odds to be unemployed after adjusting for age and gender (Adjusted OR = 1.7, 95% CI 1.4–2.3).”
> “In a typical month, among those who missed work days due to psoriasis or PsA, 62% missed 5 days or less, 6.6% missed 6–10 days, and 31% missed more than 10 days.”

Source: [Armstrong et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3532407/)

<a id="topic-2.2.1.8.2-17"></a>

###### Annual indirect costs by level of skin clearance: employed participants of the CLEAR trial

> “In the CLEAR study, 452 (67%) were employed at baseline and included in this analysis.”
> “U.S. Department of Labor data were used to calculate annual indirect costs due to work productivity loss.”
> “Associated mean annual indirect costs due to work productivity loss per worker decreased with higher PASI improvements: $10,318 for PASI < 50, $6,042 for PASI 50-74, $2,901 for PASI 75-89, and $2,233 for PASI ≥ 90.”

Source: [Feldman et al. (2018b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10398100/)

<a id="topic-2.2.1.8.2-18"></a>

###### Inability to work or study and monthly out-of-pocket spending among survey respondents

> “Overall, 29% of patients reported that they could not work or study in the week prior to the survey; of these, 98% responded that psoriasis had a very or extremely large impact on their QoL.”
> “Overall, the highest out-of-pocket costs (mean $240 per month) related to healthcare, prescriptions, doctors’ fees, alternative practitioners, dietitians, and complementary medicine, with nonprescription medicines, creams, and lotions being the next highest cost (mean $147 per month).”

Source: [Armstrong et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12634971/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Moderate-to-severe plaque psoriasis on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Extra housework, psychological pressure, and social disruption among 63 relatives and partners

> “Thirty-three subjects were interviewed and 30 replied by postal questionnaire. Twenty-eight of the 63 subjects were relatives (seven men and 21 women) and 35 were partners (16 men and 19 women).”
> “Seventy per cent stated that the treatment of their relative or partner resulted in them having to spend extra time on housework; 57% described psychological pressures including anxiety, being upset and being worried about the patient's future; 55% described social disruption due to lack of social confidence either because of embarrassment or because of the time required for care duties; 44% described limitations to holiday plans, sport and leisure activities and evenings out; 37% described limitations on their daily activities such as shopping, work and time spent with other family members; 37% felt that their close relationships had deteriorated. Only 8% described no effect at all on their QoL.”
> “The QoL of the relatives and partners (number of categories affected) was more closely related to the patients' QoL (DLQI: r = 0.77, P < 0.001; PDI: r = 0.67, P < 0.001) than to the objective disease severity scores (PASI: r = 0.34, P < 0.05).”

Source: [Eghlileb et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17459044/)

<a id="topic-2.2.1.8.3-2"></a>

###### Partner burden, including cleaning, by psoriasis severity: FamilyPso international study of 556 patients and partners

> “A prospective cohort study was conducted in 11 centers in Austria, Canada, Germany, Italy, Spain, and Turkey.”
> “The cohort consisted of 556 people with psoriasis and their partners.”
> “Self-assessed high severity of psoriasis was a predictor for a higher burden in 4/5 FamilyPso domains.”
> “The highest scores were found for the acute/general emotional strain and the cleaning domains (Fig. 3). The partners’ burden increased by severity in each domain. The steepest slopes are found with emotional strain and cleaning.”
> “The data show that emotional aspects, such as a feeling of helplessness with the chronic illness of the partner, and increased cleaning efforts add to the burden that psoriasis imposes on partners.”

Source: [Mrowietz et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12436565/)

<a id="topic-2.2.1.8.3-3"></a>

###### Burden on close relatives and partners by severity and patient quality of life: Psoriasis Registry Austria

> “250 plaque‐type psoriasis patients (58.4% males and 41.6% females) with mostly treatment‐controlled disease (mean PASI of 1.7 and Dermatology Life Quality Index (DLQI) of 4.1) were recruited from the Psoriasis Registry Austria (PsoRA) and their close relatives and partners were invited to participate in the study.”
> “Valid FamilyPso questionnaires were returned from 153 (61.2%) close relatives and partners. Correlation analysis revealed a significant association between PASI and DLQI (r = 0.512, p < 0.001), PASI and PFIS (r = 0.228, p = 0.006), and DLQI and PFIS (r = 0.210, p = 0.014).”
> “A small or larger disease burden was detected in nearly 78.7% of the male and 77.3% of the female relatives and partners quantified with categorized PFIS.”
> “The gender of the relatives and partners had no impact on the PFIS.”

Source: [Grossschaedl et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11150751/)

<a id="topic-2.2.1.8.3-4"></a>

###### Quality of life, anxiety, and depression in cohabitants of patients

> “The study included patients, cohabitants, and controls, a total of 130 participants.”
> “The presence of psoriasis impaired the quality of life of 87.8% of the cohabitants. FDLQI scores of cohabitants were significantly associated with the DLQI scores of the patients (rs = 0.554; P < .001). Anxiety and depression levels did not differ between patients and cohabitants, but were significantly higher than in the controls (P < .001).”

Source: [Martínez-García et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24836080/)

<a id="topic-2.2.1.8.3-5"></a>

###### Family Dermatology Life Quality Index: instrument for family members of patients with skin disease

> “A 10-item questionnaire, the Family Dermatology Life Quality Index (FDLQI), was finalized after modifications to the draft questionnaire based on feedback from families and dermatology professionals and on item reduction.”
> “A strong correlation was seen between the family members' FDLQI scores and patients' DLQI scores (r = 0.69), a significantly higher FDLQI score was seen for inflammatory skin diseases compared with noninflammatory diseases/isolated lesions (P < 0.0001), and there was a positive relationship between the family members' FDLQI scores and patients' disease severity (r = 0.49).”

Source: [Basra et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17300244/)

<a id="topic-2.2.1.8.3-6"></a>

###### Lifestyle, emotional, and relationship consequences for family members: focus groups and interviews

> “We conducted focus groups and interviews with 23 individuals; 12 had a family member with AD, and 11 had a family member with psoriasis.”
> “Three major themes emerged: (1) lifestyle consequences-many daily activities for family members, including but not limited to leisure activities, sleep, and cleaning, were affected by AD or psoriasis; (2) emotional consequences-family members felt frustrated, worried, or embarrassed, among other concerns, because of their loved ones' AD or psoriasis; (3) relationships-relationships between family members and their loved ones with AD or psoriasis could become strained, and though family members might try to be sympathetic, doing so could be difficult because of their lack of understanding of how these diseases feel and personally affect their loved ones.”

Source: [Snyder et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/35618988/)

<a id="topic-2.2.1.8.3-7"></a>

###### Family income by psoriasis severity: Polish specialty clinic

> “A total of 83 (45 male) psoriasis patients, treated at a Polish specialty clinic, were assessed for their financial and employment status.”
> “Patients' family income correlate negatively with psoriasis severity (Spearman's rho = -0.356; P < 0.01). Disease severity in patients with a family income below the social minimum was significantly higher (PASI: 20.5 ± 12.2) than in patients with a higher family income (PASI: 11.7 ± 7.7, P < 0.001).”
> “Family income was found to link disease severity to global QoL impairment (P < 0.05).”

Source: [Hawro et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/24852054/)

<a id="topic-2.2.1.8.3-8"></a>

###### Caregivers of children with psoriasis: meta-analysis of 21 studies

> “Twenty‐one studies were included, encompassing 1038 children and 1161 caregivers.”
> “Across studies, 84.8% of children and 96.1% of caregivers experienced some degree of HrQOL impairment. Meta‐analysis revealed a moderate positive correlation between child disease severity (PASI scores) and caregiver HrQOL burden (r = 0.463), while no significant correlation was found with child age or disease duration.”

Source: [Perlmutter et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13423114/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

Not applicable.

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Topical Therapies

<a id="topic-2.2.2.1.1-1"></a>

###### Topical corticosteroids: guideline recommendation, potency selection, and efficacy ranges by potency class

> “The use of class 1, class 2, and class 3-5 topical corticosteroids for up to 4 weeks is recommended for the treatment of plaque psoriasis not involving intertriginous areas”
> “In adults, corticosteroids in classes 2 through 5 (moderate to high potency; Table II) are generally recommended as initial therapy.”
> “For ultrahigh-potency (class 1) corticosteroids, the efficacy rates in several RCTs vary from 58% to 92%.”
> “For high-potency (class 2 and 3) corticosteroids, the efficacy rates in several RCTs vary from 68% to 74%.”
> “For moderate-potency (class 4 and 5) corticosteroids, the efficacy rates in several RCTs vary from 70% to 83%.”

Source: [Elmets et al. (2021)](https://www.jaad.org/article/S0190-9622%2820%2932288-X/fulltext)

<a id="topic-2.2.2.1.1-2"></a>

###### Topical corticosteroids: local adverse effects, tachyphylaxis, and duration limits

> “The most common local skin adverse effects of topical corticosteroid use include skin atrophy, striae, folliculitis, telangiectasia, and purpura.”
> “Tachyphylaxis may compromise the effectiveness in certain patients when used for an extended period >12 weeks.”
> “Clinicians should consider limiting the use of class 1 corticosteroids to no more than twice daily for up to 4 weeks, when possible”

Source: [Elmets et al. (2021)](https://www.jaad.org/article/S0190-9622%2820%2932288-X/fulltext)

<a id="topic-2.2.2.1.1-3"></a>

###### Topical vitamin D analogues and corticosteroid combinations: guideline recommendations and adverse effects

> “The long-term use of topical vitamin D analogues (up to 52 weeks), including calcipotriene/calcipotriene, calcitriol, tacalcitol, and maxacalcitol, is recommended for the treatment of mild to moderate psoriasis”
> “Use of combination products with calcipotriol and corticosteroids is recommended for the treatment of psoriasis”
> “Other local adverse effects can affect up to 35% of patients and include burning, pruritus, edema, peeling, dryness, and erythema.”
> “When using calcipotriene, applications of more than 100 g/wk should be avoided to minimize this risk”

Source: [Elmets et al. (2021)](https://www.jaad.org/article/S0190-9622%2820%2932288-X/fulltext)

<a id="topic-2.2.2.1.1-4"></a>

###### Topical agents added to systemic therapy in moderate to severe psoriasis: guideline recommendations

> “The addition of topical calcipotriene to standard dose methotrexate therapy is recommended for the treatment of moderate to severe psoriasis. It may lead to lower cumulative doses of methotrexate and increased time to relapse after methotrexate discontinuation”
> “The addition of calcipotriene/betamethasone to standard dose adalimumab for 16 weeks is recommended for the treatment of moderate to severe psoriasis to accelerate clearance of psoriatic plaques.”

Source: [Elmets et al. (2021)](https://www.jaad.org/article/S0190-9622%2820%2932288-X/fulltext)

<a id="topic-2.2.2.1.1-5"></a>

###### Topical agents alone among treated patients with moderate or severe psoriasis

> “Among those receiving treatment, 29.5% of patients with moderate psoriasis and 21.5% of patients with severe psoriasis were treated with topical agents alone.”

Source: [Armstrong et al. (2013d)](https://pubmed.ncbi.nlm.nih.gov/23945732/)

<a id="topic-2.2.2.1.1-6"></a>

###### Guideline evidence base for topical and UV therapy statements

> “The statements on topical and UV therapies are based on the systematic evidence synthesis last updated in 2015.”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

<a id="topic-2.2.2.1.1-7"></a>

###### Joint AAD-NPF guideline on topical therapy: scope and National Psoriasis Foundation collaboration

> “This guideline will cover the use of topical agents and alternative medicine (AM) in the treatment of psoriasis in adults as well as the assessment of disease severity”
> “This concludes the portion of the AAD-NPF Joint Guideline on care for the management of psoriasis with topical therapy.”
> “Additionally, this guideline is developed in collaboration with the National Psoriasis Foundation (NPF) and as part of the review process; the NPF medical board members provided their feedback.”

Source: [Elmets et al. (2021)](https://www.jaad.org/article/S0190-9622%2820%2932288-X/fulltext)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Phototherapy

<a id="topic-2.2.2.1.2-1"></a>

###### Narrowband UVB: guideline recommendations on monotherapy, dosing frequency, and preference over PUVA

> “NB-UVB phototherapy is recommended for adults with plaque psoriasis as monotherapy”
> “During the treatment phase, 3-times/wk dosing of NB-UVB phototherapy for adults with generalized plaque psoriasis is recommended”
> “Though less effective, NB-UVB is preferred to PUVA monotherapy for the treatment of psoriasis in adults because of enhanced safety, convenience, and cost savings”
> “Home NB-UVB phototherapy is recommended for appropriate patients with generalized plaque psoriasis as an alternative to in-office NB-UVB phototherapy”

Source: [Elmets et al. (2019b)](https://www.jaad.org/article/S0190-9622%2819%2930637-1/fulltext)

<a id="topic-2.2.2.1.2-2"></a>

###### Narrowband UVB efficacy: PASI 75 and clearance rates in pooled trials

> “Across these 9 studies, 62% of patients achieved PASI 75”
> “An average clearance rate of 68% was observed”
> “In a systematic review and meta-analysis of 8 trials, 70% of patients achieved PASI 75 with NB-UVB phototherapy”

Source: [Elmets et al. (2019b)](https://www.jaad.org/article/S0190-9622%2819%2930637-1/fulltext)

<a id="topic-2.2.2.1.2-3"></a>

###### Oral PUVA compared with narrowband UVB: efficacy, number of treatments, and adverse effects

> “Though more effective, oral PUVA causes a higher rate of adverse effects, with symptomatic erythema and blistering observed in 17% of patients versus in 7.8% with NB-UVB”
> “Fewer treatments were required to reach clearance with PUVA than with NB-UVB (17 vs 25), and there was a higher likelihood of remission 6 months following PUVA treatment than following NB-UVB treatment (odds ratio, 2.73; 95% confidence interval, 1.19-6.27)”

Source: [Elmets et al. (2019b)](https://www.jaad.org/article/S0190-9622%2819%2930637-1/fulltext)

<a id="topic-2.2.2.1.2-4"></a>

###### Treatment burden: travel to a phototherapy center and home phototherapy

> “For patients for whom travel to a phototherapy center is a limiting factor, home NB-UVB units should be considered.”
> “Of the individuals who received hospital-based phototherapy, 41.7% achieved PASI 75 after 46 treatments compared with 40.7% of those receiving home phototherapy.”
> “The burden of treatment was significantly lower, and patients were happier with their treatments when the UV light was delivered in the home phototherapy setting.”
> “To achieve maximal efficacy, treatment with targeted UVB phototherapy for adults with localized plaque psoriasis should be carried out 2-3 times/wk rather than once every 1-2 wk”

Source: [Elmets et al. (2019b)](https://www.jaad.org/article/S0190-9622%2819%2930637-1/fulltext)

<a id="topic-2.2.2.1.2-5"></a>

###### Phototherapy safety precautions: guideline recommendations

> “Long-term combination therapy with cyclosporine and NB-UVB phototherapy is not recommended for adults with generalized plaque psoriasis because of increased incidence of skin cancer”
> “NB-UVB should be used with caution in patients with a history of melanoma or multiple nonmelanoma skin cancers, history of arsenic intake, and/or prior exposure to ionizing radiation due to the potential risk of photocarcinogenesis”

Source: [Elmets et al. (2019b)](https://www.jaad.org/article/S0190-9622%2819%2930637-1/fulltext)

<a id="topic-2.2.2.1.2-6"></a>

###### Phototherapy use relative to other treatment types

> “The most frequently used phototherapy modality is UV-B, whereas methotrexate is the most commonly used oral agent.”

Source: [Armstrong et al. (2013d)](https://pubmed.ncbi.nlm.nih.gov/23945732/)

> “Of the patients lapsed and currently treated in this period, the numbers who received each treatment type were 156,409 (biologic), 222,657 (traditional oral systemic), 22,911 (phototherapy), and 293,511 (topical).”

Source: [Armstrong et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5336424/)

<a id="topic-2.2.2.1.2-7"></a>

###### Joint American Academy of Dermatology and National Psoriasis Foundation phototherapy guideline: scope and update of the 2010 guideline

> “Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy”
> “This section covers the use of phototherapy in the treatment of psoriasis in adults; psoriasis treatment in the pediatric population is addressed in the Joint American Academy of Dermatology–National Psoriasis Foundation Guidelines of Care for the Management and Treatment of Psoriasis in Pediatric Population (in preparation).”
> “was convened to update and expand on the previously published 2010 American Academy of Dermatology (AAD) psoriasis guideline”

Source: [Elmets et al. (2019b)](https://www.jaad.org/article/S0190-9622%2819%2930637-1/fulltext)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Conventional Systemic Therapies

<a id="topic-2.2.2.1.3-1"></a>

###### Methotrexate: guideline recommendations on use, comparative efficacy, dosage, and folate supplementation

> “Methotrexate is recommended for the treatment of moderate to severe psoriasis in adults.”
> “Methotrexate is less effective than adalimumab and infliximab for cutaneous psoriasis.”
> “Recommended methotrexate dosage typically ranges from 7.5 to 25 mg weekly. The dose can be given as a single dose or in 3 doses over 24 hours.”
> “Administration of folic acid or folinic acid is recommended to reduce the incidence of GI and hepatic adverse effects. Large folic acid and folinic acid doses may reduce the efficacy of methotrexate.”

Source: [Menter et al. (2020)](https://www.jaad.org/article/S0190-9622%2820%2930284-X/fulltext)

<a id="topic-2.2.2.1.3-2"></a>

###### Methotrexate efficacy in randomized trials: PASI 75 versus placebo and adalimumab

> “In a randomized controlled trial with 120 patients with psoriasis receiving subcutaneous methotrexate weekly (n = 91) or placebo (n = 29), a PASI 75 score was achieved in 41% (n = 37) of the subcutaneous methotrexate group compared with 10% of the placebo group (relative risk, 3.93; 95% confidence interval [CI], 1.31-11.81; P = .0026)”
> “Methotrexate group performed significantly better than placebo (35.5% of patients achieved PASI 75 compared with 18.9%) but was less effective than adalimumab (79.6% with PASI 75).”

Source: [Menter et al. (2020)](https://www.jaad.org/article/S0190-9622%2820%2930284-X/fulltext)

<a id="topic-2.2.2.1.3-3"></a>

###### Methotrexate oral solution: FDA-approved indication, dosage, boxed warning, and hepatotoxicity in psoriasis

> “JYLAMVO is indicated for the treatment of adults with severe psoriasis.”
> “The recommended dosage of JYLAMVO is 10 mg to 25 mg orally once weekly until an adequate response is achieved.”
> “Serious adverse reactions, including death, have been reported with methotrexate.”
> “In patients with psoriasis, fibrosis or cirrhosis may occur in the absence of symptoms or abnormal liver tests; the risk of hepatotoxicity appears to increase with total cumulative dose and generally occurs after receipt of a total cumulative dose of 1.5 g or more.”

Source: [Shorla Oncology JYLAMVO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212479s009lbl.pdf)

<a id="topic-2.2.2.1.3-4"></a>

###### Methotrexate: guideline statements on dose, principal adverse reactions, and myelosuppression

> “The recommended initial and maintenance dose is usually 15 mg MTX once weekly.”
> “The most important adverse drug reactions (ADRs) in association with MTX therapy are mucositis, MTX‐induced pneumonitis, hepatotoxicity, and myelosuppression.”
> “Another rare, but serious adverse event of MTX therapy is myelosuppression with an estimated prevalence of <1% (7/100,000 patient years).”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

<a id="topic-2.2.2.1.3-5"></a>

###### Cyclosporine: guideline recommendations and PASI response rates

> “Cyclosporine is recommended for patients with severe, recalcitrant psoriasis.”
> “Cyclosporine can be recommended as short-term interventional therapy in patients who flare up while on a pre-existing systemic therapy.”
> “At a dose of 3 mg/kg/d, 50% to 70% of patients with psoriasis achieved PASI 75 and 30% to 50% achieved PASI 90”

Source: [Menter et al. (2020)](https://www.jaad.org/article/S0190-9622%2820%2930284-X/fulltext)

<a id="topic-2.2.2.1.3-6"></a>

###### Cyclosporine: FDA-approved indication, dosage, and boxed warning for psoriasis

> “Neoral is indicated for the treatment of adult, nonimmunocompromised patients with severe (i.e., extensive and/or disabling), recalcitrant, plaque psoriasis who have failed to respond to at least one”
> “systemic therapy (e.g., PUVA, retinoids, or methotrexate) or in patients for whom other systemic therapies are contraindicated, or cannot be tolerated.”
> “The initial dose of Neoral should be 2.5 mg/kg/day.”
> “Based on patient response, dose increases of approximately 0.5 mg/kg/day should be made to a maximum of 4.0 mg/kg/day.”
> “Psoriasis patients previously treated with PUVA and to a lesser extent, methotrexate or other immunosuppressive agents, UVB, coal tar, or radiation therapy, are at an increased risk of developing skin malignancies when taking Neoral.”
> “Cyclosporine, the active ingredient in Neoral, in recommended dosages, can cause systemic hypertension and nephrotoxicity.”

Source: [Novartis NEORAL prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/050715s041,050716s041,050735s003,050736s001,050737s003,050738s001lbl.pdf)

<a id="topic-2.2.2.1.3-7"></a>

###### Cyclosporine nephropathy and malignancies in psoriasis

> “Kidney biopsies from 86 psoriasis patients treated for a mean duration of 23 months with 1.2 to 7.6 mg/kg/day of cyclosporine showed evidence of cyclosporine nephropathy in 18/86 (21%) of the patients.”
> “Tumors were reported in 32 (2.2%) of 1439 psoriasis patients treated with cyclosporine worldwide from clinical trials.”

Source: [Novartis NEORAL prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/050715s041,050716s041,050735s003,050736s001,050737s003,050738s001lbl.pdf)

<a id="topic-2.2.2.1.3-8"></a>

###### Acitretin: guideline recommendation and PASI 75 response

> “Acitretin can be recommended as monotherapy for plaque psoriasis.”
> “In one study, 23% of patients treated with acitretin 50 mg/d achieved PASI 75 after 8 weeks of therapy, with some patients experiencing complete clearance of skin disease”

Source: [Menter et al. (2020)](https://www.jaad.org/article/S0190-9622%2820%2930284-X/fulltext)

<a id="topic-2.2.2.1.3-9"></a>

###### Acitretin: FDA-approved indication, dosage, and pregnancy warning

> “SORIATANE is indicated for the treatment of severe psoriasis in adults.”
> “Therapy with SORIATANE should be initiated at 25 to 50 mg per day, given as a single dose with the main meal.”
> “SORIATANE must not be used by females who are pregnant, or who intend to become pregnant during therapy or at any time for at least 3 years following discontinuation of therapy.”

Source: [Stiefel SORIATANE prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/019821s029lbl.pdf)

<a id="topic-2.2.2.1.3-10"></a>

###### Network meta-analysis: methotrexate and ciclosporin compared with biologics, apremilast, and placebo

> “Infliximab, adalimumab, ixekizumab, and risankizumab were more effective than methotrexate (infliximab: RR 2.86, 95% CI 2.15 to 3.80; adalimumab: RR 3.73, 95% CI 2.25 to 6.19; ixekizumab: RR 2.05, 95% CI 1.43 to 2.94; risankizumab: RR 2.37, 95% CI 1.59 to 3.54).”
> “Ciclosporin and methotrexate were superior to apremilast for reaching PASI 90.”
> “There was evidence of a lower risk of SAEs for participants on methotrexate compared to placebo (RR 0.15, 95% CI 0.03 to 0.72).”
> “Our confidence in the results for non‐targeted systemic treatments is limited due to concerns regarding study conduct.”

Source: [Sbidian et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12327466/)

<a id="topic-2.2.2.1.3-11"></a>

###### Systemic nonbiologic therapy guideline scope and development under American Academy of Dermatology regulations in collaboration with the National Psoriasis Foundation

> “This guideline will cover the use of oral-systemic, nonbiologic medication in the treatment of psoriasis.”
> “This guideline has been developed in accordance with the American Academy of Dermatology (AAD)/AAD Association Administrative Regulations for Evidence-based Clinical Practice Guidelines (May 2014)”
> “Additionally, this guideline is developed in collaboration with the National Psoriasis Foundation, and as part of the review process; the National Psoriasis Foundation medical board members provided their feedback.”

Source: [Menter et al. (2020)](https://www.jaad.org/article/S0190-9622%2820%2930284-X/fulltext)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 PDE4 Inhibitors

<a id="topic-2.2.2.1.4-1"></a>

###### FDA-approved indication, dosage, and titration: apremilast

> “OTEZLA/OTEZLA XR is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.”
> “Following the 5-day titration with OTEZLA, the recommended maintenance dosage is OTEZLA 30 mg twice daily or OTEZLA XR 75 mg once daily taken orally starting on Day 6.”
> “This titration is intended to reduce the gastrointestinal symptoms associated with initial therapy.”

Source: [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf)

<a id="topic-2.2.2.1.4-2"></a>

###### Week 16 clinical response in Trials PSOR-1 and PSOR-2: apremilast label

| Endpoint at Week 16, n (%) | PSOR-1 placebo (N = 282) | PSOR-1 OTEZLA 30 mg BID (N = 562) | PSOR-2 placebo (N = 137) | PSOR-2 OTEZLA 30 mg BID (N = 274) |
| --- | --- | --- | --- | --- |
| PASI-75 | “15 (5.3)” | “186 (33.1)” | “8 (5.8)” | “79 (28.8)” |
| sPGA of clear or almost clear | “11 (3.9)” | “122 (21.7)” | “6 (4.4)” | “56 (20.4)” |

Source: [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf)

<a id="topic-2.2.2.1.4-3"></a>

###### ESTEEM 1: PASI-75 at week 16, maintenance through week 52, and adverse events

> “ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to severe plaque psoriasis.”
> “In all, 844 patients were randomized (n = 282, placebo; n = 562, apremilast).”
> “At week 16, significantly more patients taking apremilast achieved 75% or greater reduction from baseline Psoriasis Area and Severity Index score (PASI-75) (33.1%) versus placebo (5.3%, P < .0001; primary end point).”
> “Most (61.0%) patients rerandomized to apremilast at week 32 achieved PASI-75 at week 52 versus 11.7% rerandomized to placebo.”
> “During the placebo-controlled period, 55.7% and 69.3% of patients randomized to placebo and apremilast, respectively, had 1 or more adverse events.”

Source: [Papp et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26089047/)

<a id="topic-2.2.2.1.4-4"></a>

###### ESTEEM 2: PASI 75, PASI 50, and sPGA 0 or 1 at week 16 and common adverse events

> “ESTEEM 2 evaluated the efficacy and safety of apremilast 30 mg twice daily for moderate-to-severe plaque psoriasis.”
> “The modified intention-to-treat population (full analysis set) included 137 placebo and 274 apremilast patients.”
> “At week 16, significantly more apremilast patients achieved PASI 75 (28·8%), PASI 50 (55·5%) and static Physician's Global Assessment score of 0 or 1 (20·4%) vs. placebo (5·8%, 19·7%, 4·4%, respectively; P < 0·001).”
> “The most common adverse events were nausea, diarrhoea, nasopharyngitis and upper respiratory tract infection.”

Source: [Paul et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26357944/)

<a id="topic-2.2.2.1.4-5"></a>

###### Adverse reactions through week 16 in adults with moderate to severe plaque psoriasis: apremilast label

| Adverse reaction, n (%) | Placebo (N = 506) | OTEZLA 30 mg BID (N = 920) |
| --- | --- | --- |
| Diarrhea | “32 (6)” | “160 (17)” |
| Nausea | “35 (7)” | “155 (17)” |
| Tension headache | “21 (4)” | “75 (8)” |
| Headache | “19 (4)” | “55 (6)” |

Source: [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf)

<a id="topic-2.2.2.1.4-6"></a>

###### Discontinuation, depression, and weight decrease: apremilast label

> “The proportion of subjects with plaque psoriasis who discontinued treatment due to any adverse reaction was 6.1% for subjects treated with OTEZLA 30 mg twice daily and 4.1% for placebo-treated subjects.”
> “Treatment with apremilast is associated with an increased incidence of depression.”
> “During the 16-week placebo-controlled period of the 3 controlled clinical trials in adult subjects with moderate to severe plaque psoriasis, 1.3% (12/920) of subjects treated with OTEZLA reported depression compared to 0.4% (2/506) treated with placebo.”
> “During the placebo-controlled period of the trials in adults with moderate to severe plaque psoriasis, weight decrease between 5%-10% of body weight occurred in 12% (96/784) of subjects treated with OTEZLA compared to 5% (19/382) treated with placebo.”

Source: [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf)

<a id="topic-2.2.2.1.4-7"></a>

###### Apremilast: guideline recommendation, gastrointestinal adverse effects, and absence of laboratory monitoring

> “Apremilast is recommended for the treatment of moderate to severe psoriasis in adults.”
> “In those experiencing GI adverse effects, 70% to 80% occurred within the first 2 weeks, 75% to 80% were mild in severity, and 60% to 65% resolved within the first month.”
> “These benefits include oral administration and the lack of a requirement for laboratory monitoring.”
> “For patients who would prefer to avoid frequent injections as well as laboratory monitoring and are willing to accept a slower onset of skin clearance and lower likelihood of clearing, apremilast is an appropriate choice.”

Source: [Menter et al. (2020)](https://www.jaad.org/article/S0190-9622%2820%2930284-X/fulltext)

<a id="topic-2.2.2.1.4-8"></a>

###### Network meta-analysis: phosphodiesterase-4 inhibitors, serious adverse events and PASI 75 compared with biologics

> “Phosphodiesterase‐4 inhibitors had the highest SUCRA at class level in terms of SAEs (versus placebo: RR 0.76, 95% CI 0.47 to 1.23; SUCRA = 70.8)”
> “There was evidence of a difference in favour of infliximab, anti‐IL17 agents (ixekizumab, bimekizumab, and secukinumab), and risankizumab compared to ustekinumab, other anti‐TNF‐alpha agents (adalimumab, certolizumab, and etanercept), and synthetic targeted treatments (apremilast and deucravacitinib) in terms of achieving PASI 75.”

Source: [Sbidian et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12327466/)

<a id="topic-2.2.2.1.4-9"></a>

###### Network meta-analysis: estimated PASI response rates at 10 to 16 weeks for apremilast and dimethyl fumarate

| Treatment | PASI 75, % (95% CrI) | PASI 90, % (95% CrI) | PASI 100, % (95% CrI) |
| --- | --- | --- | --- |
| Apremilast, 30 mg | “30.8 (26.8-35.0)” | “12.1 (9.9-14.7)” | “2.4 (1.8-3.1)” |
| Dimethyl fumarate | “29.6 (22.0-38.3)” | “11.4 (7.5-16.7)” | “2.2 (1.2-3.8)” |
| Placebo | “5.3 (4.8-5.9)” | “1.1 (1.0-1.3)” | “0.1 (0.1-0.1)” |

Source: [Armstrong et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7042876/)

<a id="topic-2.2.2.1.4-10"></a>

###### Network meta-analysis design: bayesian analysis of short-term PASI response at 10 to 16 weeks in 60 trials and a traditional meta-analysis at 44 to 60 weeks

> “A bayesian network meta-analysis was conducted to estimate short-term PASI response rates; to account for variation across trials, an ordinal model that adjusted for reference arm response was implemented.”
> “The long-term PASI rates were estimated via a traditional meta-analysis.”
> “In a network meta-analysis of 60 clinical trials for short-term efficacy, brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa had the highest Psoriasis Area and Severity Index response rates at 10 to 16 weeks from baseline.”
> “A total of 60 trials meeting all inclusion criteria were included in the base-case NMA.”
> “The base-case analysis included all biologics, apremilast, and dimethyl fumarate.”
> “The estimated PASI response rates were summarized using posterior medians and their associated 95% credible intervals (CrIs).”

Source: [Armstrong et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7042876/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 TYK2 Inhibitors

<a id="topic-2.2.2.1.5-1"></a>

###### FDA-approved indication, dosage, and pretreatment tuberculosis evaluation: deucravacitinib

> “SOTYKTU is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.”
> “The recommended dosage of SOTYKTU is 6 mg taken orally once daily, with or without food.”
> “Evaluate patients for active and latent tuberculosis (TB) infection prior to initiating treatment with SOTYKTU.”

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

<a id="topic-2.2.2.1.5-2"></a>

###### Trial PSO-1 efficacy versus placebo and apremilast: deucravacitinib label

| Endpoint, n (%) | SOTYKTU (N=330) | Placebo (N=166) | Apremilast (N=168) |
| --- | --- | --- | --- |
| sPGA 0/1, Week 16 | “178 (54)” | “12 (7)” | “54 (32)” |
| PASI 75, Week 16 | “193 (58)” | “21 (13)” | “59 (35)” |
| PASI 90, Week 16 | “118 (36)” | “7 (4)” | “33 (20)” |

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

| Endpoint at Week 24, Trial PSO-1, n (%) | SOTYKTU (N=330) | Apremilast (N=168) |
| --- | --- | --- |
| PASI 75 | “228 (69)” | “64 (38)” |
| PASI 90 | “140 (42)” | “37 (22)” |

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

<a id="topic-2.2.2.1.5-3"></a>

###### POETYK PSO-1: week 16 PASI 75 and sPGA 0/1 versus placebo and apremilast

> “Participants were randomized 2:1:1 to deucravacitinib 6 mg every day (n = 332), placebo (n = 166), or apremilast 30 mg twice a day (n = 168) in the 52-week, double-blinded, phase 3 POETYK PSO-1 trial (NCT03624127).”
> “At week 16, response rates were significantly higher with deucravacitinib versus placebo or apremilast for PASI 75 (194 [58.4%] vs 21 [12.7%] vs 59 [35.1%]; P < .0001) and sPGA 0/1 (178 [53.6%] vs 12 [7.2%] vs 54 [32.1%]; P < .0001).”
> “Adverse event rates with deucravacitinib were similar to those with placebo and apremilast.”

Source: [Armstrong et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/35820547/)

<a id="topic-2.2.2.1.5-4"></a>

###### POETYK PSO-2: week 16 PASI 75 and sPGA 0/1 versus placebo and apremilast

> “POETYK psoriasis second trial (NCT03611751), a 52-week, double-blinded, phase 3 trial, randomized patients 2:1:1 to deucravacitinib 6 mg every day (n = 511), placebo (n = 255), or apremilast 30 mg twice a day (n = 254).”
> “At week 16, significantly more deucravacitinib-treated patients versus placebo and apremilast patients achieved ≥75% reduction from baseline in Psoriasis Area and Severity Index (53.0% vs 9.4% and 39.8%; P < .0001 vs placebo; P = .0004 vs apremilast) and static Physician's Global Assessment score of 0 or 1 (49.5% vs 8.6% and 33.9%; P < .0001 for both).”
> “The most frequent adverse event with deucravacitinib was nasopharyngitis.”
> “Serious adverse events and discontinuations due to adverse events were infrequent.”

Source: [Strober et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36115523/)

<a id="topic-2.2.2.1.5-5"></a>

###### Randomized withdrawal: maintenance of sPGA 0 or 1 at week 52 with continued deucravacitinib versus placebo

> “For subjects who were re-randomized and also had a sPGA score of 0 or 1 at Week 24, 70% (83/118) of subjects who continued on SOTYKTU maintained this response (sPGA 0 or 1) at Week 52 compared to 24% (28/119) of subjects who were re-randomized to placebo.”

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

<a id="topic-2.2.2.1.5-6"></a>

###### Adverse reactions through week 16 in Trials PSO-1 and PSO-2: deucravacitinib label

| Adverse reaction, n (%) | SOTYKTU 6 mg once daily (N=840) | Placebo (N=419) |
| --- | --- | --- |
| Upper respiratory infections | “161 (19.2)” | “62 (14.8)” |
| Blood creatine phosphokinase increased | “23 (2.7)” | “5 (1.2)” |
| Herpes simplex | “17 (2)” | “1 (0.2)” |
| Mouth ulcers | “16 (1.9)” | “0 (0.0)” |
| Folliculitis | “14 (1.7)” | “0 (0.0)” |

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

<a id="topic-2.2.2.1.5-7"></a>

###### Warnings: infections, creatine phosphokinase elevation, triglycerides, and potential JAK inhibition risks

> “In the 16-week placebo-controlled period of the pooled clinical trials (Trials PSO-1 and PSO-2), discontinuation of therapy due to adverse reactions in subjects who received SOTYKTU was 2.4%, compared to 3.8% for placebo.”
> “SOTYKTU may increase the risk of infections.”
> “The most common serious infections reported with SOTYKTU included pneumonia and COVID-19”
> “Treatment with SOTYKTU was associated with an increased incidence of asymptomatic creatine phosphokinase (CPK) elevation and rhabdomyolysis compared to treatment with placebo.”
> “Triglyceride Elevations - Treatment with SOTYKTU was associated with increases in triglyceride levels”
> “It is not known whether TYK2 inhibition may be associated with the observed or potential adverse reactions of Janus Kinase (JAK) inhibition.”

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

<a id="topic-2.2.2.1.5-8"></a>

###### Continuous deucravacitinib: PASI 90 and DLQI 0/1 through 4 years

> “In patients who received continuous deucravacitinib (n = 513), clinical and patient‐reported outcome rates were well maintained from 1 year through 4 years (e.g. PASI 90, 1 year, 45.6% [95% CI, 41.3%–50.0%], 4 years, 47.5% [42.6%–52.4%]; DLQI 0/1, 1 year, 51.5% [47.1%–55.9%], 4 years, 49.4% [44.4%–54.4%]).”

Source: [Armstrong et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12188513/)

<a id="topic-2.2.2.1.5-9"></a>

###### Deucravacitinib exposure-adjusted safety through 5 years

> “Overall, 1519 patients received one or more deucravacitinib dose; total exposure was 5046.7 PY through data cutoff (September 2, 2024).”
> “EAIRs/100 PY were comparable or decreased from the 1-year to 5-year cumulative period for adverse events (AEs) (229.23, 127.40, respectively), serious AEs (5.68, 5.06), discontinuation due to AEs (4.38, 2.09), deaths (0.20, 0.22), serious infections excluding coronavirus disease 2019 (COVID-19) (1.53, 0.94), malignancies (1.02, 0.92), major adverse cardiovascular events (0.30, 0.34), and venous thromboembolism (0.20, 0.06).”

Source: [Armstrong et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13578007/)

<a id="topic-2.2.2.1.5-10"></a>

###### Guideline statements: deucravacitinib infections, herpes zoster, laboratory changes, and malignancies

> “Deucravacitinib may increase the risk of infection.”
> “During the pivotal trials POETYK PSO‐1, PSO‐2 and the open‐label extension study, ten of the 18 patients reporting herpes zoster were less than 50 years old.”
> “Pooled data from clinical trials on changes in laboratory findings show that treatment with deucravacitinib may result in the following changes in laboratory findings: increase of creatine kinase (from asymptomatic to rhabdomyolysis), increase of triglyceride levels and increase of liver enzymes by ≥ 3‐fold of the upper limit of normal.”
> “In the pooled data from the complete treatment periods of the pivotal trials PSO‐1, PSO‐2, and the open‐label extension study (overall, 2,482 patient‐years of exposure with deucravacitinib), malignancies were reported in 22 patients (0.9 per 100 patient‐years), including eleven cases of non‐melanoma skin cancer (0.4 per 100 patient‐years) and three cases of lymphoma (0.1 per 100 patient‐years).”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

<a id="topic-2.2.2.1.5-11"></a>

###### Network meta-analysis: deucravacitinib compared with biologics and apremilast for PASI 90

> “There was evidence of a difference in favour of infliximab, anti‐IL17 agents (bimekizumab, ixekizumab, secukinumab, sonelokimab, brodalumab), and anti‐IL23 agents (risankizumab and guselkumab) compared to ustekinumab, tildrakizumab, the three anti‐TNF‐alpha agents (adalimumab, certolizumab, and etanercept), and deucravacitinib in terms of achieving PASI 90.”
> “Deucravacitinib and risankizumab were more effective than apremilast.”

Source: [Sbidian et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12327466/)

<a id="topic-2.2.2.1.5-12"></a>

###### Zasocitinib: phase 2b dose-ranging trial, PASI 75 at week 12

> “Patients were randomly assigned (1:1:1:1:1) to receive zasocitinib at 2, 5, 15, or 30 mg or placebo orally, once daily, for 12 weeks.”
> “At week 12, PASI 75 was achieved for 9 (18%), 23 (44%), 36 (68%), and 35 (67%) patients receiving zasocitinib at 2, 5, 15, and 30 mg, respectively, and 3 patients (6%) receiving placebo.”
> “Treatment-emergent adverse events occurred for 23 patients (44%) receiving placebo and 28 (53%) to 31 (62%) patients receiving the 4 different doses of zasocitinib, with no dose dependency and no clinically meaningful longitudinal differences in laboratory parameters.”

Source: [Armstrong et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11339701/)

<a id="topic-2.2.2.1.5-13"></a>

###### Zasocitinib: LATITUDE PsO 3001 and 3002 week 16 results versus placebo and apremilast

| Endpoint at Week 16 | LATITUDE PsO 3001 | LATITUDE PsO 3002 |
| --- | --- | --- |
| sPGA 0/1 | “71% zasocitinib vs 11% placebo and 32% apremilast (p<0.001)” | “69% zasocitinib vs 13% placebo and 30% apremilast (p<0.001)” |
| PASI 75 | “76% zasocitinib vs 12% placebo and 37% apremilast (p<0.001)” | “71% zasocitinib vs 12% placebo and 33% apremilast (p<0.001)” |

Source: [Takeda press release, zasocitinib NDA acceptance (2026)](https://www.takeda.com/newsroom/newsreleases/2026/fda-priority-review-zasocitinib-psoriasis/)

> “The studies were conducted in 21 countries and enrolled 693 and 1,108 participants, respectively.”
> “Scalp: 77% and 74% of patients with scalp psoriasis treated with zasocitinib achieved scalp-specific PGA (ssPGA) 0/1 response versus placebo (7% and 13%; p<0.001) and apremilast (42% and 30%; p<0.001) at week 16.”

Source: [Takeda press release, zasocitinib skin clearance across body sites (2026)](https://www.takeda.com/newsroom/newsreleases/2026/zasocitinib-phase-3-psoriasis-skin-clearance/)

<a id="topic-2.2.2.1.5-14"></a>

###### Zasocitinib versus deucravacitinib: LATITUDE Atlas week 16 results

> “In the Phase 3 LATITUDE Atlas (TAK-279 PsO 3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib across the primary and all key secondary efficacy endpoints with higher rates of complete skin clearance observed as early as week 8 and more than 2.5 times as many patients achieving complete skin clearance at week 16.”
> “36.5% of patients treated with zasocitinib (n=301) achieved complete skin clearance (Psoriasis Area and Severity Index (PASI) 100) at week 16 versus 13.9% in the deucravacitinib group (n=303; p<0.001).”
> “62.5% of patients treated with zasocitinib achieved PASI 90 at week 16 versus 34.0% in the deucravacitinib group (p<0.001).”
> “43.2% of patients treated with zasocitinib achieved clear skin (static Physician Global Assessment (sPGA) 0) at week 16 versus 18.5% in the deucravacitinib group (p<0.001).”
> “The most common adverse events across Phase 3 LATITUDE psoriasis trials were upper respiratory tract infection, nasopharyngitis and acne.”

Source: [Takeda press release, LATITUDE Atlas results (2026)](https://www.takeda.com/newsroom/newsreleases/2026/zasocitinib-superior-efficacy/)

<a id="topic-2.2.2.1.5-15"></a>

###### Zasocitinib: NDA accepted under Priority Review, PDUFA target in the first quarter of 2027

> “Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis.”
> “The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027”

Source: [Takeda press release, zasocitinib NDA acceptance (2026)](https://www.takeda.com/newsroom/newsreleases/2026/fda-priority-review-zasocitinib-psoriasis/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Oral IL-23 Receptor Antagonist Peptides

<a id="topic-2.2.2.1.6-1"></a>

###### FDA approval year, indication, dosage, and administration: icotrokinra

> “Initial U.S. Approval: 2026”
> “ICOTYDE is indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy.”
> “The recommended dosage of ICOTYDE is 200 mg administered orally once daily.”
> “Administer ICOTYDE upon waking on an empty stomach with water. Wait at least 30 minutes after taking ICOTYDE before eating food.”

Source: [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

<a id="topic-2.2.2.1.6-2"></a>

###### Trial PSO-1 efficacy versus placebo and deucravacitinib: icotrokinra label

> “Trial PSO-1 and Trial PSO-2 enrolled 1505 adults with moderate-to-severe plaque psoriasis defined as Investigator’s Global Assessment (IGA) score ≥3, a Psoriasis Area and Severity Index (PASI) score ≥12, and body surface area (BSA) involvement ≥10%.”

Source: [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

| Endpoint, Trial PSO-1, n (%) | ICOTYDE (N=311) | Placebo (N=156) | Deucravacitinib (N=307) |
| --- | --- | --- | --- |
| IGA 0 or 1 with ≥2-grade improvement, Week 16 | “213 (68)” | “17 (11)” | “154 (50)” |
| PASI 75, Week 16 | “231 (74)” | “18 (12)” | “176 (57)” |
| PASI 90, Week 16 | “171 (55)” | “6 (4)” | “91 (30)” |
| PASI 100, Week 16 | “97 (31)” | “2 (1)” | “34 (11)” |

Source: [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

| Endpoint at Week 24, Trial PSO-1, n (%) | ICOTYDE (N=311) | Deucravacitinib (N=307) |
| --- | --- | --- |
| IGA 0 or 1 with ≥2-grade improvement | “230 (74)” | “161 (52)” |
| PASI 90 | “205 (66)” | “127 (41)” |

Source: [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

<a id="topic-2.2.2.1.6-3"></a>

###### Trial PSO-2 efficacy versus placebo and deucravacitinib: icotrokinra label

| Endpoint, Trial PSO-2, n (%) | ICOTYDE (N=320) | Placebo (N=81) | Deucravacitinib (N=322) |
| --- | --- | --- | --- |
| IGA 0 or 1 with ≥2-grade improvement, Week 16 | “227 (71)” | “7 (9)” | “177 (55)” |
| PASI 90, Week 16 | “184 (58)” | “1 (1)” | “111 (34)” |

Source: [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

| Endpoint at Week 24, Trial PSO-2, n (%) | ICOTYDE (N=320) | Deucravacitinib (N=322) |
| --- | --- | --- |
| PASI 90 | “208 (65)” | “141 (44)” |

Source: [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

<a id="topic-2.2.2.1.6-4"></a>

###### ICONIC-ADVANCE 1 and 2: icotrokinra versus placebo and deucravacitinib, week 16 and week 24

> “Participants (ADVANCE 1: 774 of 988 patients screened; ADVANCE 2: 731 of 917 patients screened) were randomly assigned to icotrokinra (n=311 and 322), placebo (n=156 and 82), or deucravacitinib (n=307 and 327).”
> “Higher proportions of icotrokinra-treated versus placebo-treated participants achieved IGA 0 or 1 (ADVANCE 1: 213 [68%] of 311 vs 17 [11%] of 156, treatment difference 95% CI 58% [50-64]; ADVANCE 2: 227 [70%] of 322 vs seven [9%] of 82, 62% [53-69]; both p<0·0001) and PASI 90 (ADVANCE 1: 171 [55%] of 311 vs six [4%] of 156, treatment difference 95% CI 51% [44-57]; ADVANCE 2: 184 [57%] of 322 vs one [1%] of 82, 56% [48-62]; both p<0·0001) at week 16.”
> “To week 24, adverse event rates were lower than with icotrokinra (359 [57%] of 632) than deucravacitinib (411 [65%] of 634).”
> “Icotrokinra showed superior clinical response rates versus placebo and deucravacitinib in phase 3 moderate-to-severe plaque psoriasis trials, with similar adverse event rates to placebo.”

Source: [Stein Gold et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40976249/)

<a id="topic-2.2.2.1.6-5"></a>

###### ICONIC-ADVANCE 1 and 2 through week 52: durability of skin clearance

> “ICONIC-ADVANCE 1 and 2 randomized 1505 participants (774 and 731, respectively).”
> “Skin clearance rates among participants randomized to icotrokinra increased through week 24 and were durable through week 52, with approximately 70-75% exhibiting clear/almost clear skin (IGA 0/1, PASI 90) and approximately 50% demonstrating completely clear skin (IGA 0, PASI 100) during weeks 24-52.”
> “Participants who transitioned from placebo or deucravacitinib to icotrokinra exhibited increasing response rates that were comparable to participants randomized to icotrokinra through week 52.”

Source: [Stein Gold et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/42397072/)

<a id="topic-2.2.2.1.6-6"></a>

###### ICONIC-LEAD: icotrokinra versus placebo in adults and adolescents, week 16

> “Participants were assigned in a 2:1 ratio to receive icotrokinra at a dose of 200 mg once daily through week 24 or placebo through week 16 followed by transition to icotrokinra.”
> “At week 16, a total of 65% of the participants receiving icotrokinra and 8% of those receiving placebo had an IGA 0/1 response, and 50% and 4%, respectively, had a PASI 90 response (P<0.001 for both comparisons).”
> “Complete clearance of skin at week 16 was significantly more likely with icotrokinra than with placebo (IGA score of 0, 33% vs. 1%; PASI 100 response [100% reduction from baseline in the PASI score], 27% vs. <1%; P<0.001 for both comparisons).”
> “The percentage of participants with at least one adverse event through week 16 was 49% in each group; the most common adverse events in each group were nasopharyngitis and upper respiratory tract infection.”
> “(Funded by Johnson & Johnson; ICONIC-LEAD ClinicalTrials.gov number, NCT06095115.)”

Source: [Bissonnette et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41191940/)

<a id="topic-2.2.2.1.6-7"></a>

###### Icotrokinra in psoriasis involving high-impact sites, week 16

> “The proportions of participants achieving an IGA score of 0 or 1 in the icotrokinra and placebo groups were 56.7% and 5.8%, respectively [adjusted difference, 51.1 percentage points; 95% confidence interval (CI), 42.1 to 58.8; P<0.001].”
> “The proportions of icotrokinra-treated and placebo-treated participants achieving absence/clear or minimal/almost clear high-impact site psoriasis were as follows: scalp, 65.9% and 10.6% (difference, 55.5 percentage points; 95% CI, 44.8 to 64.4; P<0.001); genitalia, 76.5% and 21.4% (difference, 55.4 percentage points; 95% CI, 39.1 to 68.0; P<0.001); and hand and foot, 41.7% and 26.1% (difference, 16.7 percentage points; 95% CI, -6.2 to 36.8; P=0.144).”

Source: [Gooderham et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41191932/)

<a id="topic-2.2.2.1.6-8"></a>

###### Adverse reactions through week 16 and warnings: icotrokinra label

| Adverse reaction, n (%) | ICOTYDE (N=1296) | Placebo (N=568) |
| --- | --- | --- |
| Headache | “51 (4.1)” | “19 (3.3)” |
| Nausea | “15 (1.2)” | “3 (0.5)” |
| Cough | “15 (1.2)” | “1 (0.2)” |
| Fungal infection | “14 (1.1)” | “0 (0)” |

Source: [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

> “In the 16-week placebo-controlled trials in subjects with moderate-to-severe plaque psoriasis, the rate of serious infections for ICOTYDE-treated subjects was 0.2% compared to 0.4% of subjects who received placebo.”
> “Consider evaluating patients for tuberculosis (TB) infection prior to initiating treatment with ICOTYDE based on clinical judgement.”
> “Avoid use of live vaccines in patients during treatment with ICOTYDE.”

Source: [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

<a id="topic-2.2.2.1.6-9"></a>

###### Pooled safety of icotrokinra through 1 year and versus deucravacitinib through week 24

> “Through week 52, 2400 icotrokinra-treated participants contributed 1840 participant-years [PY] of follow-up.”
> “Through week 24, in the ICONIC-ADVANCE studies, rates/100 PY with icotrokinra versus deucravacitinib were as follows: AEs, 204 vs 265; serious AEs, 6.4 vs 7.2; infections, 81 vs 119; AEs leading to discontinuation, 5.7 vs 6.8.”

Source: [Lebwohl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13650227/)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 TNF Inhibitors

<a id="topic-2.2.2.1.7-1"></a>

###### Biologics guideline: recommendations for etanercept, infliximab, and adalimumab

> “Etanercept is recommended as a monotherapy treatment option in adult patients with moderate-to-severe plaque psoriasis”
> “Infliximab is recommended as a monotherapy treatment option in adult patients with moderate-to-severe plaque psoriasis”
> “Infliximab is recommended to be administered at a more frequent interval (less than every 8 weeks and as frequently as every 4 weeks during the maintenance phase) and/or at a higher dose up to 10 mg/kg for better disease control in some adult patients”
> “Adalimumab is recommended as a monotherapy treatment option for adult patients with moderate-to-severe plaque psoriasis”
> “A maintenance dose of adalimumab 40 mg/wk is recommended for better disease control in some patients”

Source: [Menter et al. (2019)](https://www.jaad.org/article/S0190-9622%2818%2933001-9/fulltext)

<a id="topic-2.2.2.1.7-2"></a>

###### Adalimumab: FDA-approved indication, dosage, and boxed warning

> “HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.”
> “The recommended subcutaneous dosage of HUMIRA for adult patients with plaque psoriasis (Ps) or uveitis (UV) [see Indications and Usage (1.7, 1.9)] is an initial dose of 80 mg, followed by 40 mg given every other week starting one week after the initial dose.”
> “Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death”
> “Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.”
> “Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including HUMIRA.”

Source: [AbbVie HUMIRA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125057s425lbl.pdf)

<a id="topic-2.2.2.1.7-3"></a>

###### Adalimumab: Study Ps-I efficacy at week 16 and maintenance through week 52

| Endpoint at Week 16, n (%) | HUMIRA 40 mg every other week (N = 814) | Placebo (N = 398) |
| --- | --- | --- |
| PGA clear or minimal | “506 (62%)” | “17 (4%)” |
| PASI 75 | “578 (71%)” | “26 (7%)” |

Source: [AbbVie HUMIRA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125057s425lbl.pdf)

> “After 52 weeks of treatment with HUMIRA, more subjects on HUMIRA maintained efficacy when compared to”
> “subjects who were re-randomized to placebo based on maintenance of PGA of “clear” or “minimal” disease (68% vs. 28%) or a PASI 75 (79% vs. 43%).”

Source: [AbbVie HUMIRA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125057s425lbl.pdf)

<a id="topic-2.2.2.1.7-4"></a>

###### Etanercept: FDA-approved indication, dosage, boxed warning, and Study II efficacy at 3 months

> “Etanercept is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.”
> “Starting Dose: 50 mg twice weekly for 3 months”
> “Maintenance Dose: 50 mg once weekly”
> “Patients treated with Etanercept are at increased risk for developing serious infections that may lead to hospitalization or death”

Source: [Amgen ENBREL prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103795s5605lbl.pdf)

| Outcome at 3 months, Study II, n (%) | Placebo (N = 204) | Etanercept 25 mg BIW (N = 204) | Etanercept 50 mg BIW (N = 203) |
| --- | --- | --- | --- |
| PASI 75 | “6 (3%)” | “66 (32%)” | “94 (46%)” |
| sPGA clear or minimal | “7 (3%)” | “75 (37%)” | “109 (54%)” |

Source: [Amgen ENBREL prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103795s5605lbl.pdf)

<a id="topic-2.2.2.1.7-5"></a>

###### Infliximab: FDA-approved indication, intravenous dosage, boxed warning, and week 10 PASI 75

> “REMICADE is indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis (Ps) who are candidates for systemic therapy and when other systemic therapies are medically less appropriate.”
> “The recommended dosage of REMICADE in adult patients is 5 mg/kg given as an intravenous induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of chronic severe (i.e., extensive and/or disabling) Ps.”
> “Patients treated with REMICADE are at increased risk for developing serious infections that may lead to hospitalization or death”

Source: [Janssen REMICADE prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/103772s5412lbl.pdf)

| PASI 75 at Week 10, n (%) | Placebo | REMICADE 3 mg/kg | REMICADE 5 mg/kg |
| --- | --- | --- | --- |
| Psoriasis Study II (EXPRESS II) | “4 (2%)” | “220 (70%)” | “237 (75%)” |
| Psoriasis Study III (SPIRIT) | “3 (6%)” | “71 (72%)” | “87 (88%)” |

Source: [Janssen REMICADE prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/103772s5412lbl.pdf)

<a id="topic-2.2.2.1.7-6"></a>

###### Certolizumab pegol: FDA-approved indication, dosage, and boxed warning

> “CIMZIA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy”
> “The recommended dose of CIMZIA for adults with moderate-to-severe plaque psoriasis is 400 mg (given as 2 subcutaneous injections of 200 mg each) every other week.”
> “For some patients (with body weight less than or equal to 90 kg), CIMZIA 400 mg (given as 2 subcutaneous injections of 200 mg each) initially and at Weeks 2 and 4, followed by 200 mg every other week can be considered”
> “Patients treated with CIMZIA are at increased risk for developing serious infections that may lead to hospitalization or death”

Source: [UCB CIMZIA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125160s315lbl.pdf)

<a id="topic-2.2.2.1.7-7"></a>

###### Decision aid: TNF inhibitors

| Agent | Roughly what proportion of people are clear or nearly clear (PASI 90) in the first 6 months? | What is the likelihood of staying on this treatment for more than 1 year? |
| --- | --- | --- |
| Adalimumab | “31%” | “74–76% chance” |
| Certolizumab pegol | “24%” | “Not known at present” |
| Etanercept | “18%” | “67–73% chance” |
| Infliximab | “91%” | “54–74% chance” |

Source: [Smith et al. (2024a)](https://academic.oup.com/bjd/article/190/2/270/7280929)

<a id="topic-2.2.2.1.7-8"></a>

###### Network meta-analysis: infliximab and other TNF inhibitors

> “At drug‐level, using SUCRA, infliximab had a better chance of reaching PASI 90 (versus placebo: RR 49.99, 95% CI 20.83 to 119.95; SUCRA = 91.8; moderate‐certainty evidence)”
> “There was also evidence of a higher risk of SAEs for participants on infliximab compared to methotrexate (RR 2.41, 95% CI 1.04 to 5.59).”
> “Guselkumab, risankizumab, ixekizumab and bimekizumab were more effective than adalimumab.”
> “Ustekinumab, secukinumab, infliximab, ixekizumab, and tildrakizumab were more effective than etanercept.”

Source: [Sbidian et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12327466/)

| Treatment | PASI 75 at 10 to 16 weeks, % (95% CrI) | PASI 90 at 10 to 16 weeks, % (95% CrI) | PASI 100 at 10 to 16 weeks, % (95% CrI) |
| --- | --- | --- | --- |
| Infliximab, 5 mg/kg | “80.4 (76.5-84.0)” | “57.4 (52.2-62.8)” | “26.5 (22.3-31.4)” |
| Certolizumab pegol, 400 mg | “71.1 (65.4-76.5)” | “45.6 (39.3-52.2)” | “17.7 (13.8-22.3)” |
| Adalimumab, 40 mg | “69.5 (66.0-72.6)” | “43.7 (40.0-47.4)” | “16.5 (14.2-19.0)” |
| Etanercept, 25 mg twice weekly/50 mg once weekly | “40.1 (35.4-45.1)” | “17.9 (14.9-21.4)” | “4.2 (3.1-5.4)” |

Source: [Armstrong et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7042876/)

<a id="topic-2.2.2.1.7-9"></a>

###### Biologic therapy guideline scope and development under American Academy of Dermatology regulations in collaboration with the National Psoriasis Foundation

> “This guideline will cover the use of biologic agents in the treatment of psoriasis in adults”
> “This guideline has been developed in accordance with the American Academy of Dermatology/AAD Association Administrative Regulations for Evidence-Based Clinical Practice Guidelines (May 2014)”
> “Additionally, this guideline has been developed in collaboration with the National Psoriasis Foundation, and as part of the review process, the National Psoriasis Foundation medical board members provided their feedback.”

Source: [Menter et al. (2019)](https://www.jaad.org/article/S0190-9622%2818%2933001-9/fulltext)

<a id="topic-2.2.2.1.7-10"></a>

###### Decision aid columns: PASI 90 in the first 6 months from network meta-analyses and staying on treatment for more than 1 year from UK real-world data

> “Roughly what proportion of people are clear or nearly clear (PASI 90) in the first 6 months?”
> “What is the likelihood of staying on this treatment for more than 1 year?”
> “Anticipated absolute effect estimates were extracted for use in the updated decision aid (Table 1).”
> “figures quoted are based on anticipated absolute effects derived from network meta-analyses of biologic therapies (and methotrexate) for chronic plaque psoriasis involving licensed biologic doses only.”
> “The percentages quoted in the column on persistence on therapy after 1 year in the decision aid are derived from UK real-world data on both the mixed biologics population”
> “and the biologic-naïve population, as indicated.”
> “it may not apply to biologic choice for subsequent lines of treatment.”

Source: [Smith et al. (2024a)](https://academic.oup.com/bjd/article/190/2/270/7280929)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 IL-12/23 Inhibitors

<a id="topic-2.2.2.1.8-1"></a>

###### Biologics guideline: ustekinumab recommendation

> “Ustekinumab is recommended as a monotherapy treatment option for use in adult patients with moderate-to-severe plaque psoriasis”

Source: [Menter et al. (2019)](https://www.jaad.org/article/S0190-9622%2818%2933001-9/fulltext)

<a id="topic-2.2.2.1.8-2"></a>

###### Ustekinumab: FDA-approved indication and weight-based dosage every 12 weeks

> “STELARA is indicated for the treatment of adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.”
> “For patients weighing 100 kg or less, the recommended dosage is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks.”
> “For patients weighing more than 100 kg, the recommended dosage is 90 mg initially and 4 weeks later, followed by 90 mg every 12 weeks.”

Source: [Janssen STELARA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125261s173lbl.pdf)

<a id="topic-2.2.2.1.8-3"></a>

###### Ustekinumab: Ps STUDY 1 and Ps STUDY 2 outcomes at week 12

| Outcome at Week 12, n (%) | Ps STUDY 1 placebo (N=255) | Ps STUDY 1 STELARA 45 mg (N=255) | Ps STUDY 1 STELARA 90 mg (N=256) | Ps STUDY 2 placebo (N=410) | Ps STUDY 2 STELARA 45 mg (N=409) | Ps STUDY 2 STELARA 90 mg (N=411) |
| --- | --- | --- | --- | --- | --- | --- |
| PASI 75 response | “8 (3%)” | “171 (67%)” | “170 (66%)” | “15 (4%)” | “273 (67%)” | “311 (76%)” |
| PGA of cleared or minimal | “10 (4%)” | “151 (59%)” | “156 (61%)” | “18 (4%)” | “277 (68%)” | “300 (73%)” |

Source: [Janssen STELARA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125261s173lbl.pdf)

<a id="topic-2.2.2.1.8-4"></a>

###### Decision aid: ustekinumab

| Agent | Roughly what proportion of people are clear or nearly clear (PASI 90) in the first 6 months? | What is the likelihood of staying on this treatment for more than 1 year? |
| --- | --- | --- |
| Ustekinumab | “34%” | “84–86% chance” |

Source: [Smith et al. (2024a)](https://academic.oup.com/bjd/article/190/2/270/7280929)

<a id="topic-2.2.2.1.8-5"></a>

###### Network meta-analysis: ustekinumab compared with other biologics and oral agents

> “Anti‐IL17 class had a better chance of reaching PASI 90 using SUCRA (versus placebo: RR 25.58, 95% CI 21.64 to 30.23; SUCRA = 99.2), followed by anti‐IL23 (versus placebo: RR 22.25, 95% CI 18.70 to 26.48; SUCRA = 86.4), anti‐IL12/23 (versus placebo: RR 17.71, 95% CI 14.68 to 21.36; SUCRA = 71.5), and anti‐TNF‐alpha (versus placebo: RR 13.33, 95% CI 11.21 to 15.85; SUCRA = 57.1).”
> “Ustekinumab was superior to certolizumab (RR 1.43, 95% CI 1.07 to 1.92).”
> “Secukinumab, ixekizumab, brodalumab, risankizumab, and bimekizumab were more effective than ustekinumab.”
> “Adalimumab, tildrakizumab, and ustekinumab were superior to etanercept, deucravacitinib, and apremilast.”
> “For reaching PASI 90 at 52 weeks, risankizumab was more effective than ustekinumab (RR 1.73, 95% CI 1.46 to 2.05).”

Source: [Sbidian et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12327466/)

| Treatment | PASI 75 at 10 to 16 weeks, % (95% CrI) | PASI 90 at 10 to 16 weeks, % (95% CrI) | PASI 100 at 10 to 16 weeks, % (95% CrI) |
| --- | --- | --- | --- |
| Ustekinumab, 45 mg ≤100 kg, 90 mg >100 kg | “69.7 (66.3-73.1)” | “43.9 (40.2-47.9)” | “16.7 (14.4-19.3)” |

Source: [Armstrong et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7042876/)

<a id="heading-2.2.2.1.9"></a>

###### 2.2.2.1.9 IL-17 Inhibitors

<a id="topic-2.2.2.1.9-1"></a>

###### Biologics guideline: recommendations for secukinumab, ixekizumab, and brodalumab, and inflammatory bowel disease

> “Secukinumab is recommended as a monotherapy treatment option in adult patients with moderate-to-severe plaque psoriasis”
> “Secukinumab is recommended at a dose of 300 mg, which is more effective than 150 mg”
> “Ixekizumab is recommended as a monotherapy treatment option for use in adult patients with moderate-to-severe plaque psoriasis”
> “Brodalumab is recommended as a monotherapy treatment option in adult patients with moderate-to-severe plaque psoriasis”
> “Although the number of patients presenting with this adverse effect in clinical trials was relatively small, it is recommended that the use of IL-17 inhibitors be avoided in patients with a personal history of or active IBD.”
> “Periodic assessment of suicidal ideation is recommended for patients treated with brodalumab and might necessitate more frequent follow-up visits”

Source: [Menter et al. (2019)](https://www.jaad.org/article/S0190-9622%2818%2933001-9/fulltext)

<a id="topic-2.2.2.1.9-2"></a>

###### Secukinumab: FDA-approved indication, dosage, and week 12 outcomes in Trials PsO1 and PsO2

> “COSENTYX® is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults and pediatric patients 6 years and older who are candidates for systemic therapy or phototherapy.”
> “The recommended dosage in adults with moderate to severe PsO is 300 mg by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter.”
> “PASI 90 response at Week 12 was achieved with COSENTYX 300 mg and 150 mg compared to placebo in 59% (145/245) and 39% (95/245) versus 1% (3/248) of subjects, respectively (Trial PsO1) and 54% (175/327) and 42% (137/327) versus 2% (5/326) of subjects, respectively (Trial PsO2).”

Source: [Novartis COSENTYX prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125504s101;761349s016lbl.pdf)

| Outcome at Week 12, Trial PsO1, n (%) | COSENTYX 300 mg (N = 245) | COSENTYX 150 mg (N = 245) | Placebo (N = 248) |
| --- | --- | --- | --- |
| PASI 75 response | “200 (82)” | “174 (71)” | “11 (4)” |
| IGA of clear or almost clear | “160 (65)” | “125 (51)” | “6 (2)” |

Source: [Novartis COSENTYX prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125504s101;761349s016lbl.pdf)

<a id="topic-2.2.2.1.9-3"></a>

###### Ixekizumab: FDA-approved indication, dosage, and week 12 outcomes in Trial 1

> “TALTZ® is indicated for the treatment of patients 6 years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.”
> “The recommended dosage in adults with moderate-to-severe plaque psoriasis is 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks.”

Source: [Eli Lilly TALTZ prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125521s032lbl.pdf)

| Outcome at Week 12, Trial 1, n (%) | TALTZ 80 mg Q2W (N=433) | Placebo (N=431) |
| --- | --- | --- |
| sPGA of 0 (clear) or 1 (minimal) | “354 (82)” | “14 (3)” |
| PASI 90 | “307 (71)” | “2 (1)” |
| PASI 100 | “153 (35)” | “0” |

Source: [Eli Lilly TALTZ prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125521s032lbl.pdf)

<a id="topic-2.2.2.1.9-4"></a>

###### Brodalumab: boxed warning for suicidal ideation and behavior, REMS, restricted indication, and dosage

> “Suicidal ideation and behavior, including completed suicides, have occurred in patients treated with SILIQ.”
> “Because of the observed suicidal behavior in subjects treated with SILIQ, SILIQ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the SILIQ REMS Program [see Warnings and Precautions (5.2)].”
> “SILIQ® (brodalumab) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.”
> “The recommended SILIQ dose is 210 mg administered by subcutaneous injection at Weeks 0, 1, and 2 followed by 210 mg every 2 weeks.”
> “If an adequate response has not been achieved after 12 to 16 weeks of treatment with SILIQ, consider discontinuing therapy.”

Source: [Bausch Health SILIQ prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761032s020lbl.pdf)

<a id="topic-2.2.2.1.9-5"></a>

###### Brodalumab versus ustekinumab and placebo: week 12 outcomes in Trial 2

| Outcome at Week 12, Trial 2, n (%) | SILIQ 210 mg Q2W (N=612) | Ustekinumab (N=300) | Placebo (N=309) |
| --- | --- | --- | --- |
| PASI 75 response | “528 (86)” | “210 (70)” | “25 (8)” |
| PASI 100 response | “272 (44)” | “65 (22)” | “2 (1)” |

Source: [Bausch Health SILIQ prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761032s020lbl.pdf)

<a id="topic-2.2.2.1.9-6"></a>

###### Bimekizumab: FDA-approved indication, dosage, suicidal ideation warning, and week 16 outcomes

> “BIMZELX is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.”
> “The recommended dosage is 320 mg by subcutaneous injection at Weeks 0, 4, 8, 12, and 16, then every 8 weeks thereafter.”
> “For patients weighing 120 kg or more, consider a dosage of 320 mg every 4 weeks after Week 16 [see Clinical Pharmacology (12.3)].”
> “An increased incidence of new onset or worsening suicidal ideation and behavior was observed in subjects treated with BIMZELX.”

Source: [UCB BIMZELX prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761151s010lbl.pdf)

| Outcome at Week 16, n (%) | Trial Ps-1 BIMZELX 320 mg every 4 weeks (N=321) | Trial Ps-1 placebo (N=83) | Trial Ps-2 BIMZELX 320 mg every 4 weeks (N=349) | Trial Ps-2 placebo (N=86) |
| --- | --- | --- | --- | --- |
| IGA 0 or 1 | “270 (84%)” | “4 (5%)” | “323 (93%)” | “1 (1%)” |
| PASI 90 | “273 (85%)” | “4 (5%)” | “317 (91%)” | “1 (1%)” |
| PASI 100 | “188 (59%)” | “0 (0%)” | “238 (68%)” | “1 (1%)” |

Source: [UCB BIMZELX prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761151s010lbl.pdf)

<a id="topic-2.2.2.1.9-7"></a>

###### BE RADIANT: bimekizumab versus secukinumab, PASI 100 at weeks 16 and 48 and oral candidiasis

> “A total of 1005 patients were screened and 743 were enrolled; 373 patients were assigned to receive bimekizumab and 370 to receive secukinumab.”
> “At week 16, a total of 230 patients (61.7%) in the bimekizumab group and 181 (48.9%) in the secukinumab group had a 100% reduction from baseline in the PASI score (PASI 100) (adjusted risk difference, 12.7 percentage points; 95% confidence interval [CI], 5.8 to 19.6); bimekizumab was shown to be noninferior and superior to secukinumab (P<0.001 for noninferiority and superiority).”
> “At week 48, a total of 250 patients (67.0%) treated with bimekizumab had a PASI 100 response, as compared with 171 patients (46.2%) treated with secukinumab (adjusted risk difference, 20.9 percentage points; 95% CI, 14.1 to 27.7; P<0.001).”
> “Oral candidiasis occurred more often with bimekizumab (72 patients, 19.3%) than with secukinumab (11 patients, 3.0%).”
> “(Funded by UCB Pharma; BE RADIANT ClinicalTrials.gov number, NCT03536884.)”

Source: [Reich et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33891380/)

<a id="topic-2.2.2.1.9-8"></a>

###### Guideline statements: bimekizumab safety profile and candidiasis

> “In the opinion of the guideline group, bimekizumab has, with the exception of candidiasis, a similar safety profile to other IL‐17 antagonists, such as ixekizumab and secukinumab, as well as the IL‐17R antagonist brodalumab.”
> “Infections: The three most common TEAEs were nasopharyngitis (19.1 per 100 person‐years; 95% CI 17.4–20.9 per 100 person‐years), oral candidiasis (12.6 per 100 person‐years; 95% CI 11.3–14.0 per 100 person‐years), and infections of the upper respiratory tract (8.9 per 100 person‐years; 95% CI 7.8–10.1 per 100 person‐years).”
> “Dual inhibition of IL‐17A and IL‐17F may impair the protective function of mucous membranes more strongly, thus increasing the risk of oral candidiasis.”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

<a id="topic-2.2.2.1.9-9"></a>

###### Decision aid: IL-17 inhibitors

| Agent | Roughly what proportion of people are clear or nearly clear (PASI 90) in the first 6 months? | What is the likelihood of staying on this treatment for more than 1 year? |
| --- | --- | --- |
| Bimekizumab | “54%” | “Not known at present” |
| Brodalumab | “50%” | “Not known at present” |
| Ixekizumab | “53%” | “77–83% chance” |
| Secukinumab | “47%” | “80–83% chance” |

Source: [Smith et al. (2024a)](https://academic.oup.com/bjd/article/190/2/270/7280929)

<a id="topic-2.2.2.1.9-10"></a>

###### Network meta-analysis: anti-IL-17 agents compared with placebo and with other classes

> “In terms of reaching PASI 90, anti‐IL17 treatments (secukinumab, ixekizumab, izokibep, brodalumab, bimekizumab, sonelokimab, and xeligekimab) were more effective than placebo (class‐level RR 27.19, 95% CI 19.49 to 37.92).”
> “At class level, anti‐IL17 treatment showed a higher proportion of participants reaching PASI 90 compared to all the interventions versus anti‐IL23 (RR 1.15, 95% CI 1.01 to 1.31); versus anti‐IL12/23 (RR 1.44, 95% CI 1.27 to 1.64); versus anti‐TNF‐alpha (RR 1.92, 95% CI 1.68 to 2.19); versus TYK‐2 inhibitors (RR 3.20, 95% CI 2.08 to 4.94); versus non‐targeted systemic treatments (RR 4.01, 95% CI 2.65 to 6.05); and versus phosphodiesterase‐4 inhibitors (RR 5.82, 95% CI 3.95 to 8.58) (Supplementary material 15).”
> “There was evidence of a difference in favour of bimekizumab, ixekizumab, and risankizumab compared to secukinumab in terms of achieving PASI 90.”

Source: [Sbidian et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12327466/)

| Treatment | PASI 75 at 10 to 16 weeks, % (95% CrI) | PASI 90 at 10 to 16 weeks, % (95% CrI) | PASI 100 at 10 to 16 weeks, % (95% CrI) |
| --- | --- | --- | --- |
| Ixekizumab, 80 mg | “88.8 (86.5-90.9)” | “70.8 (66.8-74.6)” | “39.5 (35.2-44.0)” |
| Brodalumab, 210 mg | “88.7 (86.5-90.8)” | “70.6 (66.8-74.6)” | “39.2 (35.2-43.9)” |
| Secukinumab, 300 mg | “83.1 (80.2-85.7)” | “61.4 (57.2-65.6)” | “29.9 (26.3-33.9)” |

Source: [Armstrong et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7042876/)

<a id="heading-2.2.2.1.10"></a>

###### 2.2.2.1.10 IL-23 Inhibitors

<a id="topic-2.2.2.1.10-1"></a>

###### Biologics guideline: recommendations for guselkumab and tildrakizumab

> “Guselkumab is recommended as a monotherapy treatment option for use in adult patients with moderate-to-severe plaque psoriasis”
> “The recommended dose of guselkumab is 100 mg by self-administered subcutaneous injection at wk 0, wk 4, and every 8 wk thereafter”
> “Tildrakizumab is recommended as a monotherapy treatment option in adult patients with moderate-to-severe plaque psoriasis”

Source: [Menter et al. (2019)](https://www.jaad.org/article/S0190-9622%2818%2933001-9/fulltext)

<a id="topic-2.2.2.1.10-2"></a>

###### Guselkumab: FDA-approved indication, dosage, and week 16 outcomes in Trials PsO1 and PsO2

> “TREMFYA is indicated for the treatment of adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with moderate-to-severe plaque psoriasis and who are candidates for systemic therapy or phototherapy.”
> “Administer TREMFYA by subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter.”

Source: [Janssen TREMFYA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761061s034lbl.pdf)

| Outcome at Week 16, n (%) | Trial PsO1 placebo (N=174) | Trial PsO1 TREMFYA (N=329) | Trial PsO2 placebo (N=248) | Trial PsO2 TREMFYA (N=496) |
| --- | --- | --- | --- | --- |
| IGA response of 0/1 | “12 (7)” | “280 (85)” | “21 (8)” | “417 (84)” |
| PASI 90 response | “5 (3)” | “241 (73)” | “6 (2)” | “347 (70)” |

Source: [Janssen TREMFYA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761061s034lbl.pdf)

<a id="topic-2.2.2.1.10-3"></a>

###### Risankizumab: FDA-approved indication, dosage, and week 16 and week 52 outcomes in PsO-1 and PsO-2

> “SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy.”
> “The recommended dosage for adults is 150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter [see Dosage and Administration (2.7)].”
> “In PsO-1 and PsO-2 at Week 52, subjects receiving SKYRIZI achieved sPGA 0 (58% and 60%, respectively), PASI 90 (82% and 81%, respectively), and PASI 100 (56% and 60%, respectively).”

Source: [AbbVie SKYRIZI prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761105s053lbl.pdf)

| Outcome at Week 16, n (%) | PsO-1 SKYRIZI (N=304) | PsO-1 placebo (N=102) | PsO-2 SKYRIZI (N=294) | PsO-2 placebo (N=98) |
| --- | --- | --- | --- | --- |
| sPGA 0 or 1 | “267 (88)” | “8 (8)” | “246 (84)” | “5 (5)” |
| PASI 90 | “229 (75)” | “5 (5)” | “220 (75)” | “2 (2)” |
| PASI 100 | “109 (36)” | “0 (0)” | “149 (51)” | “2 (2)” |

Source: [AbbVie SKYRIZI prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761105s053lbl.pdf)

<a id="topic-2.2.2.1.10-4"></a>

###### Tildrakizumab: FDA-approved indication, dosage, and week 12 outcomes in Trials 2 and 3

> “ILUMYA® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.”
> “The recommended dosage in adult patients with moderate-to-severe plaque psoriasis is 100 mg at Weeks 0, 4, and every 12 weeks thereafter.”

Source: [Sun Pharma ILUMYA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761067s031lbl.pdf)

| Outcome at Week 12, n (%) | Trial 2 ILUMYA 100 mg (N=309) | Trial 2 placebo (N=154) | Trial 3 ILUMYA 100 mg (N=307) | Trial 3 placebo (N=156) |
| --- | --- | --- | --- | --- |
| PGA of 0 or 1 | “179 (58)” | “11 (7)” | “168 (55)” | “7 (4)” |
| PASI 75 | “197 (64)” | “9 (6)” | “188 (61)” | “9 (6)” |
| PASI 90 | “107 (35)” | “4 (3)” | “119 (39)” | “2 (1)” |

Source: [Sun Pharma ILUMYA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761067s031lbl.pdf)

<a id="topic-2.2.2.1.10-5"></a>

###### Decision aid: IL-23 inhibitors

| Agent | Roughly what proportion of people are clear or nearly clear (PASI 90) in the first 6 months? | What is the likelihood of staying on this treatment for more than 1 year? |
| --- | --- | --- |
| Guselkumab | “44%” | “85–90% chance” |
| Risankizumab | “51%” | “Not known at present” |
| Tildrakizumab | “32%” | “Not known at present” |

Source: [Smith et al. (2024a)](https://academic.oup.com/bjd/article/190/2/270/7280929)

<a id="topic-2.2.2.1.10-6"></a>

###### Network meta-analyses: anti-IL-23 agents, adverse events, and short-term and long-term PASI 90

> “Placebo had the highest SUCRA (SUCRA 93.9) at class‐level for all adverse events, followed by anti‐IL23 (versus placebo: RR 1.01, 95% CI 0.95 to 1.06; SUCRA = 89.9), anti‐TNF agents (versus placebo: RR 1.08, 95% CI 1.03 to 1.13; SUCRA = 61.3), and anti‐IL12/23 (versus placebo: RR 1.08, 95% CI 1.01 to 1.14; SUCRA = 60.8).”
> “At class level, all treatment classes showed evidence of a higher risk of adverse events compared to placebo, except for anti‐IL23.”
> “guselkumab was more effective than adalimumab in reaching PASI 90 at 52 weeks (RR 1.59, 95% CI 1.40 to 1.81)”

Source: [Sbidian et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12327466/)

> “At weeks 44 to 60, the treatments with the highest PASI 90 rates were risankizumab-rzaa (79.4%, 95% CI, 75.5%-82.9%), guselkumab (76.5%; 95% CI, 72.1%-80.5%), brodalumab (74.0%; 95% CI, 69.3%-78.1%), and ixekizumab (73.9%; 95% CI, 69.9%-77.5%).”

Source: [Armstrong et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7042876/)

| Treatment | PASI 75 at 10 to 16 weeks, % (95% CrI) | PASI 90 at 10 to 16 weeks, % (95% CrI) | PASI 100 at 10 to 16 weeks, % (95% CrI) |
| --- | --- | --- | --- |
| Risankizumab-rzaa, 150 mg | “89.2 (86.9-91.3)” | “71.6 (67.5-75.4)” | “40.4 (35.9-45.0)” |
| Guselkumab, 100 mg | “86.8 (83.8-89.4)” | “67.3 (62.5-71.9)” | “35.7 (30.9-40.7)” |
| Tildrakizumab-asmn, 100 mg | “62.9 (57.3-68.4)” | “36.8 (31.4-42.5)” | “12.5 (9.7-15.8)” |

Source: [Armstrong et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7042876/)

<a id="topic-2.2.2.1.10-7"></a>

###### Drug survival and switching risk with IL-23 inhibitors compared with other biologics

> “Among 19,034 treatment courses (median follow‐up: 2.3 years), treatments included adalimumab (tumour necrosis factor‐alpha (TNF‐a) inhibitor, n = 6,815), ustekinumab (IL‐12/23p40 inhibitor, n = 5,639), secukinumab (IL‐17A inhibitor, n = 3,051), ixekizumab (IL‐17A inhibitor, n = 1,072), brodalumab (n = 367), guselkumab (IL‐23p19 inhibitor, n = 1,258) and risankizumab (n = 832).”
> “Guselkumab and risankizumab had the highest adjusted survival times (years [interquartile ranges]) for effectiveness (1.93 [1.91–1.95] and 1.93 [1.90–1.96], respectively).”

Source: [Motedayen Aval et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12466084/)

> “IL-23 inhibitors were associated with the lowest risk of switching compared with TNF, IL-17, and IL-12/23 inhibitors over 24 months (p < 0.0001).”
> “Switch rates varied between specific biologics, with the lowest switch rates observed for patients treated with risankizumab at 8.5% followed by guselkumab at 15.7% over 24 months.”

Source: [Armstrong et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37154473/)

<a id="heading-2.2.2.1.11"></a>

###### 2.2.2.1.11 Limitations of Current Therapies

<a id="topic-2.2.2.1.11-1"></a>

###### Summary: undertreatment, route of administration, persistence, and access

- Undertreatment: from 2003 through 2011, 23.6% to 35.5% of people with moderate psoriasis and 9.4% to 29.7% with severe psoriasis were untreated, 52.3% of those with psoriasis were dissatisfied with their treatment, and among those treated, 29.5% with moderate and 21.5% with severe psoriasis received topical agents alone. Of an estimated 1.7 million insured U.S. patients with moderate to severe psoriasis, 1 million (59%) were not treated in the preceding year, 807,000 had lapsed treatment, and 547,000 were treatment-naive; 40.9% were receiving therapy in the 12 months up to September 2012, and 22.5% of those treated received a biologic. In another study, more than 80% of psoriasis patients with ≥ 4 palms body surface area received no treatment or topical treatment only, and 45% had not seen a physician in a year.
- Route of administration: respondents in one preference study were willing to accept a reduction from approximately 70% to 40% in the proportion achieving clear or almost-clear skin to avoid injections at home and use a topical treatment. In a survey of 178 patient and 43 dermatologist respondents, both groups preferred oral to injectable treatments for moderate disease when attributes were held equal, and patients with higher needle fear were more likely to favor an oral treatment. Biologics are available only by injection or infusion. In the joint AAD-NPF phototherapy guideline, narrowband UVB is recommended 3 times weekly in the treatment phase, and travel to a phototherapy center can be a limiting factor.
- Persistence and switching: a meta-analysis of fifty-five studies estimated the proportions adherent and persistent to biological therapy at 0.61 (95% CI 0.48–0.73) and 0.63 (0.57–0.68), highest for ustekinumab and lowest for etanercept. Among 7997 biologic-treated people, switch rates were 14.4% at 12 months and 26.0% at 24 months; IL-23 inhibitors had the lowest risk of switching, with 8.5% for risankizumab and 15.7% for guselkumab over 24 months. The British Association of Dermatologists decision aid, drawing on UK real-world data, gives the likelihood of staying on treatment for more than 1 year as 67–73% for etanercept, 74–76% for adalimumab, 84–86% for ustekinumab, and 85–90% for guselkumab. Of 8,710 biologic-treated people, 11.5% switched and 31.1% discontinued, and switchers had higher adjusted total health care costs than nonswitchers (mean difference $10,120).
- Access: inability to obtain adequate insurance coverage was among the top reasons for discontinuing biological agents. Insurance plans in the USA often require patients to try and fail other treatments first (step therapy), a process that “often delays access to medically necessary treatments”. Several labels limit the indicated population: cyclosporine to severe, recalcitrant plaque psoriasis after failure of at least one systemic therapy or when other systemic therapies are contraindicated or not tolerated, brodalumab to patients who have failed to respond or lost response to other systemic therapies and only through a REMS program, and adalimumab and infliximab to patients for whom other systemic therapies are medically less appropriate.

Source: [Armstrong et al. (2013d)](https://pubmed.ncbi.nlm.nih.gov/23945732/); [Armstrong et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5336424/); [Armstrong et al. (2017c)](https://pubmed.ncbi.nlm.nih.gov/28303523/); [Lebwohl et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24576585/); [Feldman et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10471409/); [Smith et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/39079697/); [Lebwohl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13650227/); [Elmets et al. (2019b)](https://www.jaad.org/article/S0190-9622%2819%2930637-1/fulltext); [Piragine et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8953825/); [Armstrong et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37154473/); [Smith et al. (2024a)](https://academic.oup.com/bjd/article/190/2/270/7280929); [Feldman et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10398133/); [Marquez-Grap et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12126447/); [Novartis NEORAL prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/050715s041,050716s041,050735s003,050736s001,050737s003,050738s001lbl.pdf); [Bausch Health SILIQ prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761032s020lbl.pdf); [AbbVie HUMIRA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125057s425lbl.pdf); [Janssen REMICADE prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/103772s5412lbl.pdf)

<a id="topic-2.2.2.1.11-2"></a>

###### Summary: efficacy of oral agents relative to biologics, safety warnings, and monitoring

- Efficacy in network meta-analyses: in a network meta-analysis of 204 studies with 67,889 randomized participants, anti-IL17, anti-IL12/23, anti-IL23, and anti-TNF-alpha biologics showed a higher proportion of participants reaching PASI 90 than non-targeted and targeted systemic agents. At class level, the PASI 90 RR for anti-IL17 treatment was 3.20 versus TYK-2 inhibitors, 4.01 versus non-targeted systemic treatments, and 5.82 versus phosphodiesterase-4 inhibitors. Deucravacitinib and risankizumab were more effective than apremilast, and ciclosporin and methotrexate were superior to apremilast for PASI 90. A second network meta-analysis, of 60 trials, estimated PASI 90 at 10 to 16 weeks from baseline at 12.1% for apremilast and 11.4% for dimethyl fumarate, against 17.9% for etanercept, 43.7% for adalimumab, 43.9% for ustekinumab, 70.8% for ixekizumab, and 71.6% for risankizumab-rzaa. A review states that deucravacitinib was superior to apremilast and inferior to risankizumab.
- Limits of the comparative evidence: the network meta-analysis evidence is limited to induction therapy (outcomes from 8 to 24 weeks after randomisation), its participants had a mean age of 44.4 years and a baseline PASI of 20.5, and its serious adverse event analyses rested on a very low number of events. The guideline group of the EuroGuiDerm-adapted German S3 guideline stated it was not able to sufficiently differentiate recommendation levels for individual agents on PASI 90 and serious adverse events alone.
- Conventional oral agents: methotrexate achieved PASI 75 in 35.5% of patients against 79.6% with adalimumab, and acitretin 50 mg/d achieved PASI 75 in 23% after 8 weeks. Cyclosporine, methotrexate, and acitretin are described as having “limited efficacy and/or are associated with serious side effects and major monitoring requirements”.
- Safety warnings: the labels of adalimumab, etanercept, infliximab, and certolizumab pegol state an increased risk of serious infections that may lead to hospitalization or death, and the adalimumab label reports lymphoma and other malignancies in children and adolescents treated with TNF blockers. The JYLAMVO (methotrexate) label reports serious adverse reactions including death, and hepatotoxicity risk that generally occurs after a cumulative dose of 1.5 g or more. Cyclosporine can cause hypertension and nephrotoxicity (cyclosporine nephropathy in 18/86 [21%] of biopsied psoriasis patients). Acitretin must not be used by females who are pregnant or intend to become pregnant during therapy or for at least 3 years after discontinuation. Suicidal ideation and behavior, including completed suicides, have occurred with brodalumab, and bimekizumab carries a warning for suicidal ideation and behavior; oral candidiasis occurred in 19.3% with bimekizumab and 3.0% with secukinumab. The AAD-NPF biologics guideline recommends avoiding IL-17 inhibitors in patients with a personal history of or active IBD. With apremilast, depression was reported in 1.3% vs. 0.4% with placebo and weight decrease of 5%-10% in 12% vs. 5%, and diarrhea and nausea each occurred in 17%. The deucravacitinib label warns of infections, CPK elevation and rhabdomyolysis, and triglyceride elevations, and a review describes deucravacitinib as the only JAK or TYK2 inhibitor indicated for psoriasis that “does not have a boxed warning”. Class 1 topical corticosteroids are limited to up to 4 weeks, and tachyphylaxis may occur with use beyond 12 weeks.
- Screening and monitoring: deucravacitinib requires evaluation for active and latent tuberculosis before treatment and periodic evaluation of serum triglycerides; for icotrokinra, tuberculosis evaluation is considered based on clinical judgement and live vaccines are avoided. The adalimumab label directs monitoring of all patients for active tuberculosis during treatment, even if the initial latent test is negative; cyclosporine requires frequent monitoring of serum creatinine; the EuroGuiDerm-adapted guideline group monitors methotrexate with transaminases; and periodic assessment of suicidal ideation is recommended with brodalumab. Apremilast has no requirement for laboratory monitoring.

Source: [Sbidian et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12327466/); [Armstrong et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7042876/); [De Luca et al. (2026)](https://link.springer.com/article/10.1007/s40257-026-01095-2); [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/); [Menter et al. (2020)](https://www.jaad.org/article/S0190-9622%2820%2930284-X/fulltext); [Lebwohl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13650227/); [AbbVie HUMIRA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125057s425lbl.pdf); [Amgen ENBREL prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103795s5605lbl.pdf); [Janssen REMICADE prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/103772s5412lbl.pdf); [UCB CIMZIA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125160s315lbl.pdf); [Shorla Oncology JYLAMVO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212479s009lbl.pdf); [Novartis NEORAL prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/050715s041,050716s041,050735s003,050736s001,050737s003,050738s001lbl.pdf); [Stiefel SORIATANE prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/019821s029lbl.pdf); [Bausch Health SILIQ prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761032s020lbl.pdf); [UCB BIMZELX prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761151s010lbl.pdf); [Reich et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33891380/); [Menter et al. (2019)](https://www.jaad.org/article/S0190-9622%2818%2933001-9/fulltext); [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf); [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf); [Burshtein and Schlesinger (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13588483/); [Elmets et al. (2021)](https://www.jaad.org/article/S0190-9622%2820%2932288-X/fulltext); [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

<a id="topic-2.2.2.1.11-3"></a>

###### Untreated and undertreated psoriasis and treatment dissatisfaction, 2003 to 2011

> “From 2003 through 2011, patients who were untreated ranged from 36.6% to 49.2% of patients with mild psoriasis, 23.6% to 35.5% of patients with moderate psoriasis, and 9.4% to 29.7% of patients with severe psoriasis.”
> “Overall, 52.3% of patients with psoriasis and 45.5% of patients with psoriatic arthritis were dissatisfied with their treatment.”

Source: [Armstrong et al. (2013d)](https://pubmed.ncbi.nlm.nih.gov/23945732/)

<a id="topic-2.2.2.1.11-4"></a>

###### Untreated, lapsed, and switched treatment among insured U.S. patients with moderate to severe psoriasis

> “There were an estimated 1.7 million insured US patients with moderate to severe psoriasis.”
> “Of these, 1 million (59%) were not treated for their condition in the preceding year.”

Source: [Armstrong et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5336424/)

> “Of these, an estimated 807,000 patients had lapsed treatment, an additional 346,000 were receiving treatment, and 547,000 were defined as being treatment-naive.”
> “A total of 81,000 of 346,000 patients had switched treatment in the preceding year.”

Source: [Armstrong et al. (2017c)](https://pubmed.ncbi.nlm.nih.gov/28303523/)

<a id="topic-2.2.2.1.11-5"></a>

###### Insurance coverage and step therapy as barriers to biologic treatment

> “Although adverse effects and a lack of effectiveness were primary reasons for discontinuing biological agents, the inability to obtain adequate insurance coverage was among the top reasons for discontinuation.”

Source: [Armstrong et al. (2013d)](https://pubmed.ncbi.nlm.nih.gov/23945732/)

> “Despite their efficacy and safety, patients are often required by insurance plans in the USA or national formulary guidelines in other countries to try and fail other treatments first, which is a strategy called step therapy.”
> “This process often delays access to medically necessary treatments, with patients’ conditions potentially worsening each day.”

Source: [Marquez-Grap et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12126447/)

<a id="topic-2.2.2.1.11-6"></a>

###### Injection burden and preference for oral administration

> “For example, respondents were willing to accept a reduction in the percentage of patients who achieve clear or almost-clear skin after treatment from approximately 70% to 40% to avoid injections at home and use a topical treatment.”
> “Topical treatments were the most preferred option of administration followed by oral agents and intravenous infusion.”

Source: [Feldman et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10471409/)

> “Completed surveys from 178 patients and 43 dermatologists were included in the analysis.”
> “When treatment attributes were held equal, patients and dermatologists preferred oral versus injectable treatments for moderate disease.”
> “Patients with higher levels of needle fear were more likely to favor an oral treatment versus patients with lower levels of needle fear.”

Source: [Smith et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/39079697/)

> “However, biologics are only available by injection or infusion, which can be undesirable and inconvenient for many patients”

Source: [Lebwohl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13650227/)

<a id="topic-2.2.2.1.11-7"></a>

###### Adherence and persistence to biologics: meta-analysis

> “Sixty-two records met the inclusion criteria, and a meta-analysis was conducted on fifty-five studies.”
> “Overall, the proportion of adherent and persistent patients to biological therapy was 0.61 (95% confidence interval: 0.48–0.73) and 0.63 (0.57–0.68), respectively.”
> “The highest proportions were found for ustekinumab, while the lowest ones were found for etanercept.”

Source: [Piragine et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8953825/)

<a id="topic-2.2.2.1.11-8"></a>

###### Biologic switch rates at 12 and 24 months and predictors of switching

> “A total of 7997 patients were included, with overall treatment switch rates at 14.4% at 12 months and 26.0% at 24 months.”
> “Prior targeted immune modulator use, age, and female gender were predictors of switching (adjusted hazard ratio; 1.23, 1.31, and 1.40, respectively; p ≤ 0.0005).”

Source: [Armstrong et al. (2023b)](https://pubmed.ncbi.nlm.nih.gov/37154473/)

<a id="topic-2.2.2.1.11-9"></a>

###### Efficacy gap of oral agents relative to biologics: network meta-analysis

> “Biologic treatments anti‐IL17, anti‐IL12/23, anti‐IL23, and anti‐tumour necrosis factor (TNF)‐alpha showed a higher proportion of participants reaching PASI 90 than the non‐targeted systemic agents and the targeted systemic agents.”

Source: [Sbidian et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12327466/)

> “The conventional oral psoriasis therapies of cyclosporine, methotrexate, and acitretin have limited efficacy and/or are associated with serious side effects and major monitoring requirements”

Source: [Lebwohl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13650227/)

<a id="topic-2.2.2.1.11-10"></a>

###### Network meta-analysis evidence limited to induction-phase outcomes and trial populations

> “This update includes 26 new studies, taking the total number of included studies to 204, and randomised participants to 67,889 (67% men), mainly recruited from hospitals.”
> “This network meta‐analysis evidence is limited to induction therapy (outcomes measured from 8 to 24 weeks after randomisation), and is not sufficient for evaluating longer‐term outcomes in this chronic disease.”
> “Moreover, we found low numbers of studies for some of the interventions, and the young age (mean 44.4 years) and high level of disease severity (PASI 20.5 at baseline) may not be typical of people seen in daily clinical practice.”
> “Nevertheless, the SAEs analyses were based on a very low number of events with low‐certainty evidence for most comparisons.”

Source: [Sbidian et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12327466/)

> “Based on the results of the network comparisons for the outcome measures PASI 90 and SAE alone, the guideline group is not able to sufficiently differentiate the recommendation levels for the individual agents.”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

<a id="topic-2.2.2.1.11-11"></a>

###### Safety monitoring requirements of systemic therapies

> “Determination of transaminases for monitoring of potential liver damage due to MTX is the usual approach taken in the guideline group.”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

> “Patients receiving Neoral require frequent monitoring of serum creatinine (see Special Monitoring under DOSAGE AND ADMINISTRATION).”

Source: [Novartis NEORAL prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/050715s041,050716s041,050735s003,050736s001,050737s003,050738s001lbl.pdf)

> “Periodically evaluate serum triglycerides according to the clinical guidelines for hyperlipidemia while patients are receiving treatment with SOTYKTU.”

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

> “Monitor all patients for active TB during treatment, even if initial latent TB test is negative.”

Source: [AbbVie HUMIRA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125057s425lbl.pdf)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary: severity definitions and candidacy for systemic therapy

- The German S3 guideline adapted from EuroGuiDerm (Nast et al.) defines mild psoriasis as “BSA ≤ 10 and PASI ≤ 10 and DLQI ≤ 10” and moderate to severe psoriasis as “(BSA > 10 or PASI > 10) and DLQI > 10”. Mild disease is upgraded to moderate-to-severe by major involvement of visible areas or the scalp, involvement of the genitals, palms, or soles, onycholysis or onychodystrophy of at least two fingernails, pruritus leading to scratching, or recalcitrant plaques. Criteria for particularly severe psoriasis include PASI ≥ 20, DLQI ≥ 15, rapid deterioration, and severe involvement of the hands and/or feet, scalp, face, nails, or genitals.
- The most preferred statement reported by Strober et al. classifies patients as candidates for topical therapy or candidates for systemic therapy; the latter meet at least one of three criteria: body surface area >10%, disease involving special areas, or failure of topical therapy.
- The National Psoriasis Foundation classifies a patient as having mild psoriasis, managed with topical therapies, or moderate-to-severe psoriasis, which makes the patient a candidate for advanced therapies, including phototherapy and modern systemic treatments; it states that current systemic treatments include oral and biologic therapies.
- The deucravacitinib label indicates it for moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy, the icotrokinra label for the same population and for pediatric patients 12 years of age and older who weigh at least 40 kg, and the apremilast label for adults with plaque psoriasis who are candidates for phototherapy or systemic therapy. Trials PSO-1 and PSO-2 of the icotrokinra label defined moderate-to-severe plaque psoriasis as IGA score ≥3, PASI score ≥12, and BSA involvement ≥10%.

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/); [Strober et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31425723/); [National Psoriasis Foundation position statement on psoriasis severity (2025)](https://www.psoriasis.org/position-statement-on-psoriasis-severity/); [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf); [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf); [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf)

<a id="topic-2.2.2.2-2"></a>

###### Summary: guideline positions on first systemic therapy and oral agents

- EuroGuiDerm-adapted German S3 guideline (Nast et al.): when systemic treatment is initiated for the first time, the guideline suggests a biologic with a first-line label or deucravacitinib, especially for psoriasis of particular severity. It bases this on the disease burden of particularly severe psoriasis and on the results of the Cochrane review, and its classification of first-line and second-line agents follows the approved indications in the summary of product characteristics.
- In the EuroGuiDerm-adapted guideline's summary of the Cochrane network meta-analysis (Nast et al.), infliximab, the anti-IL-17 drugs, and the anti-IL-23 drugs except tildrakizumab were significantly more likely to reach PASI 90 than ustekinumab, three anti-TNF alpha agents, and deucravacitinib, and no significant difference was shown between apremilast and ciclosporin or methotrexate. Sbidian et al. state that deucravacitinib and risankizumab were more effective than apremilast and that ciclosporin and methotrexate were superior to apremilast for reaching PASI 90.
- AAD-NPF guideline on systemic nonbiologic therapies (Menter et al.): the guideline states that apremilast “is recommended for the treatment of moderate to severe psoriasis in adults” and describes it as an appropriate choice for patients who prefer to avoid frequent injections and laboratory monitoring and are willing to accept a slower onset of skin clearance and a lower likelihood of clearing. It also recommends methotrexate for moderate to severe psoriasis in adults and cyclosporine for severe, recalcitrant psoriasis.
- Preference for oral therapy: among 397 respondents, avoiding injections in favor of oral or topical treatment was more important to patients than some improvements in efficacy. The Alumis corporate presentation states “75% Patients prefer orals over injectables”.

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/); [Sbidian et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12327466/); [Menter et al. (2020)](https://www.jaad.org/article/S0190-9622%2820%2930284-X/fulltext); [Feldman et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10471409/); [Alumis corporate presentation, November 2026 (2026)](https://investors.alumis.com/static-files/08630d4b-a14b-447f-a46d-c963632af8a4)

<a id="topic-2.2.2.2-3"></a>

###### Summary: oral agents, head-to-head evidence, and the comparative evidence for envudeucitinib

- Oral agents with a U.S. label: deucravacitinib 6 mg once daily; apremilast 30 mg twice daily after a 5-day titration, or the extended-release tablet 75 mg once daily; and icotrokinra 200 mg once daily upon waking on an empty stomach, whose market introduction date is 2026-03-18 in the California HCAI new prescription drugs file. The FDA accepted the zasocitinib NDA under Priority Review, with a PDUFA target action date in the first quarter of calendar year 2027.
- Deucravacitinib versus apremilast: at week 16, PASI 75 was achieved by 58.4% with deucravacitinib, 35.1% with apremilast, and 12.7% with placebo in POETYK PSO-1, and by 53.0%, 39.8%, and 9.4% in POETYK PSO-2.
- Icotrokinra versus deucravacitinib: in Trial PSO-1 of the icotrokinra label, week 16 PASI 90 was achieved by 171 of 311 (55%) icotrokinra and 91 of 307 (30%) deucravacitinib participants and PASI 100 by 97 (31%) and 34 (11%); in Trial PSO-2, week 16 PASI 90 was achieved by 184 (58%) and 111 (34%), while Stein Gold et al. report 184 of 322 (57%) for icotrokinra in ADVANCE 2. Through week 24 of ICONIC-ADVANCE 1 and 2, adverse events occurred in 359 of 632 (57%) icotrokinra and 411 of 634 (65%) deucravacitinib participants.
- Zasocitinib: against deucravacitinib in LATITUDE Atlas (606 participants), week 16 PASI 100 was 36.5% (n=301) and 13.9% (n=303) and PASI 90 was 62.5% and 34.0%. Against apremilast at week 16, PASI 75 was 76% and 37% in LATITUDE PsO 3001 and 71% and 33% in LATITUDE PsO 3002 (Takeda press releases).
- Oral agent versus biologic: in the open-label IMMpactful trial, funded by AbbVie, PASI 90 at week 16 was achieved by 57.3% with risankizumab and 22.9% with deucravacitinib.
- Envudeucitinib: ONWARD1 and ONWARD2 compared envudeucitinib with placebo and apremilast, and STRIDE compared five envudeucitinib doses with placebo. The report holds no head-to-head trial of envudeucitinib against deucravacitinib, icotrokinra, zasocitinib, or a biologic. A review whose medical writing Alumis funded states that direct and formal indirect comparisons of oral agents “are not presently available”, and De Luca et al. state that the next-generation agents have been compared with placebo, apremilast, or deucravacitinib and have not been compared with IL-17 or IL-23 inhibitors. The Alumis corporate presentation compares PASI 100 rates of envudeucitinib (ONWARD1 and ONWARD2 at week 24), icotrokinra, and zasocitinib across trials and states that the results of this “retrospective post hoc cross-trial comparison may not be directly comparable”.
- Care setting: Alumis states that its success will depend upon physicians specializing in the treatment of the targeted diseases prescribing its product candidates. A single-center retrospective review drew on referrals for specialty medications by dermatology providers for psoriasis or atopic dermatitis and on the specialty pharmacy patient management system. In the United States, access to dermatologists “is limited in many regions”, especially in underserved and rural communities.

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf); [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf); [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf); [California HCAI new prescription drugs introduced to market, January to October 2026 (2026)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/2be5663e-8862-42e8-bd0e-3476d8baf7c3/download/new-drug-data-jan-oct-2026.csv); [Takeda press release, zasocitinib NDA acceptance (2026)](https://www.takeda.com/newsroom/newsreleases/2026/fda-priority-review-zasocitinib-psoriasis/); [Armstrong et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/35820547/); [Strober et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36115523/); [Stein Gold et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40976249/); [Takeda press release, LATITUDE Atlas results (2026)](https://www.takeda.com/newsroom/newsreleases/2026/zasocitinib-superior-efficacy/); [Magnolo et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13280295/); [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112); [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext); [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/); [De Luca et al. (2026)](https://link.springer.com/article/10.1007/s40257-026-01095-2); [Alumis corporate presentation, November 2026 (2026)](https://investors.alumis.com/static-files/08630d4b-a14b-447f-a46d-c963632af8a4); [Alumis Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000024/alms-20260930x10q.htm); [Bowles et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11852794/); [Armstrong et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6599714/)

<a id="topic-2.2.2.2-4"></a>

###### Guideline recommendation for the first systemic therapy: a biologic with a first-line label or deucravacitinib

> “If systemic treatment of psoriasis is initiated for the first time, we suggest treatment with a biologic with first‐line label or with deucravacitinib, especially for psoriasis of particular severity”
> “We recommend initiating a systemic treatment in patients with moderate to severe psoriasis according to Figure 3.”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

<a id="topic-2.2.2.2-5"></a>

###### Rationale for the guideline's first systemic therapy recommendation and first-line classification

> “The recommendation IX‐3 on the direct use of first‐line biologics or deucravacitinib is justified by the particularly high disease burden in particularly severe psoriasis and based on the results of the Cochrane review”
> “The classification of agents in 1st line and 2nd line, as presented in Figure 3, was based on the approved indications listed in the summary of product characteristics.”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

<a id="topic-2.2.2.2-6"></a>

###### PASI 90 likelihood with biologics, deucravacitinib, and apremilast in the guideline summary of the Cochrane network meta-analysis

> “Infliximab, anti‐IL‐17 drugs (bimekizumab, ixekizumab, secukinumab, and brodalumab), and anti‐IL‐23 drugs except tildrakizumab were significantly more likely to reach PASI 90 than ustekinumab, three anti‐TNF alpha agents, and deucravacitinib.”
> “No significant difference was shown between apremilast and two non‐biologic drugs: ciclosporin and MTX.”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

<a id="topic-2.2.2.2-7"></a>

###### National Psoriasis Foundation position on severity and candidacy for oral and biologic systemic therapies

> “Moderate-to-severe psoriasis is not determined solely by body surface area (BSA) involvement of 10%.”
> “These patients are all candidates for advanced therapies, including phototherapy as well as modern systemic treatments.”
> “Today’s systemic treatments include a variety of safe and highly effective oral and biologic therapies that treat inflammation throughout the body.”
> “A patient should be considered as having either 'mild' psoriasis, which can be managed with topical therapies, or a moderate-to-severe psoriasis, which makes these patients candidates for advanced therapies.”

Source: [National Psoriasis Foundation position statement on psoriasis severity (2025)](https://www.psoriasis.org/position-statement-on-psoriasis-severity/)

<a id="topic-2.2.2.2-8"></a>

###### Patient preference for oral or topical administration over injections: 397 respondents

> “A total of 397 respondents, with a mean self-assessed Psoriasis Activity and Severity Index score of 8.2 (SD, 9.8), provided data for analysis.”
> “The maximum possible improvement in treatment efficacy offered in the study was not enough to match the improvements in well being associated with some changes in mode of administration.”
> “Avoiding injections in favor of oral or topical treatment was more important to patients than some improvements in efficacy.”

Source: [Feldman et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10471409/)

<a id="topic-2.2.2.2-9"></a>

###### Investigator statement on the choice between oral and biologic therapies

> “Patients with moderate-to-severe psoriasis have to choose between oral and biologic therapies”
> “And for individuals seeking the best chance for clearance, biologics have long been superior to oral therapies.”
> “But now, with these new data on envudeucitinib, we’re seeing an exciting possibility of a new oral drug for psoriasis that can deliver high levels of efficacy in a safe manner.”

Source: [Alumis press release, ONWARD1 and ONWARD2 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-1.htm)

<a id="topic-2.2.2.2-10"></a>

###### Manufacturer statements on the intended position of envudeucitinib among oral therapies

> “In Phase 3, this translated into rapid onset of action, high rates of skin clearance, and meaningful symptom improvements that rank among the strongest reported for an oral therapy.”

Source: [Alumis press release, ONWARD1 and ONWARD2 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-1.htm)

> “The depth of clinical response, together with the favorable safety profile observed, underscores a differentiated clinical profile among marketed and investigational oral options and supports envudeucitinib’s potential to play a leading role in the treatment of patients with moderate-to-severe plaque psoriasis.”

Source: [Alumis press release, AAD 2026 ONWARD data (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_ex99-1.htm)

> “Next-generation orals expected to drive volume growth, powered by multiple brands”
> “Patients and clinicians still seek effective oral therapies”
> “75% Patients prefer orals over injectables”
> “Leading consistent PASI 100 skin clearance amongst oral therapies (ONWARD1/2 at Wk 24)”

Source: [Alumis corporate presentation, November 2026 (2026)](https://investors.alumis.com/static-files/08630d4b-a14b-447f-a46d-c963632af8a4)

<a id="topic-2.2.2.2-11"></a>

###### Prescribing specialists and uptake: manufacturer statement

> “Moreover, our success will depend upon physicians specializing in the treatment of those diseases that our product candidates target prescribing, and their patients being willing to receive, treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments they are already familiar with and for which greater clinical data may be available.”

Source: [Alumis Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000024/alms-20260930x10q.htm)

<a id="topic-2.2.2.2-12"></a>

###### Care setting: dermatology referral and specialty pharmacy dispensing of targeted therapies

> “A single-center, retrospective review of data collected from electronic health records and the specialty pharmacy patient management system was conducted.”
> “Patients were included if they had a referral for a specialty medication by a dermatology provider for PsO or AD that was discontinued because of the payer/PBM requiring step therapy or formulary alternative use from January 2021 to June 2022.”

Source: [Bowles et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11852794/)

> “The study included 24,767 patients (535 HCPro; 24,232 non-HCPro).”
> “HCPro patients had a greater frequency of initiation at a specialty pharmacy (66% vs. 56%; P < 0.001) and enrollment in AbbVie’s patient support program (71% vs. 51%; P < 0.001) as well as a lower copay for ADA ($206 vs. $265; P = 0.011).”

Source: [Hawkes et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6822976/)

<a id="topic-2.2.2.2-13"></a>

###### Access to dermatologists in underserved and rural communities

> “In the United States, access to dermatologists is limited in many regions, and this lack of access is especially pronounced among patients in underserved and rural communities”

Source: [Armstrong et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6599714/)

> “Telemedicine has the potential to allow for collaborative connected-health models to expand the reach of experienced dermatologists to help comanage patients with primary care physicians and community dermatologists who are not comfortable with newer systemic treatments for psoriasis.”

Source: [Pelet Del Toro et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10238745/)

<a id="topic-2.2.2.2-14"></a>

###### German S3 guideline adapted from the EuroGuiDerm guideline, part 1: scope and approval

> “This first part of the updated German S3 guideline on the treatment of psoriasis vulgaris covers the sections on treatment recommendations, treatment goals, and monitoring of therapies.”
> “The authors of this work have adapted, remixed, transformed, translated or built upon a previous version of the following article: EUROGUIDERM GUIDELINE FOR THE SYSTEMIC TREATMENT OF PSORIASIS by Nast A et al.”
> “The present adapted guideline did not undergo an approval procedure by the European Dermatology Forum, but has been approved by the editing German societies.”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Guideline recommendation to select systemic therapy by comorbidity and individual patient factors

> “We recommend taking into account efficacy (see Figure 1, Figure 2, and summary of the Cochrane Review), safety (see drug chapters), comorbidities (see Table 1 and Table 2 in publication Part 2, and respective chapters in the long version), and individual patient factors when choosing a systemic treatment for moderate to severe psoriasis.”
> “Accordingly, individual recommendation strengths arise individually from the examination of each patient, taking the factors effectiveness, safety, comorbidity, and other individual patient factors into account.”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

<a id="topic-2.2.2.3-2"></a>

###### Comorbidity-guided selection: inflammatory bowel disease, diabetes, cancer history, and latent tuberculosis

> “In patients with psoriasis and IBD, we recommend preferentially using approved targeted therapies with documented efficacy in these conditions:”
> “We suggest against the use of IL17 inhibitors in patients with inflammatory bowel disease.”
> “If alternative treatments are available, we suggest prescribing alternatives to MTX in patients with type 2 diabetes (with concomitant metabolic syndrome and/or signs of liver damage).”
> “For patients in remission of cancer for more than 5 years, we recommend selecting the most appropriate option for psoriasis treatment independent of the cancer.”
> “For patients with latent TB infection, we recommend choosing one of the following options:”
> “acitretin, apremilast, ciclosporin, dimethyl fumarate, MTX, or phototherapy.”
> “We suggest against the use of deucravacitinib”
> “in patients with latent TB infections unless there are no other suitable treatment options.”
> “Due to lack of data concerning the reactivation risk”

Source: [Nast et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12875186/)

<a id="topic-2.2.2.3-3"></a>

###### Conditions that make a biologic class less suitable: decision aid

> “What are some of the conditions that would make your doctor hesitant about giving you the treatment?”

Source: [Smith et al. (2024a)](https://academic.oup.com/bjd/article/190/2/270/7280929)

| Biologic class | Conditions listed in the decision aid |
| --- | --- |
| TNF inhibitors (adalimumab, certolizumab pegol, etanercept, infliximab) | “Moderate or severe heart failure, multiple sclerosis (or other conditions affecting the nerves)” |
| IL-12/23 inhibitor (ustekinumab) | “No particular condition” |
| IL-17 inhibitors (bimekizumab, brodalumab, ixekizumab, secukinumab) | “Inflammatory bowel disease (e.g. Crohn disease or ulcerative colitis), recurrent candida infection (i.e. thrush)” |

Source: [Smith et al. (2024a)](https://academic.oup.com/bjd/article/190/2/270/7280929)

<a id="topic-2.2.2.3-4"></a>

###### Agent selection by comorbidity, special population, and phenotype: U.S. reviews

> “Selection of the appropriate treatment modality has evolved substantially with the rapid expansion of available options that can be individualized based on patients' comorbidity profiles, extent of disease, prior therapeutic response, and treatment preferences.”
> “This first article of a two-part series focuses on selecting systemic therapy for PsO patients with specific inflammatory comorbidities or a history of malignancy.”

Source: [Pasumarthi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42896634/)

> “Choosing systemic therapy for psoriasis remains challenging in populations underrepresented in clinical trials, including pregnant and pediatric patients, patients with chronic infections, and those with difficult-to-treat phenotypes.”
> “Emphasis is placed on balancing efficacy, safety, monitoring burden, infection/reactivation risk, reproductive considerations, and disease phenotype.”

Source: [Karpoff et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42913858/)

<a id="topic-2.2.2.3-5"></a>

###### Body weight: overweight and early loss of biologic efficacy in severe psoriasis

> “Among the 87 patients (mean [SD] age, 42.2 [12.5] years; 24 female patients and 63 male patients) included in the study, 16 (18.4%) had to switch to other biologics because of an early loss of therapeutic efficacy.”
> “Having overweight (body mass index, >25) was the only clinically relevant factor (odds ratio, 17.3; 95% CI, 3.2-434.6; P = .009).”

Source: [Kim et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11966480/)

<a id="topic-2.2.2.3-6"></a>

###### Body weight: exposure and dosing statements in biologic labels

> “In subjects weighing more than 100 kg, 45 mg was also shown to be efficacious. However, 90 mg resulted in greater efficacy in these subjects”

Source: [Janssen STELARA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125261s173lbl.pdf)

> “Body Weight: The average plasma concentration in adult subjects weighing ≥120 kg was predicted to be at least 30% lower than those weighing < 120 kg (median of 87 kg)”

Source: [UCB BIMZELX prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761151s010lbl.pdf)

> “Risankizumab-rzaa clearance and volume of distribution increase and plasma concentrations decrease as body weight increases; however, no dose adjustment is recommended based on body weight in adult patients.”

Source: [AbbVie SKYRIZI prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761105s053lbl.pdf)

<a id="topic-2.2.2.3-7"></a>

###### Response across age, sex, race, body weight, baseline severity, and prior therapy subgroups: oral agent labels

> “Examination of age, gender, race, body weight, baseline disease severity, and prior systemic therapy did not identify differences in response to SOTYKTU at Week 16 among these subgroups.”

Source: [Bristol Myers Squibb SOTYKTU prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214958s006sdn685lbl.pdf)

> “An examination of age, gender, race, body weight, baseline disease severity, and previous treatment with systemic or biologic agents did not identify differences in response to ICOTYDE among these subgroups.”

Source: [Janssen ICOTYDE prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf)

<a id="topic-2.2.2.3-8"></a>

###### Response across age, sex, race, body weight, and prior therapy subgroups: IL-17 and IL-23 inhibitor labels

> “Examination of age, gender, race, body weight, baseline PASI score and previous treatment with systemic or biologic agents did not identify differences in response to SKYRIZI among these subgroups at Week 16.”

Source: [AbbVie SKYRIZI prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761105s053lbl.pdf)

> “Examination of age, gender, race, body weight, and previous treatment with systemic or biologic agents did not identify differences in response to TREMFYA among these subgroups.”

Source: [Janssen TREMFYA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761061s034lbl.pdf)

> “Examination of age, gender, race, body weight, and previous treatment with a biologic did not identify differences in response to TALTZ among these subgroups at Week 12.”

Source: [Eli Lilly TALTZ prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125521s032lbl.pdf)

> “Examination of age, gender, race, baseline IGA score and previous treatment with systemic or biologic agents did not identify differences in response to BIMZELX among these subgroups at Week 16.”

Source: [UCB BIMZELX prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761151s010lbl.pdf)

<a id="topic-2.2.2.3-9"></a>

###### Bimekizumab PASI 100 through 3 years by age, sex, weight, disease duration, severity, nail involvement, and prior biologic exposure

> “Subgroups of patients with moderate to severe plaque psoriasis were defined by age, sex, weight, disease duration, disease severity, nail involvement (modified Nail Psoriasis Severity Index > 0), and prior biologic exposure, at baseline.”
> “Among patients who received bimekizumab continuously for 3 years (N = 1107), PASI 100 response rates remained consistent across age (68.6% [40 to < 65 years]–73.7% [≥ 65 years]), sex (69.6% [male]–71.4% [female]), weight (63.4% [≥ 103.9 kg]–75.5% [< 74.3 kg]), disease duration (65.5% [≤ 5 years]–71.1% [> 20 years]), disease severity (67.7% [PASI 12 to < 15]–71.1% [PASI ≥ 20]), nail involvement (69.1% [yes]/71.3% [no]), and prior biologic exposure (71.7% [yes]/69.1% [no]; prior anti-TNF exposure 67.6% [yes]/70.6% [no]) subgroups; 95% CIs overlapped in all instances, indicating no meaningful differences between subgroups.”

Source: [Strober et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12619882/)

<a id="topic-2.2.2.3-10"></a>

###### Prior biologic or apremilast exposure: deucravacitinib real-world response through 52 and 104 weeks

> “Among the total 110 patients, 71 were apremilast‐naïve and 39 were apremilast‐experienced, while 95 were biologic‐naive and 15 were biologic‐experienced (Table 1).”
> “Both in biologic naive and experienced patients, mean PASI scores continued to decrease from week 0 to week 52; however, the magnitude of decrease appeared higher in biologic‐naive patients: from 15.53 to 1.30 in biologic‐naive patients (91.6% reduction) versus from 7.78 to 3.30 (57.6% reduction) in biologic‐experienced patients.”

Source: [Hagino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11975169/)

> “We studied 131 patients with moderate-to-severe psoriasis who received deucravacitinib 6 mg/day.”
> “Week 104 achieving PASI 100 and absolute PASI ≤ 1 were higher in apremilast-naïve patients (15.4% and 53.8%) than in apremilast-experienced patients (0% and 25%, respectively).”
> “Week 104 achieving PASI 75, PASI 90, PASI 100, and absolute PASI ≤ 1 were higher in biologic-naïve patients (84.6%, 57.7%, 15.4%, and 53.8%) than in biologic-experienced patients (25%, 25%, 0%, and 25%, respectively).”

Source: [Ishihara et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41657209/)

<a id="topic-2.2.2.3-11"></a>

###### Prior apremilast nonresponse: deucravacitinib response in POETYK PSO-1 and PSO-2 through week 52

> “Of 168 (PSO-1) and 254 (PSO-2) patients randomized to apremilast, 54 (32.1% [PSO-1]) and 111 (43.7% [PSO-2]) did not achieve PASI 50 (PSO-1) and PASI 75 (PSO-2) at Week 24 and were switched to deucravacitinib.”
> “PASI 75 response rates improved from 0% at Week 24 to 46.3% (PSO-1) and 42.3% (PSO-2) at Week 52.”

Source: [Armstrong et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12873009/)

<a id="topic-2.2.2.3-12"></a>

###### Prior systemic treatment status and the network meta-analysis

> “Indeed, response to biologics is different depending on treatment status (systemic‐naïve or not).”
> “However, due to the limited number of studies available for some specific comparisons, subgroup analyses and meta‐regressions were not possible.”
> “More randomised trials directly comparing active agents are needed, and these should include systematic subgroup analyses (sex, age, ethnicity, comorbidities, psoriatic arthritis).”

Source: [Sbidian et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12327466/)

<a id="topic-2.2.2.3-13"></a>

###### Asian populations: deucravacitinib network meta-analysis estimates

> “Evidence suggests the comparative efficacy of systemic therapies may be different in Asian versus White patients.”
> “The estimated PASI 75 and 90 (95% credible interval) response rates for deucravacitinib were estimated to be 66% (49%–80%) and 40% (24%–58%) in Asian populations, notably higher than placebo (6% [4%–9%] and 1% [0.8–2%]) and apremilast (24% [12%–40%] and 9% [4%–20%]).”
> “No statistically significant difference was observed in PASI 75 and 90 responses between deucravacitinib and adalimumab, certolizumab pegol, infliximab, ustekinumab, and tildrakizumab.”

Source: [Tsai et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11624152/)

<a id="topic-2.2.2.3-14"></a>

###### Japanese participants in POETYK PSO-1: week 16 and week 24 PASI 75

> “This report describes efficacy and safety in Japanese patients from this study (N = 66) who were randomly assigned to treatment with deucravacitinib 6 mg once daily (n = 32), placebo (n = 17), or apremilast 30 mg twice daily (n = 17).”
> “The proportion of Japanese patients achieving ≥75% reduction from baseline in PASI (PASI 75) score was numerically higher with deucravacitinib versus placebo and apremilast at Week 16 (78.1% vs. 11.8% and 23.5%, respectively) and versus apremilast at Week 24 (78.1% vs. 29.4%).”
> “The efficacy and safety of deucravacitinib in Japanese patients was consistent with those in the global population in POETYK PSO-1.”

Source: [Imafuku et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36882942/)

<a id="topic-2.2.2.3-15"></a>

###### Prespecified efficacy and safety subgroups in the envudeucitinib phase 2 statistical analysis plan

> “The following subgroups may be included in the analysis of safety and/or efficacy data.”
> “BSA involvement (10–20 %, > 20 %)”
> “PASI (≤ 20, > 20)”
> “Race (White, Non-white)”
> “Baseline weight category (<90 kg, ≥ 90 kg)”
> “Baseline BMI category (<30 kg/m2, ≥30 kg/ m2)”
> “Prior use of biologics (yes, no)”
> “Prior use of TYK 2 molecules (yes, no)”
> “Presence of co-morbidities (yes, no; co-morbidities considered include a history of diabetes, cardiovascular diseases, obesity, depression, hypertension, psoriatic arthritis)”

Source: [Alumis STRIDE statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/36/NCT05600036/SAP_001.pdf)

Additional sources: [Stein Gold et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42954748/); [Lovell et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39395444/)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Treat-to-target strategy: National Psoriasis Foundation Delphi consensus on instrument and evaluation timing

> “The National Psoriasis Foundation conducted a consensus-building study among psoriasis experts using the Delphi method.”
> “A total of 25 psoriasis experts participated in the Delphi process.”
> “The most preferred instrument was body surface area (BSA).”
> “The most preferred time for evaluating patient response after starting new therapies was at 3 months.”
> “During the maintenance period, evaluation every 6 months was most preferred.”
> “With defined treatment targets, clinicians and patients can regularly evaluate treatment responses and perform benefit-risk assessments of therapeutic options individualized to the patient.”

Source: [Armstrong et al. (2017a)](https://pubmed.ncbi.nlm.nih.gov/27908543/)

<a id="topic-2.2.2.4-2"></a>

###### Treatment goal monitoring and therapy modification: guideline

> “Various forms of adjustment include increasing the dosage, initiation of combination therapy, or transitioning to another drug or procedure.”
> “Treatment goals must be determined individually with the patients in a joint decision‐making process.”
> “During maintenance therapy, control of treatment goals should be done at the same intervals as the general monitoring, usually every 8 to 12 weeks.”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

<a id="topic-2.2.2.4-3"></a>

###### Tuberculosis screening before and during biologic or deucravacitinib therapy: guideline

> “A major focus of this update is the chapter on screening for tuberculosis as well as therapy selection and management in latent tuberculosis.”
> “We recommend excluding latent TB infection using interferon‐gamma release assay (IGRA) before initiating treatment with a biologic agent or deucravacitinib”
> “Deucravacitinib: due to lack of data concerning the reactivation risk”
> “We recommend against repeating IGRA just based on fixed time intervals or due to switching from one drug to another without relevant risk of exposure.”
> “We recommend repeating IGRA during treatment if there is an increased risk of TB exposure (see background text: Indications for an increased probability of an exposure risk).”

Source: [Nast et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12875186/)

<a id="topic-2.2.2.4-4"></a>

###### Latent tuberculosis testing for IL-17 and IL-23 inhibitors: NPF and IPC joint position

> “Although testing for latent tuberculosis (TB) infection has been standard practice for psoriasis patients being treated with interleukin (IL) 17 or IL-23 inhibitors, evidence for this practice is weak.”
> “87.5% of the members from the National Psoriasis Foundation Medical Board and International Psoriasis Council approved a new Joint Position Statement regarding psoriasis patients being treated with IL-17 or IL-23 inhibitors, stating that testing for latent TB infection is not required.”
> “Psoriasis experts reached consensus that routine testing for latent TB infection is not required in psoriasis patients being treated with IL-17 or IL-23 inhibitors.”

Source: [Blauvelt et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/41260526/)

<a id="topic-2.2.2.4-5"></a>

###### Tuberculosis testing requirement removed for risankizumab and absent for icotrokinra

> “Last week, the U.S. Food and Drug Administration (FDA) removed the tuberculosis (TB) testing requirement for the widely used drug risankizumab (Skyrizi), which is indicated for the treatment of psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.”
> “Following that published expert guidance, the FDA did not require TB testing for Johnson & Johnson’s new oral treatment icotrokinra (Icotyde).”

Source: [National Psoriasis Foundation, FDA drops TB testing for Skyrizi (2026)](https://www.psoriasis.org/us-fda-drops-tb-testing-requirement/)

> “Following review, the FDA determined that patients prescribed the therapy would not be required to undergo TB testing.”
> “TB testing has been a barrier for both patients and providers in the management of psoriatic disease, leading to anxiety, unnecessary treatment of TB due to false positive tests, unnecessary increases in medical costs, and delays in treatment of psoriasis”

Source: [National Psoriasis Foundation, TB testing for new oral treatment (2026)](https://www.psoriasis.org/tb-testing-new-oral-treatment/)

<a id="topic-2.2.2.4-6"></a>

###### Hepatitis B and hepatitis C screening before systemic therapy: guideline

> “We recommend screening patients for hepatitis B (HBsAg, anti‐HBs, anti‐HBc) as a routine measure before starting a treatment with ciclosporin, deucravacitinib, methotrexate, or biologics.”
> “We suggest screening patients for hepatitis C as a routine measure before starting a treatment with deucravacitinib, methotrexate, or biologics.”
> “We recommend against screening for hepatitis A, D, or E as a routine measure before starting a systemic treatment.”
> “If viral hepatitis has been excluded once before initiating an immunosuppressive therapy and there is no history‐related/laboratory evidence of infection, re‐testing is not required when changing the therapy.”

Source: [Nast et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12875186/)

<a id="topic-2.2.2.4-7"></a>

###### Pretreatment workup for deucravacitinib: guideline expert recommendations

> “Check need for vaccinations according to current vaccination recommendations including prophylactic vaccination against herpes zoster”
> “Inform patients to discontinue treatment and present for examination if they experience muscle weakness or pain, especially if these are accompanied by fatigue or fever.”
> “Not all tests may be required for all patients.”
> “The recommendations are based on expert opinions and take into account that the experience with the drug is still limited.”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

<a id="topic-2.2.2.4-8"></a>

###### Vaccination timing and live vaccines during oral and biologic therapy

> “The optimal time for vaccinations is before starting a systemic immunosuppressive therapy.”
> “In general, inactivated vaccines can be used safely in patients receiving systemic immunosuppressive therapy.”

Source: [Nast et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12875186/)

> “Using a modified Delphi process, 22 consensus statements were developed by the National Psoriasis Foundation Medical Board and COVID-19 Task Force, and infectious disease experts.”
> “Key recommendations include continuing most oral and biologic therapies without modification for patients receiving nonlive vaccines; consider interruption of methotrexate for nonlive vaccines.”
> “For patients receiving live vaccines, discontinue most oral and biologic medications before and after administration of live vaccine.”

Source: [Chat et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38331098/)

<a id="topic-2.2.2.4-9"></a>

###### Comorbidity screening: psoriatic arthritis at each visit and cardiovascular risk assessment

> “Screening patients with psoriasis for PsA is essential at each visit.”
> “CV risk assessment (screening for hypertension, diabetes, and hyperlipidemia) with national guidelines is recommended for all patients with psoriasis.”
> “Clinicians should consider early and more frequent screening for hypertension, diabetes, and hyperlipidemia in psoriasis patients who are candidates for systemic or phototherapy or who have psoriasis involving >10% of the BSA.”
> “Patients with moderate-to-severe psoriasis should have their obesity status determined annually.”

Source: [Elmets et al. (2019a)](https://www.jaad.org/article/S0190-9622%2818%2933002-0/fulltext)

> “We recommend working in collaboration with the treating gastroenterologists when prescribing a systemic therapy in psoriasis patients with concomitant chronic inflammatory bowel disease (IBD).”

Source: [Nast et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12875186/)

<a id="topic-2.2.2.4-10"></a>

###### Telemedicine management of psoriasis

> “Telemedicine utilization among dermatologists increased from under 15% to >95% after the pandemic, reflecting its marked popularity among patients and uptake for physicians.”
> “As compared with in-person care, collaborative and efficient teledermatology models equivalently improve PASI scores, BSA, and dermatology life quality index.”
> “Teledermatology is a reasonable alternative for providing long-term management of patients with psoriasis.”
> “It is important to guarantee the accessibility of in-person care for patients with psoriasis and ensure that telemedicine does not supplant such availability.”
> “The PEST should be provided to patients every 6 months to screen for PsA to help mitigate the undertreatment and delay in the diagnosis of this common comorbidity in patients with psoriasis.”

Source: [Pelet Del Toro et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10238745/)

<a id="topic-2.2.2.4-11"></a>

###### Online and in-person care: 12-month randomized equivalency trial in 296 adults

> “Overall, 296 adults with physician-diagnosed psoriasis from ambulatory clinics were randomly assigned to either online or in-person care; all were analyzed for outcomes.”
> “Across 12 months, for the online group, the mean ± standard deviation decline in Skindex-16 from baseline across follow-up visits was 9.02 ± 20.67 compared with 10.55 ± 23.50 for the in-person group.”
> “Over the 12-month study period, the in-person group had a total of 315 in-person visits; the online group had 161 online visits.”

Source: [Armstrong et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6599714/)

<a id="topic-2.2.2.4-12"></a>

###### Shared decision-making aid for biologic choice: dosing interval by agent

> “This is a decision aid to help clinicians and patients decide their treatment choice and is not a comprehensive data source or replacement for the individual drug summary of product characteristics.”

Source: [Smith et al. (2024a)](https://academic.oup.com/bjd/article/190/2/270/7280929)

| Agent | How often do I need to inject the treatment? |
| --- | --- |
| Adalimumab | “Every other week” |
| Certolizumab pegol | “Every 2 weeks” |
| Etanercept | “Once or twice a week” |
| Infliximab | “Every 8 weeks” |
| Ustekinumab | “Every 12 weeks” |
| Bimekizumab | “Every 8 weeks” |
| Brodalumab | “Every 2 weeks” |
| Ixekizumab | “Every 4 weeks” |
| Secukinumab | “Every month” |
| Guselkumab | “Every 8 weeks” |
| Risankizumab | “Every 12 weeks” |
| Tildrakizumab | “Every 12 weeks” |

Source: [Smith et al. (2024a)](https://academic.oup.com/bjd/article/190/2/270/7280929)

<a id="topic-2.2.2.4-13"></a>

###### Pharmacy-led prior authorization management in dermatology

> “Biologic agents (55.2%) and brand-name only medications (42.8%) required PA at higher rates.”
> “Pharmacy intervention resulted in shorter time to PA submission (4 days vs 1 day, P < .001) and decision (6 days vs 1 day, P < .001) and higher approval rates (63.9% vs 80.6%, P < .001) but did not decrease the total number of PAs.”
> “Patients with approved PAs had higher likelihood of disease improvement vs those with denied PAs (71.1% vs 58.0%, P = .013).”

Source: [Popatia et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31103568/)

<a id="topic-2.2.2.4-14"></a>

###### Online prescription management and specialty pharmacy support: abandonment and time to first fill

> “HCPro patients had a lower abandonment rate (6.4% vs. 13.9%; P < 0.001) and reduced days to prescription fill (7.0 vs. 14.4; P < 0.001).”
> “After controlling for baseline characteristics, abandonment odds were 43% lower for patients using HCPro (odds ratio = 0.57; P = 0.004).”

Source: [Hawkes et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6822976/)

<a id="topic-2.2.2.4-15"></a>

###### Adherence interventions including pharmacist-delivered models: systematic review of 26 studies

> “Twenty-six studies were included.”
> “Digital and technology‐supported interventions, including mobile applications, short message service reminders and electronic monitoring‐supported platforms were the most frequently evaluated and were generally associated with modest improvements in adherence when compared to usual care.”
> “Healthcare professional‐led interventions such as nurse and pharmacist delivered models demonstrated potential benefits in adherence.”
> “Across studies, improvements in adherence were more consistently observed than improvements in clinical severity and quality‐of‐life outcomes.”

Source: [Kumar et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13570483/)

<a id="topic-2.2.2.4-16"></a>

###### Step therapy before specialty medication: time to second referral in psoriasis and atopic dermatitis

> “The included patients (N = 83) were predominantly White (75%) and female (61%) with a median age of 50 years (interquartile range [IQR] = 37-61 years).”
> “62 patients were required to use step therapy, and 21 were required to use a formulary alternative.”
> “Of the patients required to use step therapy, 37 (60%) had a second referral for a specialty medication because of failing step therapy requirements, with a median time to a second referral of 75 days (IQR = 27-135).”

Source: [Bowles et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11852794/)

> “One study analyzing 194 step therapy protocols for PsO found that none were consistent with current clinical treatment guidelines and that 99.4% were more stringent than current treatment guidelines”

Source: [Marquez-Grap et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12126447/)

<a id="topic-2.2.2.4-17"></a>

###### Prior authorization burden, approval rates, and wait times for biologics

> “In September 2016, 626 PAs were generated from 9512 patient encounters.”
> “Biologic PAs cost a median of $15.80 each and took as long as 31 business days to complete.”
> “Approval rates were 99.6% for procedures, 78.9% for biologics, and 58.2% for other medications.”

Source: [Carlisle et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7450401/)

> “Records from the University of Miami Health System were reviewed, and 101 patients were included.”
> “Patients with Medicare had the shortest wait time with a mean of 7.3 days.”
> “Private insurance patients waited the longest, regardless of whether they had a PPO (37 days) or HMO (41.3 days).”

Source: [Vazquez et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36372843/)

<a id="topic-2.2.2.4-18"></a>

###### German S3 guideline adapted from EuroGuiDerm, part 2: specific clinical and comorbid situations

> “S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – part 2: Specific clinical and comorbid situations”
> “The present Part 2 of the updated German S3 guideline on the treatment of psoriasis vulgaris provides recommendations for therapy selection in special clinical situations and in the presence of comorbidities.”

Source: [Nast et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12875186/)

<a id="topic-2.2.2.4-19"></a>

###### British Association of Dermatologists guideline for biologic therapy: living guideline transition, decision aid update, and dosing question

> “The British Association of Dermatologists (BAD) published the fourth iteration of its clinical guideline for biologic therapy for people with moderate-to-severe psoriasis in 2020.”
> “In line with the BAD’s clinical guideline strategy, and in response to the rapidly changing developments in psoriasis therapeutics, the BAD guideline for biologics will be transitioning to a living guideline”
> “The GDG has also updated the decision aid.”
> “this is a research letter prepared for the Clinical Standards Unit of the British Association of Dermatologists (BAD), which includes the Therapy & Guidelines subcommittee.”
> “How often do I need to inject the treatment?”

Source: [Smith et al. (2024a)](https://academic.oup.com/bjd/article/190/2/270/7280929)

Additional sources: [Patel et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41419127/)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Summary

- Treatment goals: the EuroGuiDerm-adapted German S3 guideline (Nast et al.) names complete clearance as the fundamental goal of therapy and states that this goal is “not realistically achievable in all patients at this time”. A PASI 75 response is the minimum target at the end of the induction period, and PASI 90, an absolute PASI <2, or DLQI ≤ 1 is the desired goal. Goals are checked after 10 to 12 weeks for treatments with a fast onset of action and after 16 to 24 weeks for treatments with a slower onset, time frames that “may not always include the time of maximum therapeutic effect”.
- Body surface area targets: Armstrong et al. set the acceptable response at 3 months as BSA 3% or less or BSA improvement of 75% or more from baseline, and the target response as BSA 1% or less at 3 months and at every 6-month maintenance evaluation.
- Time to response: in an analysis of forty-five trials, the IL-17 inhibitors bimekizumab, ixekizumab, brodalumab, and secukinumab 300 mg were estimated to reach onset of PASI 90 response at approximately 6 to 8 weeks, the IL-23 inhibitors risankizumab and guselkumab at approximately 9–10 weeks, and the IL-12/23 inhibitor at 11–12 weeks; onset could not be estimated for tildrakizumab or for JAK and PDE4 inhibitors.
- Quality of life by depth of response: in 16-week pooled data, the estimated proportions achieving DLQI 0/1 were 93.0% with PASI 100, 89.3% with a 95% PASI improvement, and 83.8% with a 90% PASI improvement, and the proportions with no itching (P-SIM = 0) were 61.7%, 50.8%, and 39.8%.
- Maintenance with continuous biologic therapy: in LIMMitless, 661 of 897 enrolled participants completed the study, and at week 304, 86.0% achieved PASI 90, 54.2% PASI 100, 84.7% sPGA 0/1, and 76.3% DLQI 0/1 with risankizumab (modified nonresponder imputation). With secukinumab 300 mg, 168 participants entered the extension and 126 completed year 5; PASI 75/90/100 responses were 88.9%, 68.5%, and 43.8% at year 1 and 88.5%, 66.4%, and 41% at year 5, and DLQI 0/1 responses were 72.7% and 65.5%.

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/); [Armstrong et al. (2017a)](https://pubmed.ncbi.nlm.nih.gov/27908543/); [Papp et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12354354/); [Augustin et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11480266/); [Papp et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12436474/); [Bissonnette et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6175198/)

<a id="topic-2.2.2.7-2"></a>

###### Guideline treatment goals: PASI 75 minimum and PASI 90, absolute PASI below 2, or DLQI of 1 or less as the desired goal

> “The fundamental goal of any therapy is to achieve complete clearance of symptoms – that is, the absence of cutaneous symptoms of psoriasis.”
> “However, this goal is not realistically achievable in all patients at this time.”
> “At the end of the induction period, a PASI 75 response is the minimum target, which should be controlled for at regular intervals during the course of treatment.”
> “Reaching a PASI 90 response or an absolute PASI <2 or DLQI ≤ 1 should be the desired treatment goal.”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

<a id="topic-2.2.2.7-3"></a>

###### Treat-to-target response thresholds: BSA of 1% or less at 3 months and every 6 months

> “The acceptable response at 3 months postinitiation was either BSA 3% or less or BSA improvement 75% or more from baseline.”
> “The target response at 3 months postinitiation was BSA 1% or less.”
> “The target response at every 6 months maintenance evaluation is BSA 1% or less.”

Source: [Armstrong et al. (2017a)](https://pubmed.ncbi.nlm.nih.gov/27908543/)

<a id="topic-2.2.2.7-4"></a>

###### Time to response and timing of the treatment goal assessment

> “For treatments with a fast onset of action, treatment goals should be controlled for at the end of the induction therapy after 10 to 12 weeks; for treatments with a slower onset of action, this should be done after 16 to 24 weeks.”
> “These time frames may not always include the time of maximum therapeutic effect.”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

> “Forty-five trials were included in the main analyses.”
> “The IL-17 inhibitors bimekizumab, ixekizumab, brodalumab, and secukinumab 300 mg were estimated to provide the earliest onset of PASI 90 response at approximately 6 to 8 weeks.”
> “This was followed by the IL-23 inhibitors risankizumab and guselkumab at approximately 9–10 weeks, and the IL-12/23 inhibitor at 11–12 weeks.”
> “Onset of PASI 90 response could not be estimated by the model for tildrakizumab, and JAK and PDE4 inhibitors.”

Source: [Papp et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12354354/)

<a id="topic-2.2.2.7-5"></a>

###### Quality of life and symptom resolution at PASI 90, PASI 95, and PASI 100

> “Seven hundred and forty-three patients were randomised to treatment; 654 entered the OLE.”
> “Using 16-week pooled data, there were incremental improvements in the proportions of patients estimated by our model to achieve DLQI 0/1 with PASI 100 compared with 95% (PASI = 95%) and 90% (PASI = 90%) improvements in PASI (93.0%, 89.3%, and 83.8% achieving DLQI 0/1, respectively).”
> “Estimated proportions of patients achieving P-SIM = 0 were also higher for PASI 100 (itching: 61.7%; scaling: 82.2%; skin pain: 96.9%) than for PASI = 95% (50.8%; 72.3%; 95.7%) and PASI = 90% (39.8%; 59.5%; 94.0%).”

Source: [Augustin et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11480266/)

<a id="topic-2.2.2.7-6"></a>

###### Durability with continuous risankizumab through week 304

> “Of 897 patients enrolled in the LIMMitless study, 661 completed the study for a total of 4921.2 patient years of exposure to risankizumab.”
> “At week 304, 86.0% of patients achieved PASI 90, 54.2% achieved PASI 100, 84.7% achieved sPGA 0/1, and 76.3% achieved DLQI 0/1 (using modified nonresponder imputation).”

Source: [Papp et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12436474/)

<a id="topic-2.2.2.7-7"></a>

###### Durability with continuous secukinumab 300 mg through year 5

> “At Year 1, 168 patients entered the extension study and at the end of Year 5, 126 patients completed 300 mg (every 4 weeks) treatment.”
> “PASI 75/90/100 responses at Year 1 (88.9%, 68.5% and 43.8%, respectively) were sustained to Year 5 (88.5%, 66.4% and 41%).”
> “DLQI (dermatology life quality index) 0/1 response also sustained through 5 years (72.7% at Year 1 and 65.5% at Year 5).”

Source: [Bissonnette et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6175198/)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
